US11332790B2 - Methods for spatial analysis using RNA-templated ligation - Google Patents

Methods for spatial analysis using RNA-templated ligation Download PDF

Info

Publication number
US11332790B2
US11332790B2 US17/220,529 US202117220529A US11332790B2 US 11332790 B2 US11332790 B2 US 11332790B2 US 202117220529 A US202117220529 A US 202117220529A US 11332790 B2 US11332790 B2 US 11332790B2
Authority
US
United States
Prior art keywords
probe
capture
sequence
nucleotides
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US17/220,529
Other languages
English (en)
Other versions
US20210348221A1 (en
Inventor
James Michael Chell
Marlon Stoeckius
Jonathan Alles
Caroline Julie Gallant
Christina Galonska
Felice Alessio Bava
Layla Katiraee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
10X Genomics Inc
Original Assignee
10X Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 10X Genomics Inc filed Critical 10X Genomics Inc
Priority to US17/220,529 priority Critical patent/US11332790B2/en
Assigned to 10X GENOMICS, INC. reassignment 10X GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAVA, Felice Alessio, KATIRAEE, Layla
Assigned to SPATIAL TRANSCRIPTOMICS AB reassignment SPATIAL TRANSCRIPTOMICS AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHELL, James Michael, ALLES, Jonathan, GALLANT, Caroline Julie, GALONSKA, Christina, STOECKIUS, Marlon
Assigned to 10X GENOMICS, INC. reassignment 10X GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPATIAL TRANSCRIPTOMICS AB
Publication of US20210348221A1 publication Critical patent/US20210348221A1/en
Priority to US17/707,189 priority patent/US11560593B2/en
Publication of US11332790B2 publication Critical patent/US11332790B2/en
Application granted granted Critical
Priority to US18/100,133 priority patent/US11981965B2/en
Priority to US18/483,280 priority patent/US20240124933A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification

Definitions

  • Cells within a tissue have differences in cell morphology and/or function due to varied analyte levels (e.g., gene and/or protein expression) within the different cells.
  • the specific position of a cell within a tissue e.g., the cell's position relative to neighboring cells or the cell's position relative to the tissue microenvironment
  • RNA-templated ligation offer an alternative to indiscriminant capture of a common transcript sequence. See, e.g., Yeakley, PLoS One, 25; 12(5):e0178302 (2017), which is incorporated by reference in its entirety.
  • Targeted RNA capture is an attractive alternative to poly(A) mRNA capture in order to interrogate spatial gene expression in a sample (e.g., an FFPE tissue).
  • a sample e.g., an FFPE tissue
  • targeted RNA capture as described herein is less affected by RNA degradation associated with FFPE fixation compared to methods dependent on oligo-dT capture and reverse transcription of mRNA.
  • Further targeted RNA capture as described herein allows for sensitive measurement of specific genes of interest that otherwise might be missed with a whole transcriptomic approach.
  • Targeted RNA capture can be used to capture a defined set of RNA molecules of interest, or it can be used at a whole transcriptome level, or anything in between. When combined with the spatial methods disclosed herein, the location and abundance of the RNA targets can be determined.
  • this disclosure features a method for determining a location of an analyte in a biological sample including: (a) providing the biological sample on an array including a plurality of capture probes, where a capture probe of the plurality includes: (i) a spatial barcode and (ii) a capture domain; (b) contacting a first probe and a second probe with the biological sample, where the first probe and the second probe each include one or more sequences that are substantially complementary to sequences of the analyte, and where the second probe includes a capture probe capture domain; (c) hybridizing the first probe and the second probe to the analyte; (d) generating a ligation product by ligating the first probe and the second probe; (e) releasing the ligated product from the analyte; (f) hybridizing the ligation product to the capture domain; and (g) determining (i) all or a part of the sequence of the ligation product bound to the capture domain, or a complement thereof, and (i
  • the first probe and the second probe are substantially complementary to adjacent sequences of the analyte. In some embodiments, the first probe and the second probe hybridize to sequences that are not adjacent to each other on the analyte.
  • the method further includes hybridizing a third probe to the first probe and the second probe, where the third probe includes a first sequence that is substantially complementary to a portion of the first probe and a second sequence that is substantially complementary to a portion of the second probe.
  • hybridizing the first probe and the second probe to the analyte is performed at a first temperature.
  • hybridizing the third probe to the first probe and the second probe is performed at a second temperature.
  • the first temperature is a higher temperature than the second temperature. In some embodiments, the first temperature is from about 50° C. to about 75° C., from about 55° C. to about 70° C., or from about 60° C. to about 65° C.
  • the second temperature is from about 15° C. to about 35° C., from about 20° C. to about 30° C., or from about 25° C. to about 30° C.
  • the first probe is extended with a DNA polymerase, thereby filling in a gap between the first probe and the second probe and generating an extended first probe.
  • the first probe includes a sequence that is substantially complementary to a first target sequence of the analyte.
  • the second probe further includes: (i) a first sequence that is substantially complementary to a second target sequence of the analyte; (ii) a linker sequence; (iii) a second sequence that is substantially complementary to a third target sequence of the analyte; and (iv) a capture probe capture domain that is capable of binding to a capture domain of a capture probe.
  • the first target sequence of the analyte is directly adjacent to the second target sequence of the analyte.
  • the second target sequence is not directly adjacent to the third target sequence on the analyte.
  • the second target sequence and the third target sequence are (i) on different exons of the analyte or (ii) located within the same exon of the analyte but are not adjacent on the analyte.
  • the second probe includes a sequence that is substantially complementary to a third target sequence of the analyte.
  • the first probe includes: (i) a first sequence that is substantially complementary to a first target sequence of the analyte; (ii) a linker sequence; and (iii) second sequence that is substantially complementary to second target sequence of the analyte.
  • the second target sequence is directly adjacent to the third target sequence.
  • the first target sequence is not directly adjacent to the second target sequence on the analyte.
  • the first target sequence and second target sequence are (i) on different exons of the analyte or (ii) located within the same exon but are not directly adjacent on the analyte.
  • the linker sequence includes a total of about 1 nucleotide to about 100 nucleotides. In some embodiments, the linker further includes a barcode sequence that serves as a proxy for identifying the analyte.
  • the first probe includes at least two ribonucleic acid bases at the 3′ end, and where the second probe includes a phosphorylated nucleotide at the 5′ end.
  • generating a ligation product includes ligating (i) the first probe to the second probe or (ii) the extended first probe to the second probe using enzymatic ligation or chemical ligation, where the enzymatic ligation utilizes a ligase.
  • the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • the second probe includes a pre-adenylated phosphate group at its 5′ end, and where the first probe includes at least two ribonucleic acid bases at the 3′ end.
  • the step of generating a ligation product includes ligating a 3′ end of the first probe to the 5′ end of the second probe using a ligase that does not require adenosine triphosphate for ligase activity.
  • the ligase is selected from the group consisting of: thermostable 5′ AppDNA/RNA Ligase, truncated T4 RNA Ligase 2, truncated T4 RNA Ligase 2 K227Q, truncated T4 RNA Ligase 2 KQ, Chlorella Virus PBCV-1 DNA Ligase, or any combination thereof.
  • the first probe further includes a functional sequence, where the functional sequence is a primer sequence.
  • the method further includes providing a capture probe capture domain blocking moiety that interacts with the capture probe capture domain. In some embodiments, the method further includes releasing the capture probe capture domain blocking moiety from the capture probe capture domain prior to step (f).
  • the capture probe capture domain includes a poly-adenylated (poly(A)) sequence or a complement thereof. In some embodiments, the capture probe capture domain blocking moiety includes a poly-uridine sequence, a poly-thymidine sequence, or both.
  • releasing the poly-uridine sequence from the poly(A) sequence includes denaturing the ligation product or contacting the ligation product with an endonuclease, exonuclease or ribonuclease.
  • the capture probe capture domain includes a sequence that is complementary to all or a portion of the capture domain of the capture probe. In some embodiments, the capture probe capture domain includes a degenerate sequence.
  • the first probe and/or the second probe is a DNA probe.
  • the third probe is a DNA probe.
  • the capture probe capture domain blocking moiety is a DNA probe.
  • the releasing step (f) includes removing the ligated probe from the analyte.
  • the releasing of (i) the ligation product from the analyte or (ii) the capture probe capture domain blocking moiety from the capture domain binding domain includes contacting the ligated probe with an endoribonuclease.
  • the endoribonuclease is one or more of RNase H, RNase A, RNase C, or RNase I.
  • the RNase H includes RNase H1, RNase H2, or RNase H1 and RNase H2.
  • the biological sample is a tissue sample.
  • the tissue sample is a formalin-fixed, paraffin-embedded (FFPE) tissue sample, a fresh or a frozen tissue sample.
  • the tissue sample is the FFPE tissue sample, and the tissue sample is decrosslinked.
  • the biological sample was previously stained.
  • the biological sample was previously stained using immunofluorescence or immunohistochemistry.
  • the biological sample was previously stained using hematoxylin and eosin.
  • the method further includes contacting the biological sample with a permeabilization agent, where the permeabilization agent is selected from an organic solvent, a detergent, and an enzyme, or a combination thereof.
  • the permeabilization agent is selected from the group consisting of: an endopeptidase, a protease sodium dodecyl sulfate (SDS), polyethylene glycol tert-octylphenyl ether, polysorbate 80, and polysorbate 20, N-lauroylsarcosine sodium salt solution, saponin, Triton X-100TM, and Tween-20TM.
  • the endopeptidase is pepsin or proteinase K.
  • the method further includes, prior to step (a), fixing the biological sample.
  • the step of fixing the biological sample is performed using one or both of methanol and acetone.
  • the analyte includes RNA.
  • the RNA is an mRNA.
  • the determining step includes amplifying all or part of the ligation product specifically bound to the capture domain.
  • an amplifying product includes (i) all or part of sequence of the ligation product specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof.
  • the determining step includes sequencing.
  • the sequencing step includes in situ sequencing, Sanger sequencing methods, next-generation sequencing methods, and nanopore sequencing.
  • this disclosure features a kit including: (a) a substrate including a plurality of capture probes including a spatial barcode and a capture domain; (b) a system including: a plurality of first probes and second probes, where a first probe and a second probe each includes sequences that are substantially complementary to an analyte, and where the second probe includes a capture binding domain; and (c) instructions for performing the method of any one of the preceding claims.
  • this disclosure features a kit including: (a) an array including a plurality of capture probes; (b) a plurality of probes including a first probe and a second, where the first probe and the second probe are substantially complementary to adjacent sequences of an analyte, where the second probe includes (i) a capture probe capture domain that is capable of binding to a capture domain of the capture probe and (ii) a linker sequence; (c) a plurality of enzymes including a ribonuclease and a ligase; and (d) instructions for performing the method of any one of the preceding claims.
  • this disclosure features a kit including: (a) an array including a plurality of capture probes; (b) a plurality of probes including a first probe and a second probe, where the first probe and the second probe are substantially complementary to adjacent sequences of an analyte, where the first probe includes a linker sequence, where the second probe includes a capture probe capture domain that is capable of binding to a capture domain of the capture probe; (c) a plurality of enzymes including a ribonuclease and a ligase; and (d) instructions for performing the method of any one of the preceding claims.
  • the kit includes a second probe including a preadenylated phosphate group at its 5′ end, and a ligase that does not require adenosine triphosphate for ligase activity.
  • this disclosure features a composition including a spatial array including capture probes, where the capture probes include a spatial barcode and a capture domain, a biological sample on the spatial array where the biological sample includes a plurality of analytes of interest, a first probe oligonucleotide and a second probe oligonucleotide hybridized to an analyte and ligated together, where the first probe oligonucleotide and the second probe oligonucleotide each include a sequence that is substantially complementary to adjacent sequences of the analyte and where one of the first probe or the second probe includes a capture probe capture domain.
  • the composition further includes an RNase H enzyme. In some embodiments, the composition further includes a ligase. In some embodiments, the probe oligonucleotide that does not include a capture probe capture domain includes a functional domain.
  • each when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection, unless expressly stated otherwise, or unless the context of the usage clearly indicates otherwise.
  • a cell includes one or more cells, comprising mixtures thereof.
  • a and/or B is used herein to include all of the following alternatives: “A”, “B”, “A or B”, and “A and B”.
  • FIG. 1 shows an exemplary spatial analysis workflow.
  • FIG. 2 is a schematic diagram showing an example of a barcoded capture probe, as described herein.
  • FIG. 3 is a schematic illustrating a cleavable capture probe, wherein the cleaved capture probe can enter into a non-permeabilized cell and bind to target analytes within the sample.
  • FIG. 4 is a schematic diagram of an exemplary multiplexed spatially-barcoded feature.
  • FIG. 5 is a schematic showing the exemplary arrangement of barcoded features within an array.
  • FIG. 6 is a schematic diagram showing an exemplary workflow for RNA-templated ligation.
  • FIG. 7 is a schematic diagram showing an exemplary workflow for capturing a ligation product on a substrate that includes capture probes.
  • FIG. 8 is a schematic diagram showing an example of a first probe that includes a linker sequence and a second probe.
  • FIG. 9 is a schematic diagram showing an example of a second probe that includes a linker sequence and a first probe.
  • FIG. 10 is a schematic diagram showing an example of a first probe, a second probe, and a spanning probe.
  • FIG. 11 is a schematic diagram showing an example of an RNA-templated ligation using a first probe oligonucleotide, a second probe oligonucleotide, and a third probe oligonucleotide.
  • FIGS. 12A-12E show various approaches for chemically-mediated nucleic acid ligation.
  • FIG. 12A illustrates formation of a triazole bond.
  • FIG. 12B illustrates formation of a phosphorothioate bond.
  • FIG. 12C illustrates formation of an amide bond.
  • FIG. 12D illustrates a formation of phosphoramidate bond.
  • FIG. 12E illustrates a conjugation reaction.
  • FIG. 13 shows an exemplary RNA-templated ligation workflow.
  • FIG. 14 show enrichment PCR results for detection of various probes.
  • (1) represents band for ligation product with capture probe.
  • (2), (3) and (4) represent non-ligation products.
  • FIG. 15 shows fraction of reads for various combination of conditions and probes.
  • FIGS. 16A-16B show matrices of specific probe combinations.
  • FIGS. 17A-17C show gene expression patterns in mouse brain tissue using total probe oligonucleotide counts ( FIG. 17A ), nonspecific probe oligonucleotide counts ( FIG. 17B ), and gene-specific probe oligonucleotide counts ( FIG. 17C ).
  • FIGS. 18A-18E show target genes with spatial expression in mouse brain tissue.
  • FIGS. 19A-19F show gene expression patterns in mouse brain tissue using total probe oligonucleotide counts ( FIG. 19A ) and gene-specific probe oligonucleotide ( FIGS. 19B-19F ).
  • FIG. 20A shows median unique molecular identifiers (UMIs) per cell versus mean reads per cell for different hybridization conditions.
  • UMIs median unique molecular identifiers
  • FIG. 20B shows median genes per cell versus mean reads per cell for different hybridization conditions.
  • FIG. 21A shows hematoxylin staining for a section of a triple positive breast cancer tissue sample.
  • FIG. 21B shows median UMI per cell count versus mean read per cell for the different conditions.
  • FIG. 21C shows t-SNE projection of spots in eight different clusters.
  • FIG. 21E shows expression of estrogen receptor (ESR1).
  • FIG. 21F shows expression of estrogen receptor progesterone receptor (PGR).
  • FIG. 21G shows expression of ERBB2, also known as HER2.
  • FIG. 22A shows a hematoxylin stain for a section of Ovarian Cancer sample.
  • FIG. 22B shows median UMI per cell versus mean read per cell for the different conditions.
  • FIG. 22D shows t-SNE projection of spots in eight different clusters.
  • FIG. 23 shows median UMIs per cell versus reads per cell for different decrosslinking conditions.
  • FIG. 24 shows median UMIs per cell versus reads per cell (top panel) and median genes per cell versus reads per cell (bottom panel) for different treatment conditions (RNase).
  • FIG. 25 shows median UMIs per cell versus reads per cell (top panel) and median genes per cell versus reads per cell (bottom panel) for different treatment conditions (time and temperature).
  • Targeted RNA capture is an attractive alternative to poly(A) mRNA capture in order to interrogate spatial gene expression in FFPE tissue. Compared to poly(A) mRNA capture, targeted RNA capture is less affected by RNA degradation associated with FFPE fixation than methods dependent on oligo-dT capture and reverse transcription of mRNA; allows for sensitive measurement of specific genes of interest that otherwise might be missed with a whole transcriptomic approach; and is scalable, with demonstrated probes targeting a large fraction of the transcriptome.
  • Spatial analysis methodologies and compositions described herein can provide a vast amount of analyte and/or expression data for a variety of analytes within a biological sample at high spatial resolution, while retaining native spatial context.
  • Spatial analysis methods and compositions can include, e.g., the use of a capture probe including a spatial barcode (e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample (e.g., mammalian cell or a mammalian tissue sample) and a capture domain that is capable of binding to an analyte (e.g., a protein and/or a nucleic acid) produced by and/or present in a cell.
  • a spatial barcode e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample
  • a capture domain that is capable of binding to an analyte (
  • Spatial analysis methods and compositions can also include the use of a capture probe having a capture domain that captures an intermediate agent for indirect detection of an analyte.
  • the intermediate agent can include a nucleic acid sequence (e.g., a barcode) associated with the intermediate agent. Detection of the intermediate agent is therefore indicative of the analyte in the cell or tissue sample.
  • a “barcode” is a label, or identifier, that conveys or is capable of conveying information (e.g., information about an analyte in a sample, a bead, and/or a capture probe).
  • a barcode can be part of an analyte, or independent of an analyte.
  • a barcode can be attached to an analyte.
  • a particular barcode can be unique relative to other barcodes.
  • an “analyte” can include any biological substance, structure, moiety, or component to be analyzed.
  • target can similarly refer to an analyte of interest.
  • Analytes can be broadly classified into one of two groups: nucleic acid analytes, and non-nucleic acid analytes.
  • non-nucleic acid analytes include, but are not limited to, lipids, carbohydrates, peptides, proteins, glycoproteins (N-linked or O-linked), lipoproteins, phosphoproteins, specific phosphorylated or acetylated variants of proteins, amidation variants of proteins, hydroxylation variants of proteins, methylation variants of proteins, ubiquitylation variants of proteins, sulfation variants of proteins, viral proteins (e.g., viral capsid, viral envelope, viral coat, viral accessory, viral glycoproteins, viral spike, etc.), extracellular and intracellular proteins, antibodies, and antigen binding fragments.
  • viral proteins e.g., viral capsid, viral envelope, viral coat, viral accessory, viral glycoproteins, viral spike, etc.
  • the analyte(s) can be localized to subcellular location(s), including, for example, organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc.
  • organelles e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc.
  • analyte(s) can be peptides or proteins, including without limitation antibodies and enzymes. Additional examples of analytes can be found in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • an analyte can be detected indirectly, such as through detection of an intermediate agent, for example, a ligation product or an analyte capture agent (e.g., an oligonucleotide-conjugated antibody), such as those described herein.
  • an intermediate agent for example, a ligation product or an analyte capture agent (e.g., an oligonucleotide-conjugated antibody), such as those described herein.
  • a “biological sample” is typically obtained from the subject for analysis using any of a variety of techniques including, but not limited to, biopsy, surgery, and laser capture microscopy (LCM), and generally includes cells and/or other biological material from the subject.
  • a biological sample can be a tissue section.
  • a biological sample can be a fixed and/or stained biological sample (e.g., a fixed and/or stained tissue section).
  • stains include histological stains (e.g., hematoxylin and/or eosin) and immunological stains (e.g., fluorescent stains).
  • a biological sample e.g., a fixed and/or stained biological sample
  • Biological samples are also described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • a biological sample is permeabilized with one or more permeabilization reagents.
  • permeabilization of a biological sample can facilitate analyte capture.
  • Exemplary permeabilization agents and conditions are described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Array-based spatial analysis methods involve the transfer of one or more analytes from a biological sample to an array of features on a substrate, where each feature is associated with a unique spatial location on the array. Subsequent analysis of the transferred analytes includes determining the identity of the analytes and the spatial location of the analytes within the biological sample. The spatial location of an analyte within the biological sample is determined based on the feature to which the analyte is bound (e.g., directly or indirectly) on the array, and the feature's relative spatial location within the array.
  • a “capture probe” refers to any molecule capable of capturing (directly or indirectly) and/or labelling an analyte (e.g., an analyte of interest) in a biological sample.
  • the capture probe is a nucleic acid or a polypeptide.
  • the capture probe includes a barcode (e.g., a spatial barcode and/or a unique molecular identifier (UMI)) and a capture domain).
  • UMI unique molecular identifier
  • a capture probe can include a cleavage domain and/or a functional domain (e.g., a primer-binding site, such as for next-generation sequencing (NGS)).
  • NGS next-generation sequencing
  • more than one analyte type e.g., nucleic acids and proteins
  • a biological sample can be detected (e.g., simultaneously or sequentially) using any appropriate multiplexing technique, such as those described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • an analyte capture agent refers to an agent that interacts with an analyte (e.g., an analyte in a biological sample) and with a capture probe (e.g., a capture probe attached to a substrate or a feature) to identify the analyte.
  • the analyte capture agent includes: (i) an analyte binding moiety (e.g., that binds to an analyte), for example, an antibody or antigen-binding fragment thereof; (ii) analyte binding moiety barcode; and (iii) an analyte capture sequence.
  • an analyte binding moiety barcode refers to a barcode that is associated with or otherwise identifies the analyte binding moiety.
  • analyte capture sequence refers to a region or moiety configured to hybridize to, bind to, couple to, or otherwise interact with a capture domain of a capture probe.
  • an analyte binding moiety barcode (or portion thereof) may be able to be removed (e.g., cleaved) from the analyte capture agent. Additional description of analyte capture agents can be found in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • One method is to promote analytes or analyte proxies (e.g., intermediate agents) out of a cell and towards a spatially-barcoded array (e.g., including spatially-barcoded capture probes).
  • a spatially-barcoded array e.g., including spatially-barcoded capture probes.
  • the spatially-barcoded array populated with capture probes is contacted with a biological sample, and the biological sample is permeabilized, allowing the analyte to migrate away from the sample and toward the array.
  • the analyte interacts with a capture probe on the spatially-barcoded array.
  • Another method is to cleave spatially-barcoded capture probes from an array and promote the spatially-barcoded capture probes towards and/or into or onto the biological sample.
  • the spatially-barcoded array populated with capture probes can be contacted with a sample.
  • the spatially-barcoded capture probes are cleaved and then interact with cells within the provided biological sample.
  • the interaction can be a covalent or non-covalent cell-surface interaction.
  • the interaction can be an intracellular interaction facilitated by a delivery system or a cell penetration peptide.
  • the sample can be optionally removed for analysis.
  • the sample can be optionally dissociated before analysis.
  • the capture probes can be analyzed to obtain spatially-resolved information about the tagged cell.
  • sample preparation may include placing the sample on a slide, fixing the sample, and/or staining the biological sample for imaging.
  • the stained sample can be then imaged on the array using both brightfield (to image the sample hematoxylin and eosin stain) and/or fluorescence (to image features) modalities.
  • the sample can be destained prior to permeabilization.
  • analytes are then released from the sample and capture probes forming the spatially-barcoded array hybridize or bind the released analytes.
  • the sample is then removed from the array and the capture probes cleaved from the array.
  • the biological sample and array are then optionally imaged a second time in one or both modalities while the analytes are reverse transcribed into cDNA, and an amplicon library is prepared and sequenced. Images are then spatially-overlaid in order to correlate spatially-identified biological sample information.
  • a spot coordinate file is supplied instead. The spot coordinate file replaces the second imaging step.
  • amplicon library preparation can be performed with a unique PCR adapter and sequenced.
  • a spatially-barcoded array on a substrate where spatially-barcoded capture probes are clustered at areas called features.
  • the spatially-barcoded capture probes can include a cleavage domain, one or more functional domains, a spatial barcode, a unique molecular identifier, and a capture domain.
  • the spatially-barcoded capture probes can also include a 5′ end modification for reversible attachment to the substrate.
  • the spatially-barcoded array is contacted with a biological sample, and the sample is permeabilized through application of permeabilization reagents. Permeabilization reagents may be administered by placing the array/sample assembly within a bulk solution.
  • permeabilization reagents may be administered to the sample via a diffusion-resistant medium and/or a physical barrier such as a lid, wherein the sample is sandwiched between the diffusion-resistant medium and/or barrier and the array-containing substrate.
  • the analytes are migrated toward the spatially-barcoded capture array using any number of techniques disclosed herein.
  • analyte migration can occur using a diffusion-resistant medium lid and passive migration.
  • analyte migration can be active migration, using an electrophoretic transfer system, for example.
  • the capture probes can hybridize or otherwise bind a target analyte.
  • the biological sample can be optionally removed from the array.
  • the capture probes can be optionally cleaved from the array, and the captured analytes can be spatially-barcoded by performing a reverse transcriptase first strand cDNA reaction.
  • a first strand cDNA reaction can be optionally performed using template switching oligonucleotides.
  • a template switching oligonucleotide can hybridize to a poly(C) tail added to a 3′ end of the cDNA by a reverse transcriptase enzyme in a template independent manner.
  • the original mRNA template and template switching oligonucleotide can then be denatured from the cDNA and the spatially-barcoded capture probe can then hybridize with the cDNA and a complement of the cDNA can be generated.
  • the first strand cDNA can then be purified and collected for downstream amplification steps.
  • the first strand cDNA can be amplified using PCR, where the forward and reverse primers flank the spatial barcode and analyte regions of interest, generating a library associated with a particular spatial barcode.
  • the library preparation can be quantitated and/or quality controlled to verify the success of the library preparation steps.
  • the cDNA comprises a sequencing by synthesis (SBS) primer sequence.
  • the library amplicons are sequenced and analyzed to decode spatial information.
  • capture probes may be configured to prime, replicate, and consequently yield optionally barcoded extension products from a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a ligation product or an analyte capture agent), or a portion thereof), or derivatives thereof (see, e.g., WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663 regarding extended capture probes).
  • a template e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a ligation product or an analyte capture agent), or a portion thereof), or derivatives thereof (see, e.g., WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663 regarding extended capture probes).
  • capture probes may be configured to form ligation products with a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof), thereby creating ligations products that serve as proxies for a template.
  • a template e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof
  • a “capture probe” refers to any molecule capable of capturing (directly or indirectly) and/or labelling an analyte (e.g., an analyte of interest) in a biological sample.
  • the capture probe is a nucleic acid or a polypeptide.
  • the capture probe includes a barcode (e.g., a spatial barcode and/or a unique molecular identifier (UMI)) and a capture domain.
  • UMI unique molecular identifier
  • the capture probe can include functional sequences that are useful for subsequent processing.
  • a capture probe can be reversibly attached to a substrate via a linker.
  • the capture probe can include one or more functional sequences, which can include a sequencer specific flow cell attachment sequence, e.g., a P5 or P7 sequence, as well as functional sequence, which can include sequencing primer sequences, e.g., a R1 primer binding site, a R2 primer binding site.
  • sequence is a P7 sequence and sequence is a R2 primer binding site.
  • a capture probe can additionally include a spatial barcode and/or unique molecular identifier and a capture domain.
  • the different sequences of the capture probe need not be in the sequential manner as depicted in this example, however the capture domain should be placed in a location on the barcode wherein analyte capture and extension of the capture domain to create a copy of the analyte can occur.
  • FIG. 2 is a schematic diagram showing an example of a capture probe, as described herein.
  • the capture probe 202 is optionally coupled to a feature 201 by a cleavage domain 203 , such as a disulfide linker.
  • the capture probe can include functional sequences that are useful for subsequent processing, such as functional sequence 204 , which can include a sequencer specific flow cell attachment sequence, e.g., a P5 or P7 sequence, as well as functional sequence 205 , which can include sequencing primer sequences, e.g., a R1 primer binding site.
  • sequence 204 is a P7 sequence and sequence 205 is a R1 primer binding site.
  • a spatial barcode 206 can be included within the capture probe for use in barcoding the target analyte.
  • the functional sequences can generally be selected for compatibility with any of a variety of different sequencing systems, e.g., Ion Torrent Proton or PGM, Illumina sequencing instruments, PacBio, Oxford Nanopore, etc., and the requirements thereof.
  • functional sequences can be selected for compatibility with non-commercialized sequencing systems. Examples of such sequencing systems and techniques, for which suitable functional sequences can be used, include (but are not limited to) Ion Torrent Proton or PGM sequencing, Illumina sequencing, PacBio SMRT sequencing, and Oxford Nanopore sequencing. Further, in some embodiments, functional sequences can be selected for compatibility with other sequencing systems.
  • the spatial barcode 206 can be common to all of the probes attached to a given feature.
  • the spatial barcode can also include a capture domain 207 to facilitate capture of a target analyte.
  • FIG. 3 is a schematic illustrating a cleavable capture probe that includes a cell-penetrating peptide, wherein the cleaved capture probe can enter into a non-permeabilized cell and bind to analytes within the sample.
  • the capture probe 301 contains a cleavage domain 302 , a cell penetrating peptide 303 , a reporter molecule 304 , and a disulfide bond (—S—S—).
  • 305 represents all other parts of a capture probe, for example a spatial barcode and a capture domain.
  • FIG. 4 is a schematic diagram of an exemplary multiplexed spatially-barcoded feature.
  • the feature 401 e.g., a bead, a location on a slide or other substrate, a well on a slide or other substrate, a partition on a slide or other substrate, etc.
  • the spatially-barcoded probes of a particular feature can possess the same spatial barcode, but have different capture domains designed to associate the spatial barcode of the feature with more than one target analyte.
  • a feature may be coupled to four different types of spatially-barcoded capture probes, each type of spatially-barcoded capture probe possessing the spatial barcode 402 .
  • One type of capture probe associated with the feature includes the spatial barcode 402 in combination with a poly(T) capture domain 403 , designed to capture mRNA target analytes.
  • a second type of capture probe associated with the feature includes the spatial barcode 402 in combination with a random N-mer capture domain 404 for gDNA analysis.
  • a third type of capture probe associated with the feature includes the spatial barcode 402 in combination with a capture domain complementary to the analyte capture agent of interest 405 .
  • a fourth type of capture probe associated with the feature includes the spatial barcode 402 in combination with a capture probe that can specifically bind a nucleic acid molecule 406 that can function in a CRISPR assay (e.g., CRISPR/Cas9). While only four different capture probe-barcoded constructs are shown in FIG. 4 , capture-probe barcoded constructs can be tailored for analyses of any given analyte associated with a nucleic acid and capable of binding with such a construct. For example, the schemes shown in FIG.
  • RNA 4 can also be used for concurrent analysis of other analytes disclosed herein, including, but not limited to: (a) mRNA, a lineage tracing construct, cell surface or intracellular proteins and metabolites, and gDNA; (b) mRNA, accessible chromatin (e.g., ATAC-seq, DNase-seq, and/or MNase-seq) cell surface or intracellular proteins and metabolites, and a perturbation agent (e.g., a CRISPR crRNA/sgRNA, TALEN, zinc finger nuclease, and/or antisense oligonucleotide as described herein); (c) mRNA, cell surface or intracellular proteins and/or metabolites, a barcoded labelling agent (e.g., the MHC multimers described herein), and a V(D)J sequence of an immune cell receptor (e.g., T-cell receptor).
  • a perturbation agent can be a small molecule, an antibody, a
  • capture probes are described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663, each of which is incorporated by reference in its entirety.
  • Generation of capture probes can be achieved by any appropriate method, including those described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663, each of which is incorporated by reference in its entirety.
  • an “extended capture probe” refers to a capture probe having additional nucleotides added to the terminus (e.g., 3′ or 5′ end) of the capture probe thereby extending the overall length of the capture probe.
  • an “extended 3′ end” indicates additional nucleotides were added to the most 3′ nucleotide of the capture probe to extend the length of the capture probe, for example, by polymerization reactions used to extend nucleic acid molecules including templated polymerization catalyzed by a polymerase (e.g., a DNA polymerase or a reverse transcriptase).
  • a polymerase e.g., a DNA polymerase or a reverse transcriptase
  • extending the capture probe includes adding to a 3′ end of a capture probe a nucleic acid sequence that is complementary to a nucleic acid sequence of an analyte or intermediate agent specifically bound to the capture domain of the capture probe.
  • the capture probe is extended using reverse transcription.
  • the capture probe is extended using one or more DNA polymerases. The extended capture probes include the sequence of the capture probe and the sequence of the spatial barcode of the capture probe.
  • extended capture probes are amplified (e.g., in bulk solution or on the array) to yield quantities that are sufficient for downstream analysis, e.g., via DNA sequencing.
  • extended capture probes e.g., DNA molecules
  • act as templates for an amplification reaction e.g., a polymerase chain reaction.
  • Analysis of captured analytes (and/or intermediate agents or portions thereof), for example, including sample removal, extension of capture probes, sequencing (e.g., of a cleaved extended capture probe and/or a cDNA molecule complementary to an extended capture probe), sequencing on the array (e.g., using, for example, in situ hybridization or in situ ligation approaches), temporal analysis, and/or proximity capture is described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Some quality control measures are described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Spatial information can provide information of biological and/or medical importance.
  • the methods and compositions described herein can allow for: identification of one or more biomarkers (e.g., diagnostic, prognostic, and/or for determination of efficacy of a treatment) of a disease or disorder; identification of a candidate drug target for treatment of a disease or disorder; identification (e.g., diagnosis) of a subject as having a disease or disorder; identification of stage and/or prognosis of a disease or disorder in a subject; identification of a subject as having an increased likelihood of developing a disease or disorder; monitoring of progression of a disease or disorder in a subject; determination of efficacy of a treatment of a disease or disorder in a subject; identification of a patient subpopulation for which a treatment is effective for a disease or disorder; modification of a treatment of a subject with a disease or disorder; selection of a subject for participation in a clinical trial; and/or selection of a treatment for a subject with a disease or disorder.
  • Spatial information can provide information of biological importance.
  • the methods and compositions described herein can allow for: identification of transcriptome and/or proteome expression profiles (e.g., in healthy and/or diseased tissue); identification of multiple analyte types in close proximity (e.g., nearest neighbor analysis); determination of up- and/or down-regulated genes and/or proteins in diseased tissue; characterization of tumor microenvironments; characterization of tumor immune responses; characterization of cells types and their co-localization in tissue; and identification of genetic variants within tissues (e.g., based on gene and/or protein expression profiles associated with specific disease or disorder biomarkers).
  • a substrate functions as a support for direct or indirect attachment of capture probes to features of the array.
  • a “feature” is an entity that acts as a support or repository for various molecular entities used in spatial analysis.
  • some or all of the features in an array are functionalized for analyte capture.
  • Exemplary substrates are described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Exemplary features and geometric attributes of an array can be found in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • FIG. 5 depicts an exemplary arrangement of barcoded features within an array. From left to right, FIG. 5 shows (left) a slide including six spatially-barcoded arrays, (center) an enlarged schematic of one of the six spatially-barcoded arrays, showing a grid of barcoded features in relation to a biological sample, and (right) an enlarged schematic of one section of an array, showing the specific identification of multiple features within the array (labelled as ID 578 , ID 579 , ID 560 , etc.).
  • analytes and/or intermediate agents can be captured when contacting a biological sample with a substrate including capture probes (e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads, wells, areas on a substrate) comprising capture probes).
  • capture probes e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads, wells, areas on a substrate) comprising capture probes.
  • contact contacted
  • contacting a biological sample with a substrate refers to any contact (e.g., direct or indirect) such that capture probes can interact (e.g., bind covalently or non-covalently (e.g., hybridize)) with analytes from the biological sample.
  • Capture can be achieved actively (e.g., using electrophoresis) or passively (e.g., using diffusion). Analyte capture is further described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • spatial analysis can be performed by attaching and/or introducing a molecule (e.g., a peptide, a lipid, or a nucleic acid molecule) having a barcode (e.g., a spatial barcode) to a biological sample (e.g., to a cell in a biological sample).
  • a plurality of molecules e.g., a plurality of nucleic acid molecules
  • a plurality of barcodes e.g., a plurality of spatial barcodes
  • a biological sample e.g., to a plurality of cells in a biological sample for use in spatial analysis.
  • the biological sample after attaching and/or introducing a molecule having a barcode to a biological sample, the biological sample can be physically separated (e.g., dissociated) into single cells or cell groups for analysis.
  • Some such methods of spatial analysis are described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • one of the oligonucleotides includes at least two ribonucleic acid bases at the 3′ end and/or the other oligonucleotide includes a phosphorylated nucleotide at the 5′ end.
  • one of the two oligonucleotides includes a capture domain (e.g., a poly(A) sequence, a non-homopolymeric sequence).
  • a ligase e.g., SplintR ligase
  • the two oligonucleotides hybridize to sequences that are not adjacent to one another.
  • hybridization of the two oligonucleotides creates a gap between the hybridized oligonucleotides.
  • a polymerase e.g., a DNA polymerase
  • the ligation product is released from the analyte.
  • the ligation product is released using an endonuclease (e.g., RNAse H).
  • sequence information for a spatial barcode associated with an analyte is obtained, and the sequence information can be used to provide information about the spatial distribution of the analyte in the biological sample.
  • Various methods can be used to obtain the spatial information.
  • specific capture probes and the analytes they capture are associated with specific locations in an array of features on a substrate.
  • specific spatial barcodes can be associated with specific array locations prior to array fabrication, and the sequences of the spatial barcodes can be stored (e.g., in a database) along with specific array location information, so that each spatial barcode uniquely maps to a particular array location.
  • specific spatial barcodes can be deposited at predetermined locations in an array of features during fabrication such that at each location, only one type of spatial barcode is present so that spatial barcodes are uniquely associated with a single feature of the array.
  • the arrays can be decoded using any of the methods described herein so that spatial barcodes are uniquely associated with array feature locations, and this mapping can be stored as described above.
  • each array feature location represents a position relative to a coordinate reference point (e.g., an array location, a fiducial marker) for the array. Accordingly, each feature location has an “address” or location in the coordinate space of the array.
  • Some exemplary spatial analysis workflows are described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See, for example, the Exemplary embodiment starting with “In some non-limiting examples of the workflows described herein, the sample can be immersed . . . ” of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See also, e.g., the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev C, dated June 2020), and/or the Visium Spatial Tissue Optimization Reagent Kits User Guide (e.g., Rev C, dated July 2020).
  • the Visium Spatial Gene Expression Reagent Kits User Guide e.g., Rev C, dated June 2020
  • the Visium Spatial Tissue Optimization Reagent Kits User Guide e.g., Rev C, dated July 2020.
  • spatial analysis can be performed using dedicated hardware and/or software, such as any of the systems described in WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663, or any of one or more of the devices or methods described in WO 2020/123320.
  • Suitable systems for performing spatial analysis can include components such as a chamber (e.g., a flow cell or sealable, fluid-tight chamber) for containing a biological sample.
  • the biological sample can be mounted for example, in a biological sample holder.
  • One or more fluid chambers can be connected to the chamber and/or the sample holder via fluid conduits, and fluids can be delivered into the chamber and/or sample holder via fluidic pumps, vacuum sources, or other devices coupled to the fluid conduits that create a pressure gradient to drive fluid flow.
  • One or more valves can also be connected to fluid conduits to regulate the flow of reagents from reservoirs to the chamber and/or sample holder.
  • the systems can optionally include a control unit that includes one or more electronic processors, an input interface, an output interface (such as a display), and a storage unit (e.g., a solid state storage medium such as, but not limited to, a magnetic, optical, or other solid state, persistent, writeable and/or re-writeable storage medium).
  • the control unit can optionally be connected to one or more remote devices via a network.
  • the control unit (and components thereof) can generally perform any of the steps and functions described herein. Where the system is connected to a remote device, the remote device (or devices) can perform any of the steps or features described herein.
  • the systems can optionally include one or more detectors (e.g., CCD, CMOS) used to capture images.
  • the systems can also optionally include one or more light sources (e.g., LED-based, diode-based, lasers) for illuminating a sample, a substrate with features, analytes from a biological sample captured on a substrate, and various control and calibration media.
  • one or more light sources e.g., LED-based, diode-based, lasers
  • the systems can optionally include software instructions encoded and/or implemented in one or more of tangible storage media and hardware components such as application specific integrated circuits.
  • the software instructions when executed by a control unit (and in particular, an electronic processor) or an integrated circuit, can cause the control unit, integrated circuit, or other component executing the software instructions to perform any of the method steps or functions described herein.
  • the systems described herein can detect (e.g., register an image) the biological sample on the array.
  • Exemplary methods to detect the biological sample on an array are described in PCT Application No. 2020/061064 and/or U.S. patent application Ser. No. 16/951,854.
  • the biological sample Prior to transferring analytes from the biological sample to the array of features on the substrate, the biological sample can be aligned with the array. Alignment of a biological sample and an array of features including capture probes can facilitate spatial analysis, which can be used to detect differences in analyte presence and/or level within different positions in the biological sample, for example, to generate a three-dimensional map of the analyte presence and/or level. Exemplary methods to generate a two- and/or three-dimensional map of the analyte presence and/or level are described in PCT Application No. 2020/053655 and spatial analysis methods are generally described in WO 2020/061108 and/or U.S. patent application Ser. No. 16/951,864.
  • a map of analyte presence and/or level can be aligned to an image of a biological sample using one or more fiducial markers, e.g., objects placed in the field of view of an imaging system which appear in the image produced, as described in WO 2020/123320, PCT Application No. 2020/061066, and/or U.S. patent application Ser. No. 16/951,843.
  • Fiducial markers can be used as a point of reference or measurement scale for alignment (e.g., to align a sample and an array, to align two substrates, to determine a location of a sample or array on a substrate relative to a fiducial marker) and/or for quantitative measurements of sizes and/or distances.
  • RNA capture e.g., a derivative of an analyte (e.g., a ligation product) provides enhanced specificity with respect to detection of an analyte. This is because at least two probes specific for a target are required to hybridize to the target in order to facilitate ligation and ultimate capture of the nucleic acid.
  • analyte e.g., a ligation product
  • the methods include 101 contacting a biological sample with array of spatially-barcoded capture probes.
  • the array is on a substrate and the array includes a plurality of capture probes, wherein a capture probe of the plurality includes: (i) a spatial barcode and (ii) a capture domain.
  • the biological sample 102 is contacted with a first probe and a second probe, wherein the first probe and the second probe each include one or more sequences that are substantially complementary to sequences of the analyte, and wherein the second probe includes a capture probe capture domain; the first probe and the second probe 103 hybridize to complementary sequences in the analyte.
  • a ligation product comprising the first probe and the second probe 104 is generated, and the ligation product is released from the analyte. The liberated ligation product is then freed 105 to hybridize to the capture domain of a probe on the array.
  • a biological sample is deparaffinized, stained, and imaged 1301 .
  • probes are added to the sample and hybridize to an analyte 1303 .
  • the probes are DNA probes.
  • the probes are diribo-containing probes.
  • Probes are ligated 1304 and then released using an endonuclease such as RNAse H 1305 .
  • Ligated probes are captured on an array by a capture probe 1306 , extended using a polymerase 1307 and denatured 1308 . After quality control cleanup 1309 , the abundance and location of an analyte is determined.
  • FIG. 6 A non-limiting example of the methods disclosed herein is depicted in FIG. 6 .
  • a biological sample is contacted with a substrate including a plurality of capture probes and contacted with (a) a first probe 601 having a target-hybridization sequence 603 and a primer sequence 602 and (b) a second probe 604 having a target-hybridization sequence 605 and a capture domain (e.g., a poly-A sequence) 606
  • the first probe 601 and a second probe 604 hybridize 610 to an analyte 607 .
  • a ligase 621 ligates 620 the first probe to the second probe thereby generating a ligation product 622 .
  • the ligation product is released 630 from the analyte 631 by digesting the analyte using an endoribonuclease 632 .
  • the sample is permeabilized 640 and the ligation product 641 is able to hybridize to a capture probe on the substrate.
  • Using a spanning probe enables greater flexibility in designing RTL probes, primarily by increasing the sequences within the analyte that can be used as optional target sequences.
  • the ligation product 701 includes a capture probe capture domain 702 , which can bind to a capture probe 703 (e.g., a capture probe immobilized, directly or indirectly, on a substrate 704 ).
  • methods provided herein include contacting 705 a biological sample with a substrate 704 , wherein the capture probe 703 is affixed to the substrate (e.g., immobilized to the substrate, directly or indirectly).
  • the capture probe capture domain 702 of the ligated product specifically binds to the capture domain 706 .
  • the capture probe can also include a unique molecular identifier (UMI) 707 , a spatial barcode 708 , a functional sequence 709 , and a cleavage domain 710 .
  • UMI unique molecular identifier
  • methods provided herein include permeabilization of the biological sample such that the capture probe can more easily bind to the captured ligated probe (i.e., compared to no permeabilization).
  • reverse transcription (RT) reagents can be added to permeabilized biological samples. Incubation with the RT reagents can extend the capture probes 711 to produce spatially-barcoded full-length cDNA 712 and 713 from the captured analytes (e.g., polyadenylated mRNA).
  • Second strand reagents e.g., second strand primers, enzymes
  • cDNA can be denatured 714 from the capture probe template and transferred (e.g., to a clean tube) for amplification, and/or library construction.
  • the spatially-barcoded, full-length cDNA can be amplified 715 via PCR prior to library construction.
  • the cDNA can then be enzymatically fragmented and size-selected in order to optimize the cDNA amplicon size.
  • P5 716 , i5 717 , i7 718 , and P7 719 and can be used as sample indexes, and TruSeq Read 2 can be added via End Repair, A-tailing, Adaptor Ligation, and PCR.
  • the cDNA fragments can then be sequenced using paired-end sequencing using TruSeq Read 1 and TruSeq Read 2 as sequencing primer sites.
  • probe pairs or sets; the terms are interchangeable.
  • the probe pairs are designed so that each probe hybridizes to a sequence in an analyte that is specific to the analyte (e.g., compared to the entire genome). That is, in some instances, a single probe pair can be specific to a single analyte.
  • probes can be designed so that one of the probes of a pair is a probe that hybridizes to a specific sequence. Then, the other probe can be designed to detect a mutation of interest. Accordingly, in some instances, multiple second probes can be designed and can vary so that each binds to a specific sequence. For example, one second probe can be designed to hybridize to a wild-type sequence, and another second probe can be designed to detect a mutated sequence. Thus, in some instances, a probe set can include one first probe and two second probes (or vice versa).
  • probes can be designed so that they cover conserved regions of an analyte.
  • a probe or probe pair can hybridize to similar analytes in a biological sample (e.g., to detect conserved or similar analytes) or in different biological samples (e.g., across different species).
  • probe sets cover all or nearly all of a genome (e.g., human genome). In instances where probe sets are designed to cover an entire genome (e.g., the human genome), the methods disclosed herein can detect analytes in an unbiased manner.
  • one probe oligonucleotide pair is designed to cover one analyte (e.g., transcript). In some instances, more than one probe oligonucleotide pair (e.g., a probe pair comprising a first probe and a second probe) is designed to cover one analyte (e.g., transcript).
  • probe oligonucleotide pair does not hybridize to the entire analyte (e.g., a transcript), but instead the probe oligonucleotide pair hybridizes to a portion of the entire analyte (e.g., transcript).
  • probe oligonucleotides pair e.g., a probe pair comprising a first probe and a second probe
  • 20,000 probe oligonucleotides pair are used in the methods described herein
  • RNA capture is targeted RNA capture.
  • Targeted RNA capture using the methods disclosed herein allows for examination of a subset of RNA analytes from the entire transcriptome.
  • the subset of analytes includes an individual target RNA.
  • the subset of analytes includes two or more targeted RNAs.
  • the subset of analytes includes one or more mRNAs transcribed by one or more targeted genes.
  • the subset of analytes includes one or more mRNA splice variants of one or more targeted genes.
  • the subset of analytes includes non-polyadenylated RNAs in a biological sample.
  • the subset of analytes includes detection of mRNAs having one or more single nucleotide polymorphisms (SNPs) in a biological sample.
  • SNPs single nucleotide polymorphisms
  • the subset of analytes includes mRNAs that mediate expression of a set of genes of interest. In some embodiments, the subset of analytes includes mRNAs that share identical or substantially similar sequences, which mRNAs are translated into polypeptides having similar functional groups or protein domains. In some embodiments, the subset of analytes includes mRNAs that do not share identical or substantially similar sequences, which mRNAs are translated into proteins that do not share similar functional groups or protein domains. In some embodiments, the subset of analytes includes mRNAs that are translated into proteins that function in the same or similar biological pathways. In some embodiments, the biological pathways are associated with a pathologic disease. For example, targeted RNA capture can detect genes that are overexpressed or underexpressed in cancer.
  • the subset of analytes includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, about 475, about 500, about 600, about 700, about 800, about 900, or about 1000 analytes.
  • the methods disclosed herein can detect the abundance and location of at least 5,000, 10,000, 15,000, 20,000, or more different analytes.
  • the subset of analytes detected by targeted RNA capture methods provided herein includes a large proportion of the transcriptome of one or more cells.
  • the subset of analytes detected by targeted RNA capture methods provided herein can include at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more of the mRNAs present in the transcriptome of one or more cells.
  • the probes are DNA probes. In some instances, the probes are diribo-containing probes.
  • probe(s) and probe set(s) are described herein.
  • the methods described herein include a first probe.
  • a “first probe” can refer to a probe that hybridizes to all or a portion of an analyte and can be ligated to one or more additional probes (e.g., a second probe or a spanning probe).
  • additional probes e.g., a second probe or a spanning probe.
  • “first probe” can be used interchangeably with “first probe oligonucleotide.”
  • the first probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the first probe includes deoxyribonucleotides.
  • the first probe includes deoxyribonucleotides and ribonucleotides.
  • the first probe includes a deoxyribonucleic acid that hybridizes to an analyte, and includes a portion of the oligonucleotide that is not a deoxyribonucleic acid.
  • the portion of the first oligonucleotide that is not a deoxyribonucleic acid is a ribonucleic acid or any other non-deoxyribonucleic acid nucleic acid as described herein.
  • the first probe includes deoxyribonucleotides
  • hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the first probe includes only deoxyribonucleotides and upon hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the method includes a first probe that includes one or more sequences that are substantially complementary to one or more sequences of an analyte.
  • a first probe includes a sequence that is substantially complementary to a first target sequence in the analyte.
  • the sequence of the first probe that is substantially complementary to the first target sequence in the analyte is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the first target sequence in the analyte.
  • a first probe includes a sequence that is about 10 nucleotides to about 100 nucleotides (e.g., a sequence of about 10 nucleotides to about 90 nucleotides, about 10 nucleotides to about 80 nucleotides, about 10 nucleotides to about 70 nucleotides, about 10 nucleotides to about 60 nucleotides, about 10 nucleotides to about 50 nucleotides, about 10 nucleotides to about 40 nucleotides, about 10 nucleotides to about 30 nucleotides, about 10 nucleotides to about 20 nucleotides, about 20 nucleotides to about 100 nucleotides, about 20 nucleotides to about 90 nucleotides, about 20 nucleotides to about 80 nucleotides, about 20 nucleotides to about 70 nucleotides, about 20 nucleotides to about 60 nucleotides, about 20 nucleotides
  • a sequence of the first probe that is substantially complementary to a sequence in the analyte includes a sequence that is about 5 nucleotides to about 50 nucleotides (e.g., about 5 nucleotides to about 45 nucleotides, about 5 nucleotides to about 40 nucleotides, about 5 nucleotides to about 35 nucleotides, about 5 nucleotides to about 30 nucleotides, about 5 nucleotides to about 25 nucleotides, about 5 nucleotides to about 20 nucleotides, about 5 nucleotides to about 15 nucleotides, about 5 nucleotides to about 10 nucleotides, about 10 nucleotides to about 50 nucleotides, about 10 nucleotides to about 45 nucleotides, about 10 nucleotides to about 40 nucleotides, about 10 nucleotides to about 35 nucleotides, about 10 nucleotides to about
  • a first probe includes a functional sequence.
  • a functional sequence includes a primer sequence.
  • a first probe includes at least two ribonucleic acid bases at the 3′ end.
  • a second probe oligonucleotide comprises a phosphorylated nucleotide at the 5′ end.
  • a first probe includes at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten ribonucleic acid bases at the 3′ end.
  • a non-limiting example of a first probe 601 which can be referred to as an LHS probe, includes a functional sequence 602 , a sequence 603 that is substantially complementary to a first target sequence in the analyte 607 , and two ribonucleic acid bases at the 3′ end.
  • a first probe includes an auxiliary sequence that does not hybridize to an analyte.
  • the auxiliary sequence can be used to hybridize to additional probes.
  • the methods described herein include a second probe.
  • a “second probe” can refer to a probe that hybridizes to all or a portion of an analyte and can be ligated to one or more additional probes (e.g., a first probe or a spanning probe).
  • “second probe” can be used interchangeably with “second probe oligonucleotide.”
  • the second probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions. In some embodiments, the second probe includes deoxyribonucleotides. In some embodiments, the second probe includes deoxyribonucleotides and ribonucleotides. In some embodiments, the second probe includes a deoxyribonucleic acid that hybridizes to an analyte and includes a portion of the oligonucleotide that is not a deoxyribonucleic acid.
  • the portion of the second probe that is not a deoxyribonucleic acid is a ribonucleic acid or any other non-deoxyribonucleic acid nucleic acid as described herein.
  • the second probe includes deoxyribonucleotides
  • hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the second probe includes only deoxyribonucleotides and upon hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the method includes a second probe that includes one or more sequences that are substantially complementary to one or more sequences of an analyte.
  • a second probe includes a sequence that is substantially complementary to a second target sequence in the analyte.
  • the sequence of the second probe that is substantially complementary to the second target sequence in the analyte is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the second target sequence in the analyte.
  • a second probe includes a sequence that is about 10 nucleotides to about 100 nucleotides (e.g., a sequence of about 10 nucleotides to about 90 nucleotides, about 10 nucleotides to about 80 nucleotides, about 10 nucleotides to about 70 nucleotides, about 10 nucleotides to about 60 nucleotides, about 10 nucleotides to about 50 nucleotides, about 10 nucleotides to about 40 nucleotides, about 10 nucleotides to about 30 nucleotides, about 10 nucleotides to about 20 nucleotides, about 20 nucleotides to about 100 nucleotides, about 20 nucleotides to about 90 nucleotides, about 20 nucleotides to about 80 nucleotides, about 20 nucleotides to about 70 nucleotides, about 20 nucleotides to about 60 nucleotides, about 20 nucleotides
  • a sequence of the second probe that is substantially complementary to a sequence in the analyte includes a sequence that is about 5 nucleotides to about 50 nucleotides (e.g., about 5 nucleotides to about 45 nucleotides, about 5 nucleotides to about 40 nucleotides, about 5 nucleotides to about 35 nucleotides, about 5 nucleotides to about 30 nucleotides, about 5 nucleotides to about 25 nucleotides, about 5 nucleotides to about 20 nucleotides, about 5 nucleotides to about 15 nucleotides, about 5 nucleotides to about 10 nucleotides, about 10 nucleotides to about 50 nucleotides, about 10 nucleotides to about 45 nucleotides, about 10 nucleotides to about 40 nucleotides, about 10 nucleotides to about 35 nucleotides, about 10 nucleotides to about
  • a second probe includes a capture probe capture domain sequence.
  • a “capture probe capture domain” is a sequence, domain, or moiety that can bind specifically to a capture domain of a capture probe.
  • “capture domain capture domain” can be used interchangeably with “capture probe binding domain.”
  • a second probe includes a sequence from 5′ to 3′: a sequence that is substantially complementary to a sequence in the analyte and a capture probe capture domain.
  • a capture probe capture domain includes a poly(A) sequence. In some embodiments, the capture probe capture domain includes a poly-uridine sequence, a poly-thymidine sequence, or both. In some embodiments, the capture probe capture domain includes a random sequence (e.g., a random hexamer or octamer). In some embodiments, the capture probe capture domain is complementary to a capture domain in a capture probe that detects a particular target(s) of interest. In some embodiments, a capture probe capture domain blocking moiety that interacts with the capture probe capture domain is provided. In some embodiments, a capture probe capture domain blocking moiety includes a sequence that is complementary or substantially complementary to a capture probe capture domain.
  • a capture probe capture domain blocking moiety prevents the capture probe capture domain from binding the capture probe when present. In some embodiments, a capture probe capture domain blocking moiety is removed prior to binding the capture probe capture domain (e.g., present in a ligated probe) to a capture probe. In some embodiments, a capture probe capture domain blocking moiety includes a poly-uridine sequence, a poly-thymidine sequence, or both. In some embodiments, the capture probe capture domain sequence includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions. In some embodiments, the capture probe binding domain sequence includes at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides. In some embodiments, the capture probe binding domain sequence includes at least 25, 30, or 35 nucleotides.
  • a second probe includes a phosphorylated nucleotide at the 5′ end.
  • the phosphorylated nucleotide at the 5′ end can be used in a ligation reaction to ligate the second probe to the first probe.
  • a non-limiting example of a second probe 604 which can be referred to a RHS probe, includes a sequence 605 that is substantially complementary to a second target sequence on the analyte 607 and a capture probe capture domain 606 .
  • a second probe includes an auxiliary sequence that does not hybridize to an analyte.
  • the auxiliary sequence can be used to hybridize to additional probes.
  • the methods of target RNA capture as disclosed herein include multiple probe oligonucleotides. In some embodiments, the methods include 2, 3, 4, or more probe oligonucleotides. In some embodiments, each of the probe oligonucleotides includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions. In some embodiments, each of the probe oligonucleotides includes deoxyribonucleotides. In some embodiments, each of the probe oligonucleotides includes deoxyribonucleotides and ribonucleotides.
  • the multiple probes span different target sequences, and multiple, serial ligation steps are carried out to determine the location and abundance of an analyte.
  • the methods include a first probe and multiple second probes (or vice versa) are used, with the multiple second probes hybridizing to different sequences (e.g., wild-type versus mutant sequence, different isoforms, splice variants) in order to identify the sequence of an analyte.
  • this method can be utilized to detect single mutations (e.g., point mutations, SNPs, splice variants, etc.) or can multi-nucleotide mutations (e.g., insertions, deletions, etc.).
  • a method of analyzing a sample comprising a nucleic acid molecule may comprise providing a plurality of nucleic acid molecules (e.g., RNA molecules), where each nucleic acid molecule comprises a first target region (e.g., a first target sequence) and a second target region (e.g., a second target sequence), a plurality of first probe oligonucleotides, and a plurality of second probe oligonucleotides.
  • one or more target regions of nucleic acid molecules of the plurality of nucleic acid molecules may comprise the same sequence.
  • the first and second target regions (e.g., the first and second target sequences) of a nucleic acid molecule of the plurality of nucleic acid molecules may be adjacent to one another.
  • Also provided herein are methods for identifying a location of an analyte in a biological sample where the method includes a first probe that includes a linker and a second probe.
  • a pair of probes where the first probe includes a linker sequence enables greater flexibility in designing RTL probes, primarily by increasing the sequences within the analyte that can be used as optional target sequences.
  • a “linker sequence” can refer to one or more nucleic acids sequences on a probe (e.g., a first probe, a second probe, or a spanning probe that are disposed between sequences that hybridize to an analyte, sequences that link together the analyte specific sequences of a probe).
  • a linker includes a sequence that is not substantially complementary to either the sequence of the target analyte or to the analyte specific sequences of a first probe, a second probe, or a spanning probe.
  • the linker sequence includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides, where the sequence within the linker is not substantially complementary to the target analyte or the analyte specific sequences of a first probe, a second probe, or a spanning probe.
  • the linker sequence can include a total of about 10 nucleotides to about 100 nucleotides, or any of the subranges described herein.
  • a linker sequence includes a barcode sequence that serves as a proxy for identifying the analyte.
  • the barcode sequence is a sequence that is at least 70% identical (e.g., at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or at least 99% identical) to a sequence in the analyte.
  • the barcode sequence is located 5′ to the linker sequence.
  • the barcode sequence is located 3′ to the linker sequence.
  • the barcode sequence is disposed between two linker sequences. In such cases, the two linker sequences flanking the barcode sequence can be considered to be a part of the same linker sequence.
  • the linker sequence can include ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides.
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample includes a first probe that includes a linker sequence and a second probe comprising: (a) contacting the biological sample with a substrate including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes a capture domain and a spatial barcode; (b) contacting the biological sample with a first probe and a second probe, wherein a portion of the first probe and a portion of the second probe are substantially complementary to adjacent sequences of the analyte, wherein the first probe includes: (i) a first sequence that is substantially complementary to a first target sequence of the analyte; (ii) a linker sequence; (iii) a second sequence that is substantially complementary to a second target sequence of the analyte; and wherein the second probe includes a sequence that is substantially complementary to a third target sequence of the analyte and a capture probe capture domain that is capable of binding
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample where the method includes a first probe that includes a linker and a second probe can include the components as shown FIG. 8 .
  • a first probe 801 includes a functional sequence 802 , a first sequence 803 that sequence that is substantially complementary to a first target sequence 804 of the analyte, a linker sequence 805 ; and a second sequence 806 that is substantially complementary to a second target sequence 807 of the analyte.
  • a second probe 808 includes a sequence 809 that is substantially complementary to a third target sequence 810 of the analyte and a capture probe capture domain 811 that is capable of binding to a capture domain of a capture probe.
  • first probe includes a linker sequence
  • the first probe includes a first sequence that is substantially complementary to a first target sequence of the analyte, a linker sequence, and a second sequence that is substantially complementary to second target sequence of the analyte.
  • a first probe includes from 5′ to 3′: a first sequence that is substantially complementary to a first target sequence of the analyte, a linker sequence, and a second sequence that is substantially complementary to second target sequence of the analyte.
  • a first probe includes a linker sequence
  • the first probe includes a functional sequence.
  • a first probe includes a functional sequence, a first sequence that is substantially complementary to a first target sequence of the analyte, a linker sequence, and a second sequence that is substantially complementary to second target sequence of the analyte.
  • the functional sequence includes a primer sequence.
  • a first probe includes at least two ribonucleic acid bases at the 3′ end. In some embodiments, a first probe includes at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten ribonucleic acid bases at the 3′ end.
  • the first probe includes a sequence that is about 10 nucleotides to about 300 nucleotides (e.g., a sequence of about 10 nucleotides to about 300 nucleotides, about 10 nucleotides to about 250 nucleotides, about 10 nucleotides to about 200 nucleotides, about 10 nucleotides to about 150 nucleotides, about 10 nucleotides to about 100 nucleotides, about 10 nucleotides to about 50 nucleotides, about 50 nucleotides to about 300 nucleotides, about 50 nucleotides to about 250 nucleotides, about 50 nucleotides to about 200 nucleotides, about 50 nucleotides to about 150 nucleotides, about 50 nucleotides to about 100 nucleotides, about 100 nucleotides to about 300 nucleotides, about 100 nucleotides to about 250 nucleotides, about 10 nucleotides to about 250 nucle
  • the first probe includes a first sequence that is substantially complementary to a first target sequence of the analyte.
  • the first sequence of the first probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the first target sequence in the analyte.
  • the first sequence of the first probe that is substantially complementary to a first target sequence can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • the first probe includes a linker
  • the first probe includes a second sequence that is substantially complementary to a second target sequence of the analyte.
  • the second sequence of the first probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the second target sequence in the analyte.
  • the second sequence of the first probe that is substantially complementary to a second target sequence can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • a first probe that includes a linker sequence includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the first probe that includes a linker sequence includes deoxyribonucleotides.
  • the first probe that includes a linker sequence includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the first probe that includes a linker sequence includes only deoxyribonucleotides and upon hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • a second probe includes a sequence that is substantially complementary to a third target sequence of the analyte and a capture probe capture domain that is capable of binding to a capture domain of a capture probe.
  • a first probe includes a linker
  • a second probe includes a sequence that is about 10 nucleotides to about 100 nucleotides, or any of the subranges described herein.
  • the sequence of the second probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the third target sequence in the analyte.
  • the sequence of the second probe that is substantially complementary to a third target sequence can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • a first target sequence is not adjacent to a second target sequence.
  • the first target sequence and second target sequences are located on different exons of the same mRNA molecule.
  • the first target sequence and the second target sequence are located on the same exon of the same mRNA molecule but are not adjacent.
  • the first probe and the second probe hybridize to sequences that at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more nucleotides apart.
  • a second target sequence is directly adjacent to a third target sequence.
  • the second probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the second probe includes deoxyribonucleotides.
  • the second probe includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the second probe includes only deoxyribonucleotides and upon hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • Also provided herein are methods for identifying a location of an analyte in a biological sample where the method includes a first probe and a second probe that includes a linker sequence.
  • Using a pair of probes where the second probe includes a linker sequence enables greater flexibility in designing RTL probes, primarily by increasing the sequences within the analyte that can be used as optional target sequences.
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample where the method includes a first probe and a second probe that includes a linker includes: (a) contacting the biological sample with a substrate including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes a capture domain and a spatial barcode; (b) contacting the biological sample with a first probe and a second probe, wherein a portion of the first probe and a portion of the second probe are substantially complementary to adjacent sequences of the analyte, wherein the first probe includes a sequence that is substantially complementary to a first target sequence of the analyte, wherein the second probe includes: (i) a first sequence that is substantially complementary to a second target sequence of the analyte; (ii) a linker sequence; (iii) a second sequence that is substantially complementary to a third target sequence of the analyte; and (iv) a capture probe binding domain
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample where the method includes a first probe and a second probe that includes a linker can include the components as shown FIG. 9 .
  • a first probe 901 includes a functional sequence 902 and a sequence 903 that is substantially complementary to a first target sequence 904 of the analyte.
  • a second probe 905 includes a first sequence 906 that is substantially complementary to a second target sequence 907 of the analyte, a linker sequence 908 ; and a second sequence 909 that is substantially complementary to a second target sequence 910 of the analyte, and a capture probe capture domain 911 that is capable of binding to a capture domain of a capture probe.
  • a first probe includes a sequence that is substantially complementary to a first target sequence of the analyte.
  • a first probe includes a functional sequence.
  • a first probe includes a functional sequence and a sequence that is substantially complementary to a first target sequence of the analyte.
  • the functional sequence includes a primer sequence.
  • the first probe oligonucleotide includes from 5′ to 3′: a functional sequence, and a sequence that is substantially complementary to a first target sequence.
  • a first probe includes a sequence that is about 10 nucleotides to about 100 nucleotides, or any of the subranges described herein.
  • a sequence of a first probe that is substantially complementary to a first target sequence of the analyte is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the first target sequence in the analyte.
  • the sequence that is substantially complementary to a first target sequence can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • a first probe includes at least two ribonucleic acid bases at the 3′ end. In some embodiments, a first probe includes at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten ribonucleic acid bases at the 3′ end.
  • the first probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the first probe includes deoxyribonucleotides.
  • the first probe includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the first probe includes only deoxyribonucleotides and upon hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the second probe includes (i) a first sequence that is substantially complementary to a second target sequence of the analyte; (ii) a linker sequence (e.g., any of the exemplary linker sequences described herein); (iii) a second sequence that is substantially complementary to third target sequence of the analyte; and (iv) a capture probe capture domain (e.g., any of the exemplary capture probe capture domains described herein) that is capable of binding to a capture domain of a capture probe.
  • a linker sequence e.g., any of the exemplary linker sequences described herein
  • a capture probe capture domain e.g., any of the exemplary capture probe capture domains described herein
  • the second probe includes a linker sequence
  • the second probe includes a sequence that is about 10 nucleotides to about 300 nucleotides, or any of the subranges described herein.
  • the second probe includes a first sequence that is substantially complementary to a second target sequence of the analyte.
  • the first sequence of the second probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the second target sequence in the analyte.
  • the first sequence of the second probe that is substantially complementary to a second target sequence can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • the second probe includes a second sequence that is substantially complementary to a third target sequence of the analyte.
  • the second sequence of the second probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the third target sequence in the analyte.
  • the second sequence of the second probe that is substantially complementary to a third target sequence can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • a second target sequence is not adjacent to a third target sequence in the mRNA molecule.
  • the second target sequence and third target sequence are located on different exons of the same mRNA molecule.
  • the second target sequence and the third target sequence are located on the same exon of the same mRNA molecule but are not adjacent.
  • a first target sequence is directly adjacent to a second target sequence.
  • a second probe that includes a linker sequence includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the second probe that includes a linker sequence includes deoxyribonucleotides.
  • the second probe that includes a linker sequence includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the second probe that includes a linker sequence includes only deoxyribonucleotides and upon hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • Also provided herein are methods for identifying a location of an analyte in a biological sample where the method includes a first probe that includes a linker sequence and a second probe that includes a linker sequence.
  • Using a pair of probes where the first probe and second probe each include a linker sequence enables greater flexibility in designing RTL probes, primarily by increasing the sequences within the analyte that can be used as optional target sequences.
  • Also provided herein are methods for identifying a location of an analyte in a biological sample where the method includes a first probe, a spanning probe, and a second probe.
  • a spanning probe enables greater flexibility in designing RTL probes, primarily by increasing the sequences within the analyte that can be used as optional target sequences.
  • using a spanning probe can also be used to interrogate the variants (e.g., splice variants) that span greater distances that can be interrogated using a first or second probe with a linker sequence.
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample where the method includes a first probe, a spanning probe, and a second probe, includes: (a) contacting the biological sample with a substrate including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes a capture domain and a spatial barcode; (b) contacting the biological sample with a first probe, a second probe, and one or more spanning probes, wherein the first probe is substantially complementary to a first portion of the analyte, wherein the second probe is substantially complementary to a second portion of the analyte and further includes a capture probe binding domain, and wherein the spanning probe includes: (i) a first sequence that is substantially complementary to a first target sequence of the analyte, and (ii) a second sequence that is substantially complementary to a second target sequence of the analyte; (c) hybridizing the first probe, the second probe, and the
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample where the method includes a first probe, a second probe, and a spanning probe can include the components as shown FIG. 10 .
  • a first probe 1001 includes a functional sequence 1002 , a sequence 1003 that is substantially complementary to a first portion 1004 of the analyte.
  • a spanning probe 1005 includes a first sequence 1006 that is substantially complementary to a first target sequence 1007 of the analyte, a linker sequence 1008 , and a second sequence 1009 that is substantially complementary to a second target sequence 1010 of the analyte.
  • a second probe 1011 includes a sequence 1012 that is substantially complementary to a second portion 1013 of the analyte and a capture probe capture domain 1014 .
  • a first probe includes a sequence that is substantially complementary to a first portion of the analyte.
  • a sequence of the first probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a first portion of the analyte.
  • the sequence of the first probe that is substantially complementary to a first portion of the analyte can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • the first probe includes a functional sequence.
  • the functional sequence is a primer sequence.
  • a first probe includes at least two ribonucleic acid bases at the 3′ end. In some embodiments, a first probe includes at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten ribonucleic acid bases at the 3′ end.
  • a first probe includes from 5′ to 3′: a functional sequence, a sequence that is substantially complementary to a first portion of the analyte, and two or more ribonucleic acid bases.
  • a first probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the first probe includes deoxyribonucleotides.
  • the first probe includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the first probe includes only deoxyribonucleotides and upon hybridization of the first probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the spanning probe includes a first sequence that is substantially complementary to a first target sequence of the analyte, and a second sequence that is substantially complementary to a second target sequence of the analyte.
  • the spanning probe includes a first sequence that is substantially complementary to a first target sequence of the analyte, a functional sequence, and a second sequence that is substantially complementary to a second target sequence of the analyte.
  • a spanning probe includes from 5′ to 3′: a first sequence, a functional sequence, and a second sequence.
  • the functional sequence is a linker sequence.
  • the linker sequence can include a total of about 10 nucleotides to about 100 nucleotides, or any of the subranges described herein.
  • the functional sequence includes a barcode sequence.
  • the spanning probe can include a linker and a barcode sequence.
  • linker sequences can flank the barcode, the barcode can be 5′ to a linker sequence, or the barcode can be 3′ to a linker sequence.
  • a barcode sequence is flanked by a 5′ linker sequence (e.g., any of the exemplary linker sequences described herein) and a 3′ linker sequence (e.g., any of the exemplary linker sequences described herein).
  • the spanning probe includes from 5′ to 3′: a first sequence, a 5′ linker sequence, a barcode, a 3′ linker sequence, and a second sequence.
  • the spanning probes includes a sequence that is about 10 nucleotides to about 300 nucleotides or any of the subranges described herein.
  • a first sequence of the spanning probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the first target sequence of the analyte.
  • a second sequence of the spanning probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the second target sequence of the analyte.
  • the first sequence of the spanning probe and the second sequence of the spanning probe are substantially complementary to sequences within the same exon.
  • the first target sequence of the analyte and the second target of the analyte are located within the same exon. In such cases, the first target sequence and the second target sequence are not directly adjacent.
  • the first sequence of the spanning probe and the second sequence of the spanning probe are substantially complementary to sequences within the different exons of the same gene.
  • the first target sequence of the analyte and the second target sequence of the analyte are located on different exons of the same gene.
  • the spanning probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the spanning probe includes deoxyribonucleotides.
  • the spanning probe includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the spanning probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the spanning probe includes only deoxyribonucleotides and upon hybridization of the spanning probe to the mRNA molecule results in a DNA:RNA hybrid.
  • a second probe includes a sequence that is substantially complementary to a second portion of the analyte and a capture probe capture domain (e.g., any of the exemplary capture probe capture domains described herein).
  • a sequence of the second probe is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a second portion of the analyte.
  • the sequence of the second probe that is substantially complementary to a second portion of the analyte can include a sequence that is about 5 nucleotides to about 50 nucleotides, or any of the subranges described herein.
  • the first portion of the analyte is directly adjacent to the first target sequence, and/or the second portion of the analyte is directly adjacent to the second target sequence.
  • the sequence of the first probe is ligated to the first sequence of the spanning probe
  • the sequence of the second probe is ligated to the second sequence of the spanning probe.
  • the spanning probe includes at least two ribonucleic acid based at the 3′ end
  • the first probe includes at least two ribonucleic acids at the 3′ end, or both.
  • the spanning probe includes a phosphorylated nucleotide at the 5′ end
  • the second probe includes a phosphorylated nucleotide at the 5′ end, or both.
  • a second probe includes ribonucleotides, deoxyribonucleotides, and/or synthetic nucleotides that are capable of participating in Watson-Crick type or analogous base pair interactions.
  • the second probe includes deoxyribonucleotides.
  • the second probe includes deoxyribonucleotides and ribonucleotides.
  • hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • the second probe includes only deoxyribonucleotides and upon hybridization of the second probe to the mRNA molecule results in a DNA:RNA hybrid.
  • Also provided herein are methods for identifying a location of an analyte in a biological sample where the method includes a first probe, at least two spanning probes, and a second probe.
  • Using two or more spanning probes enables greater flexibility in designing RTL probes, primarily by increasing the sequences within the analyte that can be used as optional target sequences.
  • using two or more spanning probe can also be used to interrogate the variants (e.g., splice variants) that span greater distances that can be interrogated using one spanning probe.
  • a non-limiting example of a method for identifying a location of an analyte in a biological sample where the method includes a first probe, two or more spanning probes, and a second probe, includes: (a) contacting the biological sample with a substrate including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes a capture domain and a spatial barcode; (b) contacting the biological sample with a first probe, a second probe, and two spanning probes, wherein the first probe is substantially complementary to a first portion of the analyte, wherein the second probe is substantially complementary to a second portion of the analyte and further includes a capture probe binding domain, and wherein the first spanning probe includes: (i) a first sequence that is substantially complementary to a first target sequence of the analyte, and (ii) a second sequence that is substantially complementary to a second target sequence of the analyte; and the second spanning probe includes (i) a third sequence that
  • the methods that include one or more spanning probes include at least two, at least three, at least four, at least five, or more spanning probes.
  • the one or more spanning probes includes (i) a third sequence that is substantially complementary to a third target sequence of the analyte, and (ii) a fourth sequence that is substantially complementary to a fourth target sequence of the analyte.
  • the method includes two (or more) spanning probes, the first target sequence is located in a first exon, the second target sequence is located in a second exon, and the third target sequence and the fourth target sequence are located in a third exon. In some embodiments where the method includes two (or more) spanning probes, the first target sequence is located in a first exon, the second target sequence is located in a second exon, and the third target sequence is located in a third exon, and the fourth target sequence is located in a fourth exon. In some embodiments where the method includes two (or more) spanning probes, the first target sequence and the second target sequences are located in a first exon, and the third target sequence and the fourth target sequence are located in a second exon.
  • the first target sequence and the second target sequences are located in a first exon, and the third target sequence is located in a second exon, and the fourth target sequence is located in a third exon.
  • the method includes ligating: the first probe to the spanning probe, the spanning probe to the one or more additional spanning probes, and the one or more additional spanning probes spanning oligonucleotide to the second probe, thereby creating a ligation product that includes one or more sequences that are substantially complementary to the analyte.
  • the method includes ligating: the first probe to the one or more additional spanning probes, the one or more additional spanning probes to the spanning probe, and the spanning probe to the second probe, thereby creating a ligation product that includes one or more sequences that are substantially complementary to the analyte.
  • each additional spanning probe can include a functional sequence (e.g., any of the functional sequence described herein).
  • each additional spanning probe can include a linker sequence (e.g., any of the exemplary linker sequences described herein).
  • each additional spanning probe can include a barcode sequence (e.g., any of the exemplary barcode sequences described herein) and a linker sequence (e.g., any of the linker sequences described herein).
  • a linker sequences can flank the barcode
  • the barcode can be 5′ to a linker sequence, or the barcode can be 3′ to a linker sequence.
  • a barcode sequence is flanked by a 5′ linker sequence (e.g., any of the exemplary linker sequences described herein) and a 3′ linker sequence (e.g., any of the exemplary linker sequences described herein).
  • an additional spanning probe can include from 5′ to 3′: a first sequence, a 5′ linker sequence, a barcode, a 3′ linker sequence, and a second sequence.
  • biological samples can be stained using a wide variety of stains and staining techniques.
  • the biological sample is a section on a slide (e.g., a 10 ⁇ m section).
  • the biological sample is dried after placement onto a glass slide.
  • the biological sample is dried at 42° C. In some instances, drying occurs for about 1 hour, about 2, hours, about 3 hours, or until the sections become transparent.
  • the biological sample can be dried overnight (e.g., in a desiccator at room temperature).
  • a sample can be stained using any number of biological stains, including but not limited to, acridine orange, Bismarck brown, carmine, coomassie blue, cresyl violet, DAPI, eosin, ethidium bromide, acid fuchsine, hematoxylin, Hoechst stains, iodine, methyl green, methylene blue, neutral red, Nile blue, Nile red, osmium tetroxide, propidium iodide, rhodamine, or safranin.
  • the methods disclosed herein include imaging the biological sample. In some instances, imaging the sample occurs prior to deaminating the biological sample.
  • the sample can be stained using known staining techniques, including Can-Grunwald, Giemsa, hematoxylin and eosin (H&E), Jenner's, Leishman, Masson's trichrome, Papanicolaou, Romanowsky, silver, Sudan, Wright's, and/or Periodic Acid Schiff (PAS) staining techniques.
  • PAS staining is typically performed after formalin or acetone fixation. In some instances, the stain is an H&E stain.
  • the biological sample can be stained using a detectable label (e.g., radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes) as described elsewhere herein.
  • a biological sample is stained using only one type of stain or one technique.
  • staining includes biological staining techniques such as H&E staining.
  • staining includes identifying analytes using fluorescently-conjugated antibodies.
  • a biological sample is stained using two or more different types of stains, or two or more different staining techniques.
  • a biological sample can be prepared by staining and imaging using one technique (e.g., H&E staining and brightfield imaging), followed by staining and imaging using another technique (e.g., IHC/IF staining and fluorescence microscopy) for the same biological sample.
  • one technique e.g., H&E staining and brightfield imaging
  • another technique e.g., IHC/IF staining and fluorescence microscopy
  • biological samples can be destained.
  • Methods of destaining or discoloring a biological sample are known in the art, and generally depend on the nature of the stain(s) applied to the sample.
  • H&E staining can be destained by washing the sample in HCl, or any other acid (e.g., selenic acid, sulfuric acid, hydroiodic acid, benzoic acid, carbonic acid, malic acid, phosphoric acid, oxalic acid, succinic acid, salicylic acid, tartaric acid, sulfurous acid, trichloroacetic acid, hydrobromic acid, hydrochloric acid, nitric acid, orthophosphoric acid, arsenic acid, selenous acid, chromic acid, citric acid, hydrofluoric acid, nitrous acid, isocyanic acid, formic acid, hydrogen selenide, molybdic acid, lactic acid, acetic acid, carbonic acid, hydrogen sulfide, or combinations thereof).
  • destaining can include 1, 2, 3, 4, 5, or more washes in an acid (e.g., HCl).
  • destaining can include adding HCl to a downstream solution (e.g., permeabilization solution).
  • destaining can include dissolving an enzyme used in the disclosed methods (e.g., pepsin) in an acid (e.g., HCl) solution.
  • other reagents can be added to the destaining solution to raise the pH for use in other applications. For example, SDS can be added to an acid destaining solution in order to raise the pH as compared to the acid destaining solution alone.
  • one or more immunofluorescence stains are applied to the sample via antibody coupling.
  • Such stains can be removed using techniques such as cleavage of disulfide linkages via treatment with a reducing agent and detergent washing, chaotropic salt treatment, treatment with antigen retrieval solution, and treatment with an acidic glycine buffer.
  • Methods for multiplexed staining and destaining are described, for example, in Bolognesi et al., J. Histochem. Cytochem. 2017; 65(8): 431-444, Lin et al., Nat Commun. 2015; 6:8390, Pirici et al., J. Histochem. Cytochem. 2009; 57:567-75, and Glass et al., J. Histochem. Cytochem. 2009; 57:899-905, the entire contents of each of which are incorporated herein by reference.
  • immunofluorescence or immunohistochemistry protocols can be performed as a part of, or in addition to, the exemplary spatial workflows presented herein.
  • tissue sections can be fixed according to methods described herein.
  • the biological sample can be transferred to an array (e.g., capture probe array), wherein analytes (e.g., proteins) are probed using immunofluorescence protocols.
  • analytes e.g., proteins
  • the sample can be rehydrated, blocked, and permeabilized (3 ⁇ SSC, 2% BSA, 0.1% Triton X, 1 U/ ⁇ 1 RNAse inhibitor for 10 minutes at 4° C.) before being stained with fluorescent primary antibodies (1:100 in 3 ⁇ SSC, 2% BSA, 0.1% Triton X, 1 U/ ⁇ 1 RNAse inhibitor for 30 minutes at 4° C.).
  • the biological sample can be washed, coverslipped (in glycerol+1 U/ ⁇ 1 RNAse inhibitor), imaged (e.g., using a confocal microscope or other apparatus capable of fluorescent detection), washed, and processed according to analyte capture or spatial workflows described herein.
  • a glycerol solution and a cover slip can be added to the sample.
  • the glycerol solution can include a counterstain (e.g., DAPI).
  • an antigen retrieval buffer can improve antibody capture in IF/IHC protocols.
  • An exemplary protocol for antigen retrieval can be preheating the antigen retrieval buffer (e.g., to 95° C.), immersing the biological sample in the heated antigen retrieval buffer for a predetermined time, and then removing the biological sample from the antigen retrieval buffer and washing the biological sample.
  • optimizing permeabilization can be useful for identifying intracellular analytes.
  • Permeabilization optimization can include selection of permeabilization agents, concentration of permeabilization agents, and permeabilization duration. Tissue permeabilization is discussed elsewhere herein.
  • blocking an array and/or a biological sample in preparation of labeling the biological sample decreases nonspecific binding of the antibodies to the array and/or biological sample (decreases background).
  • Some embodiments provide for blocking buffers/blocking solutions that can be applied before and/or during application of the label, wherein the blocking buffer can include a blocking agent, and optionally a surfactant and/or a salt solution.
  • a blocking agent can be bovine serum albumin (BSA), serum, gelatin (e.g., fish gelatin), milk (e.g., non-fat dry milk), casein, polyethylene glycol (PEG), polyvinyl alcohol (PVA), or polyvinylpyrrolidone (PVP), biotin blocking reagent, a peroxidase blocking reagent, levamisole, Carnoy's solution, glycine, lysine, sodium borohydride, pontamine sky blue, Sudan Black, trypan blue, FITC blocking agent, and/or acetic acid.
  • the blocking buffer/blocking solution can be applied to the array and/or biological sample prior to and/or during labeling (e.g., application of fluorophore-conjugated antibodies) to the biological sample.
  • the biological sample is deparaffinized.
  • Deparaffinization can be achieved using any method known in the art.
  • the biological samples is treated with a series of washes that include xylene and various concentrations of ethanol.
  • methods of deparaffinization include treatment of xylene (e.g., three washes at 5 minutes each).
  • the methods further include treatment with ethanol (e.g., 100% ethanol, two washes 10 minutes each; 95% ethanol, two washes 10 minutes each; 70% ethanol, two washes 10 minutes each; 50% ethanol, two washes 10 minutes each).
  • the biological sample can be washed with deionized water (e.g., two washes for 5 minutes each). It is appreciated that one skilled in the art can adjust these methods to optimize deparaffinization.
  • the biological sample is decrosslinked.
  • the biological sample is decrosslinked in a solution containing TE buffer (comprising Tris and EDTA).
  • the TE buffer is basic (e.g., at a pH of about 9).
  • decrosslinking occurs at about 50° C. to about 80° C.
  • decrosslinking occurs at about 70° C.
  • decrosslinking occurs for about 1 hour at 70° C.
  • the biological sample can be treated with an acid (e.g., 0.1M HCl for about 1 minute). After the decrosslinking step, the biological sample can be washed (e.g., with 1 ⁇ PBST).
  • the methods of preparing a biological sample for probe application include permeabilizing the sample.
  • the biological sample is permeabilized using a phosphate buffer.
  • the phosphate buffer is PBS (e.g., 1 ⁇ PBS).
  • the phosphate buffer is PBST (e.g., 1 ⁇ PBST).
  • the permeabilization step is performed multiple times (e.g., 3 times at 5 minutes each).
  • the methods of preparing a biological sample for probe application include steps of equilibrating and blocking the biological sample.
  • equilibrating is performed using a pre-hybridization (pre-Hyb) buffer.
  • pre-Hyb buffer is RNase-free.
  • pre-Hyb buffer contains no bovine serum albumin (BSA), solutions like Denhardt's, or other potentially nuclease-contaminated biological materials.
  • BSA bovine serum albumin
  • the equilibrating step is performed multiple times (e.g., 2 times at 5 minutes each; 3 times at 5 minutes each).
  • the biological sample is blocked with a blocking buffer.
  • the blocking buffer includes a carrier such as tRNA, for example yeast tRNA such as from brewer's yeast (e.g., at a final concentration of 10-20 ⁇ g/mL). In some instances, blocking can be performed for 5, 10, 15, 20, 25, or 30 minutes.
  • any of the foregoing steps can be optimized for performance. For example, one can vary the temperature.
  • the pre-hybridization methods are performed at room temperature. In some instances, the pre-hybridization methods are performed at 4° C. (in some instances, varying the timeframes provided herein).
  • the methods of targeted RNA capture provided herein include hybridizing a first probe oligonucleotide and a second probe oligonucleotide (e.g., a probe pair).
  • the first and second probe oligonucleotides each include sequences that are substantially complementary to one or more sequences (e.g., one or more target sequences) of an analyte of interest.
  • the first probe and the second probe bind to complementary sequences that are completely adjacent (i.e., no gap of nucleotides) to one another or are on the same transcript.
  • the methods include hybridization of probe sets, wherein the probe pairs are in a medium at a concentration of about 1 to about 100 nM.
  • the concentration of the probe pairs is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, or 500 nM.
  • the concentration of the probe pairs is 5 nM.
  • the probe sets are diluted in a hybridization (Hyb) buffer. In some instances, the probe sets are at a concentration of 5 nM in Hyb buffer.
  • probe hybridization occurs at about 50° C. In some instances, the temperature of probe hybridization ranges from about 30° C. to about 75° C., from about 35° C. to about 70° C., or from about 40° C. to about 65° C.
  • the temperature is about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., about
  • the hybridization buffer includes SSC (e.g., 1 ⁇ SSC) or SSPE. In some instances, the hybridization buffer includes formamide or ethylene carbonate. In some instances, the hybridization buffer includes one or more salts, like Mg salt for example MgCl 2 , Na salt for example NaCl, Mn salt for example MnCl 2 . In some instances, the hybridization buffer includes Denhardt's solution, dextran sulfate, ficoll, PEG or other hybridization rate accelerators. In some instances, the hybridization buffer includes a carrier such as yeast tRNA, salmon sperm DNA, and/or lambda phage DNA. In some instances, the hybridization buffer includes one or more blockers.
  • the hybridization buffer includes RNase inhibitor(s).
  • the hybridization buffer can include BSA, sequence specific blockers, non-specific blockers, EDTA, RNase inhibitor(s), betaine, TMAC, or DMSO.
  • a hybridization buffer can further include detergents such as Tween, Triton-X 100, sarkosyl, and SDS.
  • the hybridization buffer includes nuclease-free water, DEPC water.
  • the complementary sequences to which the first probe oligonucleotide and the second probe oligonucleotide bind are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 125, about 150, about 175, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, or about 1000 nucleotides away from each other.
  • Gaps between the probe oligonucleotides may first be filled prior to ligation, using, for example, Mu polymerase, DNA polymerase, RNA polymerase, reverse transcriptase, VENT polymerase, Taq polymerase, and/or any combinations, derivatives, and variants (e.g., engineered mutants) thereof.
  • nucleotides are ligated between the first and second probe oligonucleotides.
  • deoxyribonucleotides are ligated between the first and second probe oligonucleotides.
  • the biological sample is washed with a post-hybridization wash buffer.
  • the post-hybridization wash buffer includes one or more of SSC, yeast tRNA, formamide, ethylene carbonate, and nuclease-free water.
  • the method described utilizes oligonucleotides that include deoxyribonucleic acids (instead of strictly utilizing ribonucleotides) at the site of ligation. Utilizing deoxyribonucleic acids in the methods described herein create a more uniform efficiency that can be readily-controlled and flexible for various applications.
  • the methods disclosed herein include contacting a biological sample with a plurality of oligonucleotides (e.g., probes) including a first oligonucleotide (e.g., a first probe) and a second oligonucleotide (e.g., a second probe), wherein the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) are complementary to a first sequence present in an analyte and a second sequence present in the analyte, respectively; hybridizing the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) to the analyte at a first temperature; hybridizing the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.
  • FIG. 11 A non-limiting example of this method is shown in FIG. 11 .
  • a biological sample including an analyte 1101 is contacted with a first probe 1102 and a second probe 1103 .
  • the first probe 1102 and the second probe 1103 hybridize to the analyte at a first target sequence 1104 and a second target sequence 1105 , respectively.
  • the first probe and the second probe include free ends 1107 - 1110 .
  • the first and second target sequences are not directly adjacent in the analyte.
  • unbound first and second probes are washed away.
  • a third oligonucleotide 1106 hybridizes to the first and the second probes at 1108 and 1109 , respectively.
  • the first probe is extended 1112 and a ligation product is created that includes the first probe sequence and the second probe sequence.
  • the third oligonucleotide is used to “bind” the first probe and the second probe together.
  • the first probe and the second probe bound together by the third oligonucleotide can be referred to as a ligation product.
  • the ligation product then is contacted with a substrate 1111 , and the ligation product is bound to a capture probe 1113 of the substrate 1111 on the array at distinct spatial positions.
  • the biological sample is contacted with the substrate 1111 prior to being contacted with the first probe and the second probe.
  • the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) hybridize to an analyte at a first temperature.
  • the first temperature ranges from about 50° C. to about 75° C., from about 55° C. to about 70° C., or from about 60° C. to about 65° C.
  • the first temperature is about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., or about 70° C.
  • a wash step is performed to remove unbound oligonucleotides (e.g., probes).
  • the wash step can be performed using any of the wash methods and solutions described herein.
  • a third oligonucleotide e.g., a splint oligonucleotide
  • the third oligonucleotide is an oligonucleotide.
  • the third oligonucleotide is a DNA oligonucleotide.
  • the third oligonucleotide includes a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a portion of the first probe oligonucleotide (e.g., a portion of the first probe that is not hybridized to the analyte (e.g., an auxiliary sequence)).
  • a portion of the first probe oligonucleotide e.g., a portion of the first probe that is not hybridized to the analyte (e.g., an auxiliary sequence)
  • the third oligonucleotide includes a sequence that is 100% complementary to a portion of the first oligonucleotide (e.g., the first probe). In some embodiments, the third oligonucleotide includes a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a portion of the second probe oligonucleotide (e.g., a portion of the second probe that is not hybridized to the analyte (e.g., an auxiliary sequence)).
  • a portion of the second probe oligonucleotide e.g., a portion of the second probe that is not hybridized to the analyte (e.g., an auxiliary sequence)
  • the third oligonucleotide includes a sequence that is 100% complementary to a portion of the second oligonucleotide (e.g., the second probe). In some embodiments, the third oligonucleotide hybridizes to the first oligonucleotide (e.g., the first probe) at the complementary portion. In some embodiments, the third oligonucleotide hybridizes to the second oligonucleotide (e.g., the second probe) at the complementary portion.
  • the third oligonucleotide hybridizes to the first oligonucleotide (e.g., the first probe) and to the second oligonucleotide (e.g., the second probe) at a second temperature.
  • the second temperature is lower than the first temperature at which the first and second oligonucleotides (e.g., the first and second probes) bind the analyte.
  • the second temperature ranges from about 15° C. to about 35° C., from about 20° C. to about 30° C., or from about 25° C. to about 30° C.
  • the first temperature is about 15° C., about 16° C., about 17° C., about 18° C., about 19° C., about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., or about 35° C.
  • Methods including a third, or splint, oligonucleotide have been described in U.S. Patent Pub. No. 2019/0055594A1, which is herein incorporated by reference in its entirety.
  • a wash step is performed to remove unbound third oligonucleotides.
  • the wash step can be performed using any of the wash methods and solutions described herein.
  • the first and second oligonucleotides e.g., the first and second probes
  • the third oligonucleotide is bound to (e.g., hybridized to) the first and second oligonucleotides (e.g., at portions of the first and second probes that are not bound to the analyte).
  • the first oligonucleotide e.g., the first probe
  • the second oligonucleotide e.g., the second probe
  • the third oligonucleotide are added to the biological sample at the same time.
  • the temperature is adjusted to the first temperature to allow the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) to hybridize to the analyte in the biological sample.
  • the temperature is adjusted to the second temperature to allow the third oligonucleotide to hybridize to the first oligonucleotide and the second oligonucleotide.
  • a third oligonucleotide hybridizes to a first probe and a second probe that are hybridized to targets sequences that are not directly adjacent in the analyte
  • the third oligonucleotide is extended to fill the gap between the first probe and the second probe.
  • a polymerase e.g., a DNA polymerase
  • the first probe 1102 is extended 1112 to fill the gap 1114 between the first probe 1102 and the second probe 1103 .
  • a ligation step is performed. Ligation can be performed using any of the methods described herein.
  • the step includes ligation of the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe), forming a ligation product.
  • the third oligonucleotide serves as an oligonucleotide splint to facilitate ligation of the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe).
  • ligation is chemical ligation.
  • ligation is enzymatic ligation.
  • the ligase is a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • a first probe and a second probe are hybridized to the analyte in a hybridization buffer.
  • the hybridization buffer contains formamide.
  • the hybridization buffer is formamide free.
  • Formamide is not human friendly and it is a known health hazard. Chemically, it can oxidize over time, thereby impacting reagent shelf life and, most importantly, reagent efficacy.
  • the methods described herein can include formamide-free buffers, including formamide-free hybridization buffer.
  • the formamide-free hybridization buffer is a saline-sodium citrate (SSC) hybridization buffer.
  • the SSC is present in the SSC hybridization buffer from about 1 ⁇ SSC to about 6 ⁇ SSC (e.g., about 1 ⁇ SSC to about 5 ⁇ SSC, about 1 ⁇ SSC to about 4 ⁇ SSC, about 1 ⁇ SSC to about 3 ⁇ SSC, about 1 ⁇ SSC to about 2 ⁇ SSC, about 2 ⁇ SSC to about 6 ⁇ SSC, about 2 ⁇ SSC to about 5 ⁇ SSC, about 2 ⁇ SSC to about 4 ⁇ SSC, about 2 ⁇ SSC to about 3 ⁇ SSC, about 3 ⁇ SSC to about 5 ⁇ SSC, about 3 ⁇ SSC to about 4 ⁇ SSC, about 4 ⁇ SSC to about 6 ⁇ SSC, about 4 ⁇ SSC to about 6 ⁇ SSC, about 4 ⁇ SSC to about 5 ⁇ SSC, or about 5 ⁇ SSC to about 6 ⁇ SSC).
  • the SSC is present in the SSC hybridization buffer from about 1 ⁇ SSC to about 6 ⁇
  • the SSC hybridization buffer comprises a solvent.
  • the solvent comprises ethylene carbonate instead of formamide (2020, Kalinka et al., Scientia Agricola 78(4):e20190315).
  • ethylene carbonate is present in the SSC hybridization buffer from about 10% (w/v) to about 25% (w/v) (e.g., about 10% (w/v) to about 20% (w/v), about 10% (w/v) to about 15% (w/v), about 15% (w/v) to about 25% (w/v), about 15% (w/v) to about 20% (w/v), or about 20% (w/v) to about 25% (w/v)).
  • ethylene carbonate is present in the SSC hybridization buffer from about 15% (w/v) to about 20% (w/v). In some embodiments, ethylene carbonate is present in the SSC hybridization buffer at about 10% (w/v), about 11% (w/v), about 12% (w/v), about 13% (w/v), about 14% (w/v), about 15% (w/v), about 16% (w/v), about 17% (w/v), about 18% (w/v), about 19% (w/v), about 20% (w/v), about 21% (w/v), about 22% (w/v), about 23% (w/v), about 24% (w/v), or about 25% (w/v). In some embodiments, ethylene carbonate is present in the SSC hybridization buffer at about 13% (w/v).
  • the SSC hybridization buffer is at a temperature from about 40° C. to about 60° C. (e.g., about 40° C. to about 55° C., about 40° C. to about 50° C., about 40° C. to about 45° C., about 45° C. to about 60° C., about 45° C. to about 55° C., about 45° C. to about 50° C., about 50° C. to about 60° C., about 50° C. to about 55° C., or about 55° C. to about 60° C.). In some embodiments, the SSC hybridization buffer is at temperature from about 45° C. to about 55° C., or any of the subranges described herein.
  • the SSC hybridization buffer is at a temperature of about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., or about 60° C. In some embodiments, the SSC hybridization buffer is at a temperature of about 50° C.
  • the SSC hybridization buffer further comprises one or more of a carrier, a crowder, or an additive.
  • a carrier that can be included in the hybridization buffer include: yeast tRNA, salmon sperm DNA, lambda phage DNA, glycogen, and cholesterol.
  • a molecular crowder that can be included in the hybridization buffer include: Ficoll, dextran, Denhardt's solution, and PEG.
  • additives that can be included in the hybridization buffer include: binding blockers, RNase inhibitors, Tm adjustors and adjuvants for relaxing secondary nucleic acid structures (e.g., betaine, TMAC, and DMSO).
  • a hybridization buffer can include detergents such as SDS, Tween, Triton-X 100, and sarkosyl (e.g., N-Lauroylsarcosine sodium salt).
  • detergents such as SDS, Tween, Triton-X 100, and sarkosyl (e.g., N-Lauroylsarcosine sodium salt).
  • sarkosyl e.g., N-Lauroylsarcosine sodium salt
  • the methods disclosed herein also include a wash step.
  • the wash step removes any unbound probes. Wash steps could be performed between any of the steps in the methods disclosed herein.
  • a wash step can be performed after adding probes to the biological sample. As such, free/unbound probes are washed away, leaving only probes that have hybridized to an analyte.
  • multiple (i.e., at least 2, 3, 4, 5, or more) wash steps occur between the methods disclosed herein. Wash steps can be performed at times (e.g., 1, 2, 3, 4, or 5 minutes) and temperatures (e.g., room temperature; 4° C. known in the art and determined by a person of skill in the art.
  • wash steps are performed using a wash buffer.
  • the wash buffer includes SSC (e.g., 1 ⁇ SSC).
  • the wash buffer includes PBS (e.g., 1 ⁇ PBS).
  • the wash buffer includes PBST (e.g., 1 ⁇ PBST).
  • the wash buffer can also include formamide or be formamide free.
  • the one or more unhybridized first probes, one or more unhybridized second probes, or both are removed from the array.
  • the one or more unhybridized first, second, and/or spanning probes are removed from the array.
  • the one or more unhybridized first probes, one or more unhybridized second probes, or one or more third oligonucleotides, or all the above, are removed from the array.
  • a pre-hybridization buffer is used to wash the sample.
  • a phosphate buffer is used.
  • multiple wash steps are performed to remove unbound oligonucleotides.
  • removing includes washing the one or more unhybridized probes (e.g., a first probe, a second probe, a spanning probe, additional spanning probes, and a third oligonucleotide) from the array in a formamide-free wash buffer.
  • unhybridized probes e.g., a first probe, a second probe, a spanning probe, additional spanning probes, and a third oligonucleotide
  • the formamide-free wash buffer is an SSC wash buffer.
  • SSC is present in the SSC wash buffer from about 0.01 ⁇ SSC to about 1 ⁇ SSC (e.g., about 0.01 ⁇ SSC to about 0.5 ⁇ SSC, 0.01 ⁇ SSC to about 0.1 ⁇ SSC, about 0.01 ⁇ SSC to about 0.05 ⁇ SSC, about 0.05 ⁇ SSC to about 1 ⁇ SSC, about 0.05 ⁇ SSC to about 0.5 ⁇ SSC, about 0.05 ⁇ SSC to about 0.1 ⁇ SSC, about 0.1 ⁇ SSC to about 1 ⁇ SSC, about 0.1 ⁇ SSC to about 0.5 ⁇ SSC, or about 0.5 ⁇ SSC to about 1 ⁇ SSC).
  • SSC is present in the SSC wash buffer at about 0.01 ⁇ SSC, about 0.02 ⁇ SSC, about 0.03 ⁇ SSC, about 0.04 ⁇ SSC, about 0.05 ⁇ SSC, about 0.06 ⁇ SSC, about 0.07 ⁇ SSC, about 0.08 ⁇ SSC, about 0.09 ⁇ SSC, about 0.1 ⁇ SSC, about 0.2 ⁇ SSC, about 0.3 ⁇ SSC, about 0.4 ⁇ SSC, about 0.5 ⁇ SSC, about 0.6 ⁇ SSC, about 0.7 ⁇ SSC, about 0.8 ⁇ SSC, about 0.9 ⁇ SSC, or about 0.1 ⁇ SSC. In some embodiments, SSC is present in the SSC wash buffer at about 0.1 ⁇ SSC.
  • the SSC wash buffer comprises a detergent.
  • the detergent comprises sodium dodecyl sulfate (SDS).
  • SDS is present in the SSC wash buffer from about 0.01% (v/v) to about 0.5% (v/v) (e.g., about 0.01% (v/v) to about 0.4% (v/v), about 0.01% (v/v) to about 0.3% (v/v), about 0.01% (v/v) to about 0.2% (v/v), about 0.01% (v/v) to about 0.1% (v/v), about 0.05% (v/v) to about 0.5% (v/v), about 0.05% (v/v) to about 0.4% (v/v), about 0.05% (v/v) to about 0.3% (v/v), about 0.05% (v/v) to about 0.2% (v/v), about 0.05% (v/v) to about 0.1% (v/v), about 0.1% (v/v) to about 0.5% (v/v/v), about 0.1% (v/
  • the SDS is present the SSC wash buffer at about 0.01% (v/v), about 0.02% (v/v), about 0.03% (v/v), about 0.04% (v/v), about 0.05% (v/v), about 0.06% (v/v), about 0.07% (v/v), about 0.08% (v/v), about 0.09% (v/v), about 0.10% (v/v), about 0.2% (v/v), about 0.3% (v/v), about 0.4% (v/v), or about 0.5% (v/v), In some embodiments, the SDS is present in the SSC wash buffer at about 0.1% (v/v). In some embodiments, sarkosyl may be present in the SSC wash buffer.
  • the SSC wash buffer comprises a solvent.
  • the solvent comprises ethylene carbonate.
  • ethylene carbonate is present in the SSC wash buffer from about 10% (w/v) to about 25% (w/v), or any of the subranges described herein. In some embodiments, ethylene carbonate is present in the SSC wash buffer from about 15% (w/v) to about 20% (w/v). In some embodiments, ethylene carbonate is present in the SSC wash buffer at about 16% (w/v).
  • the SSC wash buffer is at a temperature from about 50° C. to about 70° C. (e.g., about 50° C. to about 65° C., about 50° C. to about 60° C., about 50° C. to about 55° C., about 55° C. to about 70° C., about 55° C. to about 65° C., about 55° C. to about 60° C., about 60° C. to about 70° C., about 60° C. to about 65° C., or about 65° C. to about 70° C.). In some embodiments, the SSC wash buffer is at a temperature from about 55° C. to about 65° C.
  • the SSC wash buffer is at a temperature about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., or about 70° C. In some embodiments, the SSC wash buffer is at a temperature of about 60° C.
  • the method includes releasing the ligation product, where releasing is performed after the array is washed to remove the one or more unhybridized first and second probes.
  • the probe e.g., a first probe, a second probe, a spanning probe, additional spanning probes, and/or a third oligonucleotide
  • the probe e.g., a first probe, a second probe, a spanning probe, additional spanning probes, and/or a third oligonucleotide
  • Ligation can be performed enzymatically or chemically, as described herein.
  • the ligation is an enzymatic ligation reaction, using a ligase (e.g., T4 RNA ligase (Rnl2), a SplintR ligase, a single stranded DNA ligase, or a T4 DNA ligase).
  • a ligase e.g., T4 RNA ligase (Rnl2), a SplintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • the probes e.g., a first probe, a second probe, a spanning probe, additional spanning probes, and/or a third oligonucleotide
  • the probes may be considered ligated.
  • a polymerase catalyzes synthesis of a complementary strand of the ligation product, creating a double-stranded ligation product.
  • the polymerase is DNA polymerase.
  • the polymerase has 5′ to 3′ polymerase activity.
  • the polymerase has 3′ to 5′ exonuclease activity for proofreading.
  • the polymerase has 5′ to 3′ polymerase activity and 3′ to 5′ exonuclease activity for proofreading.
  • the probe (e.g., a first probe, a second probe, a spanning probe, additional spanning probes, and/or a third oligonucleotide) may each comprise a reactive moiety such that, upon hybridization to the target and exposure to appropriate ligation conditions, the probe oligonucleotides may ligate to one another.
  • probe oligonucleotides that include a reactive moiety are ligated chemically.
  • a first probe capable of hybridizing to a first target region (e.g., a first target sequence or a first portion) of a nucleic acid molecule may comprise a first reactive moiety
  • a second probe oligonucleotide capable of hybridizing to a second target region (e.g., a second target sequence or a second portion) of the nucleic acid molecule may comprise a second reactive moiety.
  • the first and second probes are hybridized to the first and second target regions (e.g., first and second target sequences) of the nucleic acid molecule, the first and second reactive moieties may be adjacent to one another.
  • a reactive moiety of a probe may be selected from the non-limiting group consisting of azides, alkynes, nitrones (e.g., 1,3-nitrones), strained alkenes (e.g., trans-cycloalkenes such as cyclooctenes or oxanorbornadiene), tetrazines, tetrazoles, iodides, thioates (e.g., phorphorothioate), acids, amines, and phosphates.
  • the first reactive moiety of a first probe may comprise an azide moiety
  • a second reactive moiety of a second probe may comprise an alkyne moiety.
  • the first and second reactive moieties may react to form a linking moiety.
  • a reaction between the first and second reactive moieties may be, for example, a cycloaddition reaction such as a strain-promoted azide-alkyne cycloaddition, a copper-catalyzed azide-alkyne cycloaddition, a strain-promoted alkyne-nitrone cycloaddition, a Diels-Alder reaction, a [3+2] cycloaddition, a [4+2] cycloaddition, or a [4+1] cycloaddition; a thiol-ene reaction; a nucleophilic substation reaction; or another reaction.
  • a cycloaddition reaction such as a strain-promoted azide-alkyne cycloaddition, a copper-catalyzed azide-alkyne cycloaddition, a
  • reaction between the first and second reactive moieties may yield a triazole moiety or an isoxazoline moiety.
  • a reaction between the first and second reactive moieties may involve subjecting the reactive moieties to suitable conditions such as a suitable temperature, pH, or pressure and providing one or more reagents or catalysts for the reaction.
  • a reaction between the first and second reactive moieties may be catalyzed by a copper catalyst, a ruthenium catalyst, or a strained species such as a difluorooctyne, dibenzylcyclooctyne, or biarylazacyclooctynone.
  • Reaction between a first reactive moiety of a first probe hybridized to a first target region (e.g., a first target sequence or first portion) of the nucleic acid molecule and a second reactive moiety of a third probe oligonucleotide hybridized to a second target region (e.g., a first target sequence or a first portion) of the nucleic acid molecule may link the first probe and the second probe to provide a ligated probe.
  • the first and second probe may be considered ligated.
  • reaction of the first and second reactive moieties may comprise a chemical ligation reaction such as a copper-catalyzed 5′ azide to 3′ alkyne “click” chemistry reaction to form a triazole linkage between two probe oligonucleotides.
  • a chemical ligation reaction such as a copper-catalyzed 5′ azide to 3′ alkyne “click” chemistry reaction to form a triazole linkage between two probe oligonucleotides.
  • an iodide moiety may be chemically ligated to a phosphorothioate moiety to form a phosphorothioate bond
  • an acid may be ligated to an amine to form an amide bond
  • a phosphate and amine may be ligated to form a phosphoramidate bond.
  • FIGS. 12A-12E illustrates examples of representative reactions.
  • FIG. 12A shows a chemical ligation reaction of an alkyne moiety 1202 and an azide moiety 1204 reacting under copper-mediated cycloaddition to form a triazole linkage 1206 .
  • FIG. 12B shows a chemical ligation reaction of a phosphorothioate group 1208 with an iodide group 1210 to form a phosphorothioate linkage 1212 .
  • FIG. 12C shows a chemical ligation reaction of an acid 1214 and amine 1216 to form an amide linkage 1218 .
  • FIG. 12D shows a chemical ligation reaction of a phosphate moiety 1220 and an amine moiety 1222 to form a phosphoramidate linkage 1224 .
  • FIG. 12E shows a conjugation reaction of two species 1226 and 1228 .
  • ligation is performed in a ligation buffer.
  • the ligation buffer can include T4 RNA Ligase Buffer 2, enzyme (e.g., RNL2 ligase), and nuclease free water.
  • the ligation buffer can include Tris-HCl pH7.5, MnCl2, ATP, DTT, surrogate fluid (e.g., glycerol), enzyme (e.g., SplintR ligase), and nuclease-free water.
  • the ligation buffer includes additional reagents.
  • the ligation buffer includes adenosine triphosphate (ATP) is added during the ligation reaction.
  • ATP adenosine triphosphate
  • DNA ligase-catalyzed sealing of nicked DNA substrates is first activated through ATP hydrolysis, resulting in covalent addition of an AMP group to the enzyme. After binding to a nicked site in a DNA duplex, the ligase transfers the AMP to the phosphorylated 5′-end at the nick, forming a 5′-5′ pyrophosphate bond.
  • the ligase catalyzes an attack on this pyrophosphate bond by the OH group at the 3′-end of the nick, thereby sealing it, whereafter ligase and AMP are released. If the ligase detaches from the substrate before the 3′ attack, e.g. because of premature AMP reloading of the enzyme, then the 5′ AMP is left at the 5′-end, blocking further ligation attempts. In some instances, ATP is added at a concentration of about 10 about 100 about 1000 or about 10000 ⁇ M during the ligation reaction.
  • cofactors that aid in joining of the probe oligonucleotides are added during the ligation process.
  • the cofactors include magnesium ions (Mg 2+ ).
  • the cofactors include manganese ions (Mn 2+ ).
  • Mg 2+ is added in the form of MgCl 2 .
  • Mn 2+ is added in the form of MnCl 2 .
  • the concentration of MgCl 2 is at about 1 mM, at about 10 mM, at about 100 mM, or at about 1000 mM.
  • the concentration of MnCl 2 is at about 1 mM, at about 10 mM, at about 100 mM, or at about 1000 mM.
  • the ligation product includes a capture probe capture domain, which can bind to a capture probe (e.g., a capture probe immobilized, directly or indirectly, on a substrate).
  • methods provided herein include contacting a biological sample with a substrate, wherein the capture probe is affixed to the substrate (e.g., immobilized to the substrate, directly or indirectly).
  • the capture probe capture domain of the ligated probe specifically binds to the capture domain.
  • the biological sample is washed with a post-ligation wash buffer.
  • the post-ligation wash buffer includes one or more of SSC (e.g., 1 ⁇ SSC), ethylene carbonate or formamide, and nuclease free water.
  • the biological sample is washed at this stage at about 50° C. to about 70° C. In some instances, the biological sample is washed at about 60° C.
  • a location of a target nucleic acid in a biological sample that include: (a) contacting the biological sample with a substrate comprising a plurality of capture probes, where a capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (b) hybridizing a target nucleic acid in the biological sample with a first probe and a second probe, where the first probe comprises, from 3′ to 5′, a sequence substantially complementary to the capture domain and a sequence that is substantially complementary to a first sequence in the target nucleic acid and has a pre-adenylated phosphate group at its 5′ end; the second probe comprises a sequence substantially complementary to a second sequence in the target nucleic acid; (c) generating a ligation product by ligating a 3′ end of the second probe to the 5′ end of the first probe using a ligase that does not require adenosine triphosphate for ligase activity; (d) releasing the
  • the ligase that does not require adenosine triphosphate for ligase activity e.g., thermostable 5′ AppDNA/RNA Ligase, truncated T4 RNA Ligase 2 (trRnl2), truncated T4 RNA Ligase 2 K227Q, truncated T4 RNA Ligase 2 KQ, Chlorella Virus PBCV-1 DNA Ligase, and combinations thereof). See, e.g., Nichols et al., “RNA Ligases,” Curr. Protocol. Molec. Biol.
  • T4 RNA Ligase 2 Truncated Active Site Mutants: Improved Tools for RNA Analysis,” BMC Biotechnol. 11: 72 (2011); and Ho et al., “Bacteriophage T4 RNA Ligase 2 (gp24.1) Exemplifies a Family of RNA Ligases Found in All Phylogenetic Domains,” PNAS 99(20):12709-14 (2002), which are hereby incorporated by reference in their entirety for a description of T4 RNA Ligases and truncated T4 RNA Ligases.
  • Thermostable 5′ AppDNA/RNA Ligase is an enzyme belonging to the Ligase family that catalyzes the ligation of the 3′ end of ssRNA or ssDNA to a 5′-adenylated ssDNA or 5′-adenylated ssRNA.
  • Truncated T4 RNA Ligase 2 is an enzyme belonging to the Ligase family that catalyzes the ligation of dsRNA nicks and ssRNA to ssRNA.
  • Truncated T4 RNA Ligase 2 K227Q is an enzyme belonging to the Ligase family that catalyzes the ligation of the 3′ end of ssRNA to 5′ adenylated ssDNA and 5′ adenylated ssRNA. It has a reduction of side products as compared to truncated T4 RNA Ligase 2.
  • Truncated T4 RNA Ligase 2 KQ is an enzyme belonging to the Ligase family that catalyzes the ligation of the 3′ end of ssRNA to 5′ adenylated ssDNA and 5′ adenylated ssRNA. It is a preferred choice for ligation of ssRNA to preadenylated adapters and has a reduction of side products as compared to truncated T4 RNA Ligase 2.
  • the T4 RNA Ligase comprises a K227Q mutation. See Viollet et al., “T4 RNA Ligase 2 Truncated Active Site Mutants: Improved Tools for RNA Analysis,” BMC Biotechnol. 11, which is hereby incorporated by reference in its entirety.
  • cofactors that aid in ligation of the first and second probe are added during ligation.
  • the cofactors include magnesium ions (Mg 2+ ).
  • the cofactors include manganese ions (Mn 2+ ).
  • Mg 2+ is added in the form of MgCl 2 .
  • Mn 2+ is added in the form of MnCl 2 .
  • the concentration of MgCl 2 is at about 1 mM to about 10 mM. In some instances, the concentration of MnCl 2 is at about 1 mM to about 10 mM.
  • the ligation occurs at a pH in the range of about 6.5 to about 9.0, about 6.5 to about 8.0, or about 7.5 to about 8.0.
  • the ligation buffer includes an enzyme storage buffer.
  • the enzymes storage buffer includes glycerol.
  • the ligation buffer is supplemented with glycerol.
  • the glycerol is present in the ligation buffer at a total volume of 15% v/v.
  • the methods provided herein include a permeabilizing step.
  • permeabilization occurs using a protease.
  • the protease is an endopeptidase.
  • Endopeptidases that can be used include but are not limited to trypsin, chymotrypsin, elastase, thermolysin, pepsin, clostripan, glutamyl endopeptidase (GluC), ArgC, peptidyl-asp endopeptidase (ApsN), endopeptidase LysC and endopeptidase LysN.
  • the endopeptidase is pepsin.
  • the biological sample is permeabilized.
  • the biological sample is permeabilized contemporaneously with or prior to contacting the biological sample with a first probe and a second probe, hybridizing the first probe and the second probe to the analyte, generating a ligation product by ligating the first probe and the second probe, and releasing the ligated product from the analyte.
  • methods provided herein include permeabilization of the biological sample such that the capture probe can more easily bind to the captured ligated probe (i.e., compared to no permeabilization).
  • reverse transcription (RT) reagents can be added to permeabilized biological samples. Incubation with the RT reagents can produce spatially-barcoded full-length cDNA from the captured analytes (e.g., polyadenylated mRNA).
  • Second strand reagents e.g., second strand primers, enzymes
  • the permeabilization step includes application of a permeabilization buffer to the biological sample.
  • the permeabilization buffer includes a buffer (e.g., Tris pH 7.5), MgCl2, sarkosyl detergent (e.g., sodium lauroyl sarcosinate), enzyme (e.g., proteinase K, and nuclease free water.
  • the permeabilization step is performed at 37° C.
  • the permeabilization step is performed for about 20 minutes to 2 hours (e.g., about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 1.5 hours, or about 2 hours).
  • the releasing step is performed for about 40 minutes.
  • the ligation product is released from the analyte.
  • a ligation product is released from the analyte using an endoribonuclease.
  • the endoribonuclease is RNase H, RNase A, RNase C, or RNase I.
  • the endoribonuclease is RNase H.
  • RNase H is an endoribonuclease that specifically hydrolyzes the phosphodiester bonds of RNA, when hybridized to DNA. RNase H is part of a conserved family of ribonucleases which are present in many different organisms.
  • RNase H There are two primary classes of RNase H: RNase H1 and RNase H2. Retroviral RNase H enzymes are similar to the prokaryotic RNase H1. All of these enzymes share the characteristic that they are able to cleave the RNA component of an RNA:DNA heteroduplex.
  • the RNase H is RNase H1, RNase H2, or RNase H1, or RNase H2.
  • the RNase H includes but is not limited to RNase HII from Pyrococcus furiosus , RNase HII from Pyrococcus horikoshi , RNase HI from Thermococcus litoralis , RNase HI from Thermus thermophilus , RNAse HI from E. coli , or RNase HII from E. coli.
  • the releasing step is performed using a releasing buffer.
  • the release buffer includes one or more of a buffer (e.g., Tris pH 7.5), enzyme (e.g., RNAse H) and nuclease-free water.
  • the releasing step is performed at 37° C.
  • the releasing step is performed for about 20 minutes to 2 hours (e.g., about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 1.5 hours, or about 2 hours). In some instances, the releasing step is performed for about 30 minutes.
  • the releasing step occurs before the permeabilization step. In some instances, the releasing step occurs after the permeabilization step. In some instances, the releasing step occurs at the same time as the permeabilization step (e.g., in the same buffer).
  • a capture probe capture domain is blocked prior to adding a second probe oligonucleotide to a biological sample. This prevents the capture probe capture domain from prematurely hybridizing to the capture domain.
  • a blocking probe is used to block or modify the free 3′ end of the capture probe capture domain.
  • a blocking probe can be hybridized to the capture probe capture domain of the second probe to mask the free 3′ end of the capture probe capture domain.
  • a blocking probe can be a hairpin probe or partially double stranded probe.
  • the free 3′ end of the capture probe capture domain of the second probe can be blocked by chemical modification, e.g., addition of an azidomethyl group as a chemically reversible capping moiety such that the capture probes do not include a free 3′ end.
  • a blocking probe can be referred to as a capture probe capture domain blocking moiety.
  • the blocking probes can be reversibly removed.
  • blocking probes can be applied to block the free 3′ end of either or both the capture probe capture domain and/or the capture probes. Blocking interaction between the capture probe capture domain and the capture probe on the substrate can reduce non-specific capture to the capture probes.
  • the blocking probes can be removed from the 3′ end of the capture probe capture domain and/or the capture probe, and the ligation product can migrate to and become bound by the capture probes on the substrate.
  • the removal includes denaturing the blocking probe from capture probe capture domain and/or capture probe. In some embodiments, the removal includes removing a chemically reversible capping moiety. In some embodiments, the removal includes digesting the blocking probe with an RNase (e.g., RNase H).
  • RNase e.g., RNase H
  • the blocking probes are oligo (dT) blocking probes.
  • the oligo (dT) blocking probes can have a length of 15-30 nucleotides.
  • the oligo (dT) blocking probes can have a length of 10-50 nucleotides, e.g., 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 10-20, 10-15, 15-50, 15-45, 15-40, 15-35, 15-30, 15-25, 15-20, 20-50, 20-45, 20-40, 20-35, 20-30, 20-25, 25-50, 25-45, 25-40, 25-35, 25-30, 30-50, 30-45, 30-40, 30-35, 35-50, 35-45, 35-40, 40-50, 40-45, or 45-50 nucleotides.
  • the analyte capture agents can be blocked at different temperatures (e.g., 4° C. and 37° C.).
  • the sample is a fresh tissue.
  • the sample is a frozen sample.
  • the sample was previously frozen.
  • the sample is a formalin-fixed, paraffin embedded (FFPE) sample.
  • Subjects from which biological samples can be obtained can be healthy or asymptomatic individuals, individuals that have or are suspected of having a disease (e.g., cancer) or a pre-disposition to a disease, and/or individuals that are in need of therapy or suspected of needing therapy.
  • the biological sample can include one or more diseased cells.
  • a diseased cell can have altered metabolic properties, gene expression, protein expression, and/or morphologic features. Examples of diseases include inflammatory disorders, metabolic disorders, nervous system disorders, and cancer.
  • the biological sample includes cancer or tumor cells. Cancer cells can be derived from solid tumors, hematological malignancies, cell lines, or obtained as circulating tumor cells.
  • the biological sample is a heterogenous sample.
  • the biological sample is a heterogenous sample that includes tumor or cancer cells and/or stromal cells,
  • the cancer is breast cancer.
  • the breast cancer is triple positive breast cancer (TPBC).
  • the breast cancer is triple negative breast cancer (TNBC).
  • the cancer is colorectal cancer. In some instances, the cancer is ovarian cancer. In certain embodiments, the cancer is squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's or non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, myeloma, salivary gland carcinoma, kidney cancer, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, or a type of head or neck cancer.
  • the cancer treated is desmoplastic melanoma, inflammatory breast cancer, thymoma, rectal cancer, anal cancer, or surgically treatable or non-surgically treatable brain stem glioma.
  • the subject is a human.
  • FFPE samples generally are heavily cross-linked and fragmented, and therefore this type of sample allows for limited RNA recovery using conventional detection techniques.
  • methods of targeted RNA capture provided herein are less affected by RNA degradation associated with FFPE fixation than other methods (e.g., methods that take advantage of oligo-dT capture and reverse transcription of mRNA).
  • methods provided herein enable sensitive measurement of specific genes of interest that otherwise might be missed with a whole transcriptomic approach.
  • FFPE samples are stained (e.g., using H&E).
  • H&E histone deacetylase
  • the methods disclosed herein are compatible with H&E will allow for morphological context overlaid with transcriptomic analysis.
  • some samples may be stained with only a nuclear stain, such as staining a sample with only hematoxylin and not eosin, when location of a cell nucleus is needed.
  • a biological sample e.g. tissue section
  • methanol stained with hematoxylin and eosin
  • fixing, staining, and imaging occurs before one or more probes are hybridized to the sample.
  • a destaining step e.g., a hematoxylin and eosin destaining step
  • destaining can be performed by performing one or more (e.g., one, two, three, four, or five) washing steps (e.g., one or more (e.g., one, two, three, four, or five) washing steps performed using a buffer including HCl).
  • the images can be used to map spatial gene expression patterns back to the biological sample.
  • a permeabilization enzyme can be used to permeabilize the biological sample directly on the slide.
  • the FFPE sample is deparaffinized, permeabilized, equilibrated, and blocked before target probe oligonucleotides are added.
  • deparaffinization includes multiple washes with xylenes.
  • deparaffinization includes multiple washes with xylenes followed by removal of xylenes using multiple rounds of graded alcohol followed by washing the sample with water.
  • the water is deionized water.
  • equilibrating and blocking includes incubating the sample in a pre-Hyb buffer.
  • the pre-Hyb buffer includes yeast tRNA.
  • permeabilizing a sample includes washing the sample with a phosphate buffer.
  • the buffer is PBS.
  • the buffer is PBST.
  • a removal step can optionally be performed to remove all or a portion of the biological sample from the substrate.
  • the removal step includes enzymatic and/or chemical degradation of cells of the biological sample.
  • the removal step can include treating the biological sample with an enzyme (e.g., a proteinase, e.g., proteinase K) to remove at least a portion of the biological sample from the substrate.
  • the removal step can include ablation of the tissue (e.g., laser ablation).
  • analyte e.g., detecting the location of an analyte, e.g., a biological analyte
  • a biological sample e.g., present in a biological sample
  • the method comprising: (a) optionally staining and/or imaging a biological sample on a substrate; (b) permeabilizing (e.g., providing a solution comprising a permeabilization reagent to) the biological sample on the substrate; (c) contacting the biological sample with an array comprising a plurality of capture probes, wherein a capture probe of the plurality captures the biological analyte; and (d) analyzing the captured biological analyte, thereby spatially detecting the biological analyte; wherein the biological sample is fully or partially removed from the substrate.
  • a biological sample is not removed from the substrate.
  • the biological sample is not removed from the substrate prior to releasing a capture probe (e.g., a capture probe bound to an analyte) from the substrate.
  • a capture probe e.g., a capture probe bound to an analyte
  • such releasing comprises cleavage of the capture probe from the substrate (e.g., via a cleavage domain).
  • such releasing does not comprise releasing the capture probe from the substrate (e.g., a copy of the capture probe bound to an analyte can be made and the copy can be released from the substrate, e.g., via denaturation).
  • the biological sample is not removed from the substrate prior to analysis of an analyte bound to a capture probe after it is released from the substrate. In some embodiments, the biological sample remains on the substrate during removal of a capture probe from the substrate and/or analysis of an analyte bound to the capture probe after it is released from the substrate. In some embodiments, the biological sample remains on the substrate during removal (e.g., via denaturation) of a copy of the capture probe (e.g., complement).
  • a copy of the capture probe e.g., complement
  • analysis of an analyte bound to capture probe from the substrate can be performed without subjecting the biological sample to enzymatic and/or chemical degradation of the cells (e.g., permeabilized cells) or ablation of the tissue (e.g., laser ablation).
  • the biological sample e.g., permeabilized cells
  • ablation of the tissue e.g., laser ablation
  • At least a portion of the biological sample is not removed from the substrate.
  • a portion of the biological sample can remain on the substrate prior to releasing a capture probe (e.g., a capture prove bound to an analyte) from the substrate and/or analyzing an analyte bound to a capture probe released from the substrate.
  • at least a portion of the biological sample is not subjected to enzymatic and/or chemical degradation of the cells (e.g., permeabilized cells) or ablation of the tissue (e.g., laser ablation) prior to analysis of an analyte bound to a capture probe from the substrate.
  • analyte e.g., detecting the location of an analyte, e.g., a biological analyte
  • a biological sample e.g., present in a biological sample
  • permeabilizing e.g., providing a solution comprising a permeabilization reagent to
  • the biological sample on the substrate
  • contacting the biological sample with an array comprising a plurality of capture probes wherein a capture probe of the plurality captures the biological analyte
  • analyzing the captured biological analyte thereby spatially detecting the biological analyte; where the biological sample is not removed from the substrate.
  • methods for spatially detecting a biological analyte of interest from a biological sample that include: (a) staining and imaging a biological sample on a substrate; (b) providing a solution comprising a permeabilization reagent to the biological sample on the substrate; (c) contacting the biological sample with an array on a substrate, wherein the array comprises one or more capture probe pluralities thereby allowing the one or more pluralities of capture probes to capture the biological analyte of interest; and (d) analyzing the captured biological analyte, thereby spatially detecting the biological analyte of interest; where the biological sample is not removed from the substrate.
  • the method further includes subjecting a region of interest in the biological sample to spatial transcriptomic analysis.
  • one or more of the capture probes includes a capture domain.
  • one or more of the capture probes comprises a unique molecular identifier (UMI).
  • UMI unique molecular identifier
  • one or more of the capture probes comprises a cleavage domain.
  • the cleavage domain comprises a sequence recognized and cleaved by a uracil-DNA glycosylase, apurinic/apyrimidinic (AP) endonuclease (APE1), U uracil-specific excision reagent (USER), and/or an endonuclease VIII.
  • one or more capture probes do not comprise a cleavage domain and is not cleaved from the array.
  • a capture probe can be extended (an “extended capture probe,” e.g., as described herein).
  • extending a capture probe can include generating cDNA from a captured (hybridized) RNA. This process involves synthesis of a complementary strand of the hybridized nucleic acid, e.g., generating cDNA based on the captured RNA template (the RNA hybridized to the capture domain of the capture probe).
  • the captured (hybridized) nucleic acid e.g., RNA
  • acts as a template for the extension e.g., reverse transcription, step.
  • the capture probe is extended using reverse transcription.
  • reverse transcription includes synthesizing cDNA (complementary or copy DNA) from RNA, e.g., (messenger RNA), using a reverse transcriptase.
  • reverse transcription is performed while the tissue is still in place, generating an analyte library, where the analyte library includes the spatial barcodes from the adjacent capture probes.
  • the capture probe is extended using one or more DNA polymerases.
  • a capture domain of a capture probe includes a primer for producing the complementary strand of a nucleic acid hybridized to the capture probe, e.g., a primer for DNA polymerase and/or reverse transcription.
  • the nucleic acid, e.g., DNA and/or cDNA, molecules generated by the extension reaction incorporate the sequence of the capture probe.
  • the extension of the capture probe e.g., a DNA polymerase and/or reverse transcription reaction, can be performed using a variety of suitable enzymes and protocols.
  • a full-length DNA (e.g., cDNA) molecule is generated.
  • a “full-length” DNA molecule refers to the whole of the captured nucleic acid molecule. However, if a nucleic acid (e.g., RNA) was partially degraded in the tissue sample, then the captured nucleic acid molecules will not be the same length as the initial RNA in the tissue sample.
  • the 3′ end of the extended probes e.g., first strand cDNA molecules, is modified. For example, a linker or adaptor can be ligated to the 3′ end of the extended probes.
  • RNA ligase a single stranded ligation enzyme
  • CircligaseTM available from Lucigen, Middleton, Wis.
  • template switching oligonucleotides are used to extend cDNA in order to generate a full-length cDNA (or as close to a full-length cDNA as possible).
  • a second strand synthesis helper probe (a partially double stranded DNA molecule capable of hybridizing to the 3′ end of the extended capture probe), can be ligated to the 3′ end of the extended probe, e.g., first strand cDNA, molecule using a double stranded ligation enzyme such as T4 DNA ligase.
  • a polynucleotide tail e.g., a poly(A) tail, is incorporated at the 3′ end of the extended probe molecules. In some embodiments, the polynucleotide tail is incorporated using a terminal transferase active enzyme.
  • double-stranded extended capture probes are treated to remove any unextended capture probes prior to amplification and/or analysis, e.g., sequence analysis. This can be achieved by a variety of methods, e.g., using an enzyme to degrade the unextended probes, such as an exonuclease enzyme, or purification columns.
  • extended capture probes are amplified to yield quantities that are sufficient for analysis, e.g., via DNA sequencing.
  • the first strand of the extended capture probes e.g., DNA and/or cDNA molecules
  • acts as a template for the amplification reaction e.g., a polymerase chain reaction.
  • the amplification reaction incorporates an affinity group onto the extended capture probe (e.g., RNA-cDNA hybrid) using a primer including the affinity group.
  • the primer includes an affinity group and the extended capture probes includes the affinity group.
  • the affinity group can correspond to any of the affinity groups described previously.
  • the extended capture probes including the affinity group can be coupled to a substrate specific for the affinity group.
  • the substrate can include an antibody or antibody fragment.
  • the substrate includes avidin or streptavidin and the affinity group includes biotin.
  • the substrate includes maltose and the affinity group includes maltose-binding protein.
  • the substrate includes maltose-binding protein and the affinity group includes maltose.
  • amplifying the extended capture probes can function to release the extended probes from the surface of the substrate, insofar as copies of the extended probes are not immobilized on the substrate.
  • the extended capture probe or complement or amplicon thereof is released.
  • the step of releasing the extended capture probe or complement or amplicon thereof from the surface of the substrate can be achieved in a number of ways.
  • an extended capture probe or a complement thereof is released from the array by nucleic acid cleavage and/or by denaturation (e.g., by heating to denature a double-stranded molecule).
  • the extended capture probe or complement or amplicon thereof is released from the surface of the substrate (e.g., array) by physical means.
  • the extended capture probe is indirectly immobilized on the array substrate, e.g., via hybridization to a surface probe, it can be sufficient to disrupt the interaction between the extended capture probe and the surface probe.
  • Methods for disrupting the interaction between nucleic acid molecules include denaturing double stranded nucleic acid molecules are known in the art.
  • a straightforward method for releasing the DNA molecules i.e., of stripping the array of extended probes is to use a solution that interferes with the hydrogen bonds of the double stranded molecules.
  • the extended capture probe is released by an applying heated solution, such as water or buffer, of at least 85° C., e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99° C.
  • a solution including salts, surfactants, etc. that can further destabilize the interaction between the nucleic acid molecules is added to release the extended capture probe from the substrate.
  • the extended capture probe is released from the surface of the substrate by cleavage.
  • the cleavage domain of the extended capture probe can be cleaved by any of the methods described herein.
  • the extended capture probe is released from the surface of the substrate, e.g., via cleavage of a cleavage domain in the extended capture probe, prior to the step of amplifying the extended capture probe.
  • probes complementary to the extended capture probe can be contacted with the substrate.
  • the biological sample can be in contact with the substrate when the probes are contacted with the substrate.
  • the biological sample can be removed from the substrate prior to contacting the substrate with probes.
  • the probes can be labeled with a detectable label (e.g., any of the detectable labels described herein).
  • probes that do not specially bind (e.g., hybridize) to an extended capture probe can be washed away.
  • probes complementary to the extended capture probe can be detected on the substrate (e.g., imaging, any of the detection methods described herein).
  • probes complementary to an extended capture probe can be about 4 nucleotides to about 100 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 10 nucleotides to about 90 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 20 nucleotides to about 80 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 30 nucleotides to about 60 nucleotides long.
  • probes (e.g., detectable probes) complementary to an extended capture probe can be about 40 nucleotides to about 50 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about
  • about 1 to about 100 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • about 1 to about 10 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • about 10 to about 100 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • about 20 to about 90 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • about 30 to about 80 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • about 40 to about 70 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • about 50 to about 60 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe.
  • the probes can be complementary to a single analyte (e.g., a single gene). In some embodiments, the probes can be complementary to one or more analytes (e.g., analytes in a family of genes). In some embodiments, the probes (e.g., detectable probes) can be for a panel of genes associated with a disease (e.g., cancer, Alzheimer's disease, Parkinson's disease).
  • a disease e.g., cancer, Alzheimer's disease, Parkinson's disease.
  • the ligated probe and capture probe can be amplified or copied, creating a plurality of cDNA molecules.
  • cDNA can be denatured from the capture probe template and transferred (e.g., to a clean tube) for amplification, and/or library construction.
  • the spatially-barcoded cDNA can be amplified via PCR prior to library construction.
  • the cDNA can then be enzymatically fragmented and size-selected in order to optimize for cDNA amplicon size.
  • P5 and P7 sequences directed to capturing the amplicons on a sequencing flowcell can be appended to the amplicons, i7, and i5 can be used as sample indexes, and TruSeq Read 2 can be added via End Repair, A-tailing, Adaptor Ligation, and PCR.
  • the cDNA fragments can then be sequenced using paired-end sequencing using TruSeq Read 1 and TruSeq Read 2 as sequencing primer sites.
  • the additional sequences are directed toward Illumina sequencing instruments or sequencing instruments that utilize those sequences; however a skilled artisan will understand that additional or alternative sequences used by other sequencing instruments or technologies are also equally applicable for use in the aforementioned methods.
  • sequencing can be performed on the intact sample.
  • sequenced polynucleotides can be, for example, nucleic acid molecules such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single stranded DNA or DNA/RNA hybrids, and nucleic acid molecules with a nucleotide analog).
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • variants or derivatives thereof e.g., single stranded DNA or DNA/RNA hybrids, and nucleic acid molecules with a nucleotide analog
  • Sequencing of polynucleotides can be performed by various systems. More generally, sequencing can be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR and droplet digital PCR (ddPCR), quantitative PCR, real time PCR, multiplex PCR, PCR-based single plex methods, emulsion PCR), and/or isothermal amplification.
  • PCR polymerase chain reaction
  • ddPCR digital PCR and droplet digital PCR
  • quantitative PCR quantitative PCR
  • real time PCR real time PCR
  • multiplex PCR multiplex PCR
  • PCR-based single plex methods emulsion PCR
  • kits that include one or more reagents to detect one or more analytes described herein.
  • the kit includes a substrate comprising a plurality of capture probes comprising a spatial barcode and the capture domain.
  • the kit includes a plurality of probes (e.g., a first probe, a second probe, one or more spanning probes, and/or a third oligonucleotide).
  • a non-limiting example of a kit used to perform any of the methods described herein includes: (a) a substrate comprising a plurality of capture probes comprising a spatial barcode and a capture domain; (b) a system comprising: a plurality of first probes and second probes, wherein a first probe and a second probe each comprises sequences that are substantially complementary to an analyte, and wherein the second probe comprises a capture binding domain; and (c) instructions for performing the method of any one of the preceding claims.
  • kit used to perform any of the methods described herein includes: (a) an array comprising a plurality of capture probes; (b) a plurality of probes comprising a first probe and a second, wherein the first probe and the second probe are substantially complementary to adjacent sequences of an analyte, wherein the second probe comprises (i) a capture probe binding domain that is capable of binding to a capture domain of the capture probe and (ii) a linker sequence; (c) a plurality of enzymes comprising a ribonuclease and a ligase; and (d) instructions for performing the method of any one of the preceding claims.
  • kit used to perform any of the methods described herein includes: (a) an array comprising a plurality of capture probes; (b) a plurality of probes comprising a first probe and a second probe, wherein the first probe and the second probe are substantially complementary to adjacent sequences of an analyte, wherein the first probe includes a linker sequence, wherein the second probe comprises a capture probe binding domain that is capable of binding to a capture domain of the capture probe; (c) a plurality of enzymes comprising a ribonuclease and a ligase; and (d) instructions for performing the method of any one of the preceding claims.
  • the kit includes a second probe that includes a preadenylated phosphate group at its 5′ end and a first probe comprising at least two ribonucleic acid bases at the 3′ end.
  • RNA-templated ligation on an FFPE-fixed sample was performed as described in FIG. 13 .
  • FFPE-fixed samples were deparaffinized, stained (e.g., H&E stain), and imaged 1301 .
  • Samples were destained (e.g., using HCl) and decrosslinked 1302 .
  • samples treated with pre-hybridization buffer e.g., hybridization buffer without the first and second probes
  • probes were added to the sample, probes hybridized, and samples were washed 1303 .
  • Ligase was added to the samples to ligate hybridized probes to generate a ligation product and samples were then washed 1304 .
  • Probes were released from the analyte by contacting the biological sample with RNAse H 1305 . Samples were then permeabilized to facilitate capture of the ligation product by the capture probes on the substrate 1306 . Ligation products that hybridized to the capture probes were then extended 1307 . The extended capture probes were denatured 1308 . Denatured, extended capture probes were indexed and the amplified libraries were subjected to quality control 1309 before being sequenced.
  • FFPE sectioned mouse brain tissue slides were deparaffinized, permeabilized with PBST, and equilibrated with a pre-Hyb buffer twice for 5 minutes each. Decrosslinking the sample was performed using either a TE decrosslinking reagent or a PBS-tween decrosslinking reagent.
  • TE decrosslinking 100 ⁇ l of TE buffer (pH 9.0) (Genemed 10-0046) was added per sample. Samples treated with TE were subjected to a thermal cycler protocol according to Table 1.
  • RTL probes were designed to hybridize to adjacent sequences of each analyte (e.g., mRNA sequence) of interest in the genome, including estrogen receptor, progesterone receptor, and ERBB2, also known as HER2.
  • 20,056 probe pairs e.g., RHS and LHS probes
  • RHS and LHS probes were added to each tissue sample to capture 19,490 different genes.
  • Two RTL probes a left-hand side (LHS) probe and a right-hand side (RHS) probe (see e.g., FIG. 6 )
  • LHS left-hand side
  • RHS right-hand side
  • the hybridization buffer included SSC, formamide or an equivalent, yeast tRNA as carrier and the RHS and LHS DNA probes.
  • One probe oligonucleotide (e.g., the RHS probe or the 3′ probe) comprises a non-target functional sequence at its 5′ end while the other probe oligonucleotide (e.g., the LHS probe or the 5′ probe) comprises a non-target polyA sequence at their 3′ ends.
  • the DNA probes were added to the tissue samples and incubated at 50° C. for 2 hours and 30 minutes according to thermal cycler protocol described in Table 3.
  • Hybridization Thermal Cycler Protocol Hyb Lid Temp: 50 C., Volume: 100 uL Step Temp Time Pre-heat 50° C. ⁇ Hyb 50° C. 2 hours and 30 minutes Hold for post hyb washes 50° C. ⁇ Hold 22° C. ⁇
  • Post-hybridization wash buffer included: SSC, yeast tRNA and nuclease free water.
  • each sample was incubated with RNL2 T4 DNA ligase reaction mixture (ligation mix).
  • the ligase reaction mixture included: T4 RNA Ligase Buffer (NEB B0293S), RNL2 ligase and nuclease free water.
  • tissue samples were washed twice for 5 minutes at 60° C. in a SSC/formamide post ligation wash buffer.
  • RNAse H was added to digest the RNA strand of the hybridized RNA:DNA duplex. Briefly, the RNA of the DNA:RNA hybrids was digested by incubating the samples with RNase H mix for 30 minutes at 37° C., where the RNAse H mix included: RNAse H buffer and RNaseH. Following the incubation and while the same remained at 37° C., the biological sample was permeabilized to release the ligated RTL probes using 1.25 mg/mL Proteinase K.
  • the Proteinase K solution included (per sample): Tris (pH 7.5), MgCl 2 , Sarkosyl, or SDS, Proteinase K (Enzyme), and nuclease free water. The sample was incubated at 37° C. for at least 5 minutes in the Proteinase K solution. The samples were then washed three times with 2 ⁇ SSC.
  • the released, ligated DNA probes that served as a proxy for the target mRNA were allowed to hybridize to the capture domain on the capture probe immobilized on the spatial array via the polyA tail on the 3′ end of the RHS probe.
  • the captured ligated probes were copied, using the capture probe as a template and the extension product was released from the spatial array. Briefly, the tissues were incubated with a second strand extension mix comprising Kapa Hifi DNA polymerase for 25 minutes at 53° C. Following incubation, the second strand extension mix was removed from the tissues and the tissues were washed with 2 ⁇ SSC.
  • KOH KOH
  • KAPA SYBR FAST qPCR master mix KAPA SYBR master mix was prepared by adding qPCR primer cDNA_F and qPCR primer sRNA_R2.
  • the thermal cycler protocol included: 3 minutes at 98° C.; 30 cycles with 5 seconds at 98° C., and 30 seconds at 63° C.
  • samples were indexed using an Amp Mix that included dual indexing primers and an Amp Mix. Nucleic acids were then sequenced and analyzed.
  • FIGS. 14-19 spatial expression of ligated probe pairs highlights underlying mouse brain tissue physiology.
  • Arrow 1 points to a PCR band that represents desired ligation products, whereas arrows 2, 3 and 4 represent non-ligation products.
  • FIG. 15 shows non-specific probe detected as a fraction of total reads for each condition.
  • FIGS. 16A-B shows most probe combinations are specific. The arrows indicate RHS probes that had increased background and therefore include some non-specific hybridization.
  • gene-specific LHS+RHS probes overlay with the tissue footprint (see FIGS. 17A-C with black circle indicating tissue footprint).
  • probes specific for various genes were added to the sample in Hybridization buffer first for 30 minutes at 60° C., and then for 2 hours at 45° C. (See, e.g., FIG. 18 and FIG. 19 ).
  • target-specific UMIs were counted, a more detailed expression pattern was observed. See, e.g., FIGS. 19B-19F .
  • This analysis revealed that longer hybridization led to higher sensitivity. Referring to FIGS. 18A-18E , white circles indicate spots reporting expression for the indicated gene.
  • This example demonstrates that RTL can be performed on a sample in order to identify analyte abundance and spatial location in an unbiased manner.
  • TPBC triple positive
  • HER2, estrogen receptor, and progesterone receptor-positive breast cancer sample preserved by FFPE processing was examined for analyte abundance and spatial location.
  • the TPBC samples were queried with DNA probes via RNA-templated ligation methods. Before the ligation step, the TPBC tissue samples were deparaffinized and stained per established protocols. For example, FFPE TPBC tissue samples were prewarmed in a water bath (40° C.), sectioned (10 ⁇ m), dried at 42° C. for several hours and placed in a desiccator at room temperature overnight.
  • the dry, sectioned tissues were deparaffinized by baking at 60° C., moved through a series of xylene and EtOH washes, rinsed in water several times. Following rinsing, the deparaffinized tissues were stained with hematoxylin per established protocols. The stained tissues were imaged, identifying regions of tumor and stroma. See FIG. 21A .
  • the tissues were decrosslinked to remove formaldehyde crosslinks within the sample thereby releasing the analytes for RNA templated ligation. Briefly, the tissue samples were incubated with an HCl solution for 1 minute, repeated twice for a total of 3 minutes. Following HCl incubations, the tissue sections were incubated at 70° C. for 1 hour in TE pH 9.0. TE was removed and the tissues were incubation in 1 ⁇ PBS-Tween for 15 minutes.
  • RTL probes were designed to hybridize to adjacent sequences of each analyte (e.g., mRNA sequence) of interest in the genome, including estrogen receptor, progesterone receptor, and ERBB2, also known as HER2.
  • analyte e.g., mRNA sequence
  • ERBB2 ERBB2
  • Probes were designed from targets derived from Appris (see, Rodriguez et al., Nucleic Acids Research, 46: D213-217, doi: 10.1093/nar/gkx997 (2016), which is herein incorporated by reference in its entirety) and GENCODE. All probe pairs were non-overlapping and include generally about 1 probe pair per gene.
  • 20056 probe pairs e.g., RHS and LHS probes
  • 20056 probe pairs were added to each tissue sample to capture 19,490 different genes, including ESR1, PGR and HER2, in the human genome.
  • Two RTL probes a left-hand side (LHS) probe and a right-hand side (RHS) probe (see, e.g., FIG. 6 )
  • LHS left-hand side
  • RHS right-hand side
  • the DNA probes (1 nm of each probe) were added to the tissue samples in a hybridization buffer for hybridizing the DNA probes to their respective mRNA targets.
  • One probe oligonucleotide e.g., the RHS probe or the 3′ probe
  • the other probe oligonucleotide e.g., the LHS probe or the 5′ probe
  • hybridization buffer with the DNA probes was added to the tissue samples and the tissues were incubated at 50° C. of approximately 21 ⁇ 2 hrs.
  • the hybridization/DNA probe buffer was removed and the tissues washed by addition of a post hybridization buffer without DNA probes and incubation at 50° C. for 5 minutes, for a total of 3 post hybridization washes.
  • SplintR N-(NEB) in a ligation buffer was added to each tissue sample and the tissues were incubated at 37° C. for 60 minutes. Following DNA probe ligation the tissue samples were washed twice for 5 minutes at 60° C. in a SSC/formamide post ligation wash buffer.
  • RNA of the DNA:RNA hybrids was digested by incubating the tissues with RNase H for 30 minutes at 37° C. The biological sample then was permeabilized to release the ligated RTL probes and contacted with a plurality of capture probes attached to a slide. In particular, after 30 minutes, the tissues were washed and permeabilized by adding 1.25 mg/ml Proteinase K, incubated at 37° C. for at least 5 minutes and then washed to remove the protease.
  • the released, ligated DNA probes that served as a proxy for the target mRNA were allowed to hybridize to the capture domain on the capture probe (capture probes immobilized on the spatial array) via the polyA tail on the 3′ end of the RHS probe.
  • the captured ligated probes were copied, using the capture probe as a template and the extension product was released from the spatial array. Briefly, the tissues were incubated with a second strand extension mix comprising Kapa Hifi DNA polymerase (Roche) for 25 minutes at 53° C. Following incubation, the extension mix was removed from the tissues and the tissues were washed with SSC.
  • a solution of KOH was added to each of the tissue wells, the tissues were incubated at room temperature for 10 minutes to release the extension product from the spatial array and the supernatant from each tissue well was transferred for quantitation, library preparation and sequencing on the Illumina NextSeq sequencing instrument.
  • spots assigned to a cluster are outside the indicated circle on the plot.
  • each spot on the array is assigned to a cluster and each cluster is indicated, in part, by circles.
  • spots are assigned to a cluster but are not within the indicated circles on the array.
  • Embodiment A1 A method for determining a location of an analyte in a biological sample comprising:
  • Embodiment A2 The method of Embodiment A1, wherein the capture probe further comprises one or more functional domains, a unique molecular identifier, a cleavage domain, and combinations thereof.
  • Embodiment A3 The method of Embodiment A1 or A2, wherein the array comprises one or more features on a substrate.
  • Embodiment A4 The method of Embodiment A3, wherein the one or more features comprises a bead.
  • Embodiment A5 The method of Embodiment A3, wherein the substrate comprises a slide.
  • Embodiment A6 The method of any one of Embodiments A1-A5, wherein the formamide-free hybridization buffer is a saline-sodium citrate (SSC) hybridization buffer.
  • SSC saline-sodium citrate
  • Embodiment A7 The method of Embodiment A6, wherein SSC is present in the SSC hybridization buffer from about 1 ⁇ SSC to about 6 ⁇ SSC.
  • Embodiment A8 The method of Embodiments A6 or A7, wherein SSC is present in the SSC hybridization buffer from about 2 ⁇ SSC to about 4 ⁇ SSC.
  • Embodiment A9 The method of any one of Embodiments A6-A8, wherein the SSC hybridization buffer comprises a solvent.
  • Embodiment A10 The method of Embodiment A9, wherein the solvent comprises ethylene carbonate.
  • Embodiment A11 The method of any one of Embodiments A6-A10, wherein ethylene carbonate is present in the SSC hybridization buffer from about 10% (w/v) to about 25% (w/v).
  • Embodiment A12 The method of any one of Embodiments A6-A11, wherein ethylene carbonate is present in the SSC hybridization buffer from about 15% (w/v) to about 20% (w/v).
  • Embodiment A13 The method of any one of Embodiments A6-A12, wherein ethylene carbonate is present in the SSC hybridization buffer at about 13% (w/v).
  • Embodiment A14 The method of any one of Embodiments A6-A13, wherein the SSC hybridization buffer is at a temperature from about 40° C. to about 60° C.
  • Embodiment A15 The method of any one of Embodiments A6-A14, wherein the SSC hybridization buffer is at temperature from about 45° C. to about 55° C.
  • Embodiment A16 The method of any one Embodiments A6-A15, where in the SSC hybridization buffer is at a temperature of about 50° C.
  • Embodiment A17 The method of any one of Embodiments A6-A16, wherein the SSC hybridization buffer further comprises one or more of a yeast tRNA, a crowder, or an additive.
  • Embodiment A18 The method of any one of Embodiments A1-A17, wherein ligating in step (d) comprises a ligase.
  • Embodiment A19 The method of Embodiment A18, wherein the ligase is one or more of a T4 RNA ligase (Rnl2), a SplintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • the ligase is one or more of a T4 RNA ligase (Rnl2), a SplintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • Embodiment A20 The method of Embodiment A19, wherein the ligase is a T4 DNA ligase.
  • Embodiment A21 The method of any one of Embodiments A1-A20, further comprising removing one or more unhybridized first probe oligonucleotides, one or more unhybridized second probe oligonucleotides, or both, from the array.
  • Embodiment A22 The method of Embodiment A21, wherein the removing comprises washing the one or more unhybridized first probe oligonucleotides, the one or more unhybridized second probe oligonucleotides, or both, from the array in a formamide-free wash buffer.
  • Embodiment A23 The method of Embodiment A21 or A22, wherein the formamide-free wash buffer is an SSC wash buffer.
  • Embodiment A24 The method of any one of Embodiments A21-A23, wherein SSC is present in the SSC wash buffer from about 0.01 ⁇ SSC to about 1 ⁇ SSC.
  • Embodiment A25 The method of any one of Embodiments A21-A24, wherein SSC is present in the SSC wash buffer at about 0.1 ⁇ SSC.
  • Embodiment A26 The method of any one of Embodiments A21-A25, wherein the SSC wash buffer comprises a detergent.
  • Embodiment A27 The method of Embodiment A26, wherein the detergent comprises sodium dodecyl sulfate (SDS).
  • SDS sodium dodecyl sulfate
  • Embodiment A28 The method of any one of Embodiments A21-A26, wherein SDS is present in the SSC wash buffer from about 0.01% (v/v) to about 0.5% (v/v).
  • Embodiment A29 The method of any one of Embodiments A21-A28, wherein the SDS is present in the SSC wash buffer at about 0.1% (v/v).
  • Embodiment A30 The method of any one of Embodiments A21-A29, wherein the SSC wash buffer comprises a solvent.
  • Embodiment A31 The method of any one of Embodiments A21-A30, wherein the solvent comprises ethylene carbonate.
  • Embodiment A32 The method of any one of Embodiments A21-A31, wherein ethylene carbonate is present in the SSC wash buffer from about 10% (w/v) to about 25% (w/v).
  • Embodiment A33 The method of any one of Embodiments A21-A32, wherein ethylene carbonate is present in the SSC wash buffer from about 15% (w/v) to about 20% (w/v).
  • Embodiment A34 The method of any one of Embodiments A21-A33, wherein ethylene carbonate is present in the SSC wash buffer at about 16% (w/v).
  • Embodiment A35 The method of any one of Embodiments A21-A34, wherein the SSC wash buffer is at a temperature from about 50° C. to about 70° C.
  • Embodiment A36 The method of any one of Embodiments A21-A35, wherein the SSC wash buffer is at temperature from about 55° C. to about 65° C.
  • Embodiment A37 The method of any one Embodiments A21-A36, where in the SSC wash buffer is at a temperature of about 60° C.
  • Embodiment A38 The method of any one of Embodiments A1-A37, wherein releasing in step (e) comprises contacting the ligation product with an endoribonuclease.
  • Embodiment A39 The method of Embodiment A38, wherein the endoribonuclease is one or more of RNase H, RNase A, RNase C, or RNase I.
  • Embodiment A40 The method of Embodiment A38 or A39, wherein the endoribonuclease is RNAse H.
  • Embodiment A41 The method of Embodiment A40, wherein the RNase H comprises RNase H1, RNase H2, or both.
  • Embodiment A42 The method of any one Embodiments A1-A41, further comprising extending a 3′ end of the capture probe using the ligation product as a template for an extension reaction.
  • Embodiment A43 The method of Embodiment A42, wherein extending the 3′ end of the capture probe comprises reverse transcribing the analyte, thereby generating a sequence complementary to the analyte.
  • Embodiment A44 The method of Embodiment A43, wherein reverse transcribing the analyte comprises a reverse transcriptase.
  • Embodiment A45 The method of any of one of Embodiments A1-A44, wherein the analyte is RNA.
  • Embodiment A46 The method of any of one of Embodiments A1-A45, wherein the RNA is an mRNA.
  • Embodiment A47 The method of any one of Embodiments A1-A46, wherein the biological sample is a tissue sample.
  • Embodiment A48 The method of Embodiment A47, wherein the tissue sample is a tissue section.
  • Embodiment A49 The method of any one of Embodiments A1-A46, wherein the biological sample a fresh frozen biological sample.
  • Embodiment A50 The method of any one of Embodiments A1-A46, wherein the biological sample is a fixed biological sample.
  • Embodiment A51 The method of Embodiment A41, wherein the fixed biological sample is a formalin-fixed paraffin-embedded sample.
  • Embodiment A52 The method of any one of Embodiments A1-A51, wherein the method further comprises permeabilizing the biological sample.
  • Embodiment A53 The method of Embodiment A52, wherein permeabilizing the biological sample occurs before releasing the ligation product from the analyte.
  • Embodiment A54 The method of Embodiment A52 or A53, wherein permeabilizing the biological sample comprises an endopeptidase.
  • Embodiment A55 The method of any one of Embodiments A1-A54, wherein the method further comprises amplifying the ligation product prior to contacting the biological sample with the array.
  • Embodiment A56 The method of any one of Embodiments A1-A55, wherein determining in step (f) comprises sequencing.
  • Embodiment A57 The method of any one of Embodiments A1-A56, wherein the method further comprises a capture probe capture domain blocking moiety that specifically binds the capture probe capture domain.
  • Embodiment A58 The method of any one of Embodiments A1-A57, further comprising releasing the capture probe capture domain blocking moiety from the capture probe capture domain prior to contacting the biological sample with the array.
  • Embodiment A59 The method of any one of Embodiments A1-A58, wherein the capture probe capture domain comprises a homopolymeric sequence.
  • Embodiment A60 The method of Embodiment A59, wherein the capture probe capture domain comprises a poly(A) sequence.
  • Embodiment B A method for identifying a location of an analyte in a biological sample, the method comprising:
  • the first probe comprises a sequence that is substantially complementary to a first target sequence of the analyte
  • the second probe comprises:
  • Embodiment B2 The method of Embodiment B1, wherein the second probe comprises from 5′ to 3′: a first sequence, a linker sequence, a second sequence, and a capture probe capture domain.
  • Embodiment B3 The method of any one of Embodiments B1-B2, wherein the first target sequence of the analyte is directly adjacent to the second target sequence of the analyte.
  • Embodiment B4 The method of any one of Embodiments B1-B3, wherein the second target sequence is not directly adjacent to the third target sequence on the analyte.
  • Embodiment B5 The method of any one of Embodiments B1-B4, wherein the second target sequence and the third target sequence are on different exons of the analyte.
  • Embodiment B6 The method of any one of Embodiments B1-B4, wherein the second target sequence and the third target sequence are within the same exon of the analyte but are not directly adjacent.
  • Embodiment B7 The method of any one of Embodiments B1-B6, wherein the linker sequence comprises a total of about 1 nucleotide to about 100 nucleotides.
  • Embodiment B8 The method of Embodiment B7, wherein the linker further comprises a barcode sequence that serves as a proxy for identifying the analyte.
  • Embodiment B9 A method for identifying a location of an analyte in a biological sample, the method comprising:
  • the first probe comprises:
  • the second probe comprises a sequence that is substantially complementary to a third target sequence of the analyte and a capture probe capture domain that is capable of binding to a capture domain of a capture probe;
  • Embodiment B10 The method of Embodiment F9, wherein the second target sequence is directly adjacent to the third target sequence.
  • Embodiment B11 The method of any one of Embodiments B9-B10, wherein the first probe comprises from 5′ to 3′: a first sequence, a linker sequence, and a second sequence.
  • Embodiment B12 The method of any one of Embodiments B9-B11, wherein the first probe further comprises a functional sequence.
  • Embodiment B13 The method of Embodiment B13, wherein the functional sequence is a primer sequence.
  • Embodiment B14 The method of Embodiment B12 or B13, wherein the first probe comprises from 5′ to 3′: a functional sequence, a first sequence, a linker sequence, and a second sequence.
  • Embodiment B15 The method of any one of Embodiments B9-B14, wherein the first target sequence is not directly adjacent to the second target sequence on the analyte.
  • Embodiment B16 The method of Embodiment B15, wherein the first target sequence and second target sequence of are on different exons.
  • Embodiment B17 The method of Embodiment B15, wherein the first target sequence and the second target sequence are within the same exon but are not directly adjacent.
  • Embodiment B18 The method of any one of Embodiments B9-B17, wherein the linker sequence comprises a total of about 1 nucleotide to about 100 nucleotides.
  • Embodiment B19 The method of Embodiment B18, wherein the linker further comprises a barcode sequence that serves as a proxy for identifying the analyte.
  • Embodiment B20 A method for identifying a location of an analyte in a biological sample, the method comprising:
  • first probe is substantially complementary to a first portion of the analyte
  • the second probe is substantially complementary to a second portion of the analyte and further comprises a capture probe capture domain
  • spanning probe comprises:
  • Embodiment B21 The method of Embodiment B20, wherein the spanning oligonucleotide further comprises a functional sequence.
  • Embodiment B22 The method of Embodiment B20 or B, wherein the spanning oligonucleotides comprises from 5′ to 3′: a first sequence, a functional sequence, and a second sequence.
  • Embodiment B23 The method of any one of Embodiments B20-B22, wherein the functional sequences comprises a linker sequence.
  • Embodiment B24 The method of Embodiment B23, wherein the linker sequence comprises a total of about 1 nucleotides to about 100 nucleotides.
  • Embodiment B25 The method of any one of Embodiments B20-B24, wherein the functional sequences comprises a barcode sequence.
  • Embodiment B26 The method of Embodiment B25, wherein the barcode sequence comprises a sequence that serves as a proxy for identifying the analyte.
  • Embodiment B27 The method of any one of Embodiments B20-B26, wherein the functional sequence comprises one or more linker sequences and a barcode sequence.
  • Embodiment B28 The method of Embodiment B27, wherein the functional sequence comprises a barcode sequence flanked by linker sequences.
  • Embodiment B29 The method of any one of Embodiments B20-B28, wherein the linker sequence comprises a total of about 1 nucleotides to about 100 nucleotides.
  • Embodiment B30 The method of any one of Embodiments B20-B29, wherein the first sequence of the spanning probe and the second sequence of the spanning probe are substantially complementary to sequences within the same exon.
  • Embodiment B31 The method of Embodiment B30, wherein the first target sequence of the analyte and the second target of the analyte are located within the same exon.
  • Embodiment B32 The method of any one of Embodiments B20-B29, wherein the first sequence of the spanning probe and the second sequence of the spanning probe are substantially complementary to sequences within the different exons of the same gene.
  • Embodiment B33 The method of Embodiment B32, wherein the first target sequence of the analyte and the second target sequence of the analyte are located on different exons of the same gene.
  • Embodiment B34 The method of any one of Embodiments B20-33, wherein the first portion of the analyte is directly adjacent to the first target sequence, and/or wherein the second portion of the analyte is directly adjacent to the second target sequence.
  • Embodiment B35 The method of any one of Embodiments B20-B34, wherein the spanning probe comprises at least two ribonucleic acid based at the 3′ end.
  • Embodiment B36 The method of any one of Embodiments B20-B35, wherein the spanning probe comprises a phosphorylated nucleotide at the 5′ end.
  • Embodiment B37 The method of any one of Embodiments B20-B36, wherein the one or more spanning probes comprises one spanning probe.
  • Embodiment B38 The method of any one of Embodiments B20-B36, wherein the one or more spanning probes comprises at least two, at least three, at least four, at least five, or more spanning probes.
  • Embodiment B39 The method of Embodiment B38, wherein the one or more spanning probes comprise:
  • Embodiment B40 The method of Embodiment B39, wherein the first target sequence is located in a first exon, the second target sequence is located in a second exon, and the third target sequence and the fourth target sequence are located in a third exon.
  • Embodiment B41 The method of Embodiments B39, wherein the first target sequence is located in a first exon, the second target sequence is located in a second exon, and the third target sequence is located in a third exon, and the fourth target sequence is located in a fourth exon.
  • Embodiment B42 The method of any one of Embodiments B38-B41, wherein the method comprises ligating:
  • Embodiment B43 The method of any one of Embodiments B38-B42, wherein the one or more additional spanning probes oligonucleotide further comprises a functional sequence.
  • Embodiment B44 The method of Embodiment B43, wherein the functional sequences comprises (i) a linker sequence, (ii) a barcode sequence, or (ii) one or more linkers and a barcode sequence.
  • Embodiment B45 The method of any one of Embodiments B38-B44, wherein the one or more additional spanning probes comprises at least two ribonucleic acid based at the 3′ end.
  • Embodiment B46 The method of any one of Embodiments B38-B45, wherein the one or more additional spanning probes comprises a phosphorylated nucleotide at the 5′ end.
  • Embodiment B47 The method of any one of Embodiments B20-B46, wherein the first probe further comprises a functional sequence.
  • Embodiment B48 The method of Embodiment B47, wherein the functional sequence is a primer sequence.
  • Embodiment B49 The method of any one of the preceding Embodiments, wherein the first probe comprises at least two ribonucleic acid bases at the 3′ end.
  • Embodiment B50 The method of any one of the preceding Embodiments, wherein the second probe comprises a phosphorylated nucleotide at the 5′ end.
  • Embodiment B51 The method of any one of the preceding Embodiments, wherein the method further comprises providing a capture probe capture domain blocking moiety that interacts with the capture probe capture domain.
  • Embodiment B52 The method of Embodiment B51, wherein the method further comprises releasing the capture probe capture domain blocking moiety from the capture probe capture domain prior to step (f).
  • Embodiment B53 The method of any one of the preceding Embodiments, wherein the capture probe capture domain comprises a poly-adenylated (poly(A)) sequence or a complement thereof.
  • Embodiment B54 The method of Embodiment B53, wherein the capture probe capture domain blocking moiety comprises a poly-uridine sequence, a poly-thymidine sequence, or both.
  • Embodiment B55 The method of Embodiment B52, wherein releasing the poly-uridine sequence from the poly(A) sequence comprises denaturing the ligation product or contacting the ligation product with an endonuclease or exonuclease.
  • Embodiment B56 The method of any one of the preceding Embodiments, wherein the capture probe capture domain comprises a sequence that is complementary to all or a portion of the capture domain of the capture probe.
  • Embodiment B57 The method of any one of the preceding Embodiments, wherein the capture probe capture domain comprises a degenerate sequence.
  • Embodiment B58 The method of any one of the preceding Embodiments, wherein the ligation step comprises using enzymatic ligation or chemical ligation.
  • Embodiment B59 The method of Embodiment B58, wherein the enzymatic ligation utilizes a ligase.
  • Embodiment B60 The method of Embodiment B59, wherein the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • Embodiment B61 The method of Embodiment B60, wherein the ligase is a T4 RNA ligase 2 (Rnl2) ligase.
  • the ligase is a T4 RNA ligase 2 (Rnl2) ligase.
  • Embodiment B62 The method of any one of the preceding Embodiments, wherein the first probe, the second probe, and the one or more spanning probes are DNA probes.
  • Embodiment B63 The method of Embodiment B62, wherein the steps (b) and (c) each creates a RNA: DNA hybrid.
  • Embodiment B64 The method of any one of the preceding Embodiments, wherein steps (b) and (c) are performed at substantially the same time.
  • Embodiment B65 The method of any one of the preceding Embodiments, wherein the biological sample comprises a FFPE sample.
  • Embodiment B66 The method of Embodiment B65, wherein the tissue sample is the FFPE tissue sample, and the tissue sample is decrosslinked.
  • Embodiment B67 The method of any one of the preceding Embodiments, wherein the biological sample comprises a tissue section.
  • Embodiment B68 The method of any one of the preceding Embodiments, wherein the biological sample comprises a fresh frozen sample.
  • Embodiment B69 The method of any one of the preceding Embodiments, wherein the biological sample comprises live cells.
  • Embodiment B70 The method of any one of the preceding Embodiments, wherein the analyte comprises RNA and/or DNA.
  • Embodiment B71 The method of any one of the preceding Embodiments, wherein the analyte is RNA.
  • Embodiment B72 The method of Embodiment B71, wherein the RNA is an mRNA.
  • Embodiment B73 The method of any one of the preceding Embodiments, wherein the biological sample was previously stained.
  • Embodiment B74 The method of Embodiment B73, wherein the biological sample was previously stained using hematoxylin and eosin (H&E).
  • H&E hematoxylin and eosin
  • Embodiment B75 The method of Embodiment B73 or B74, wherein the biological sample was previously stained using immunofluorescence or immunohistochemistry.
  • Embodiment B76 The method of any one of the preceding Embodiments, wherein the method further comprises contacting the biological sample with a permeabilization agent.
  • Embodiment B77 The method of any one of the preceding Embodiments, wherein the releasing step comprises removing the ligated probe from the analyte.
  • Embodiment B78 The method of Embodiment B77, wherein the releasing step comprises contacting the ligated probe with an endoribonuclease.
  • Embodiment B79 The method of Embodiment B78, wherein the endoribonuclease is one or more of RNase H, RNase A, RNase C, or RNase I.
  • Embodiment B80 The method of Embodiment B79, wherein the RNase H comprises RNase H1, RNase H2, or
  • Embodiment B81 The method of any one of the preceding Embodiments, wherein the determining step comprises amplifying all or part of the ligation product specifically bound to the capture domain.
  • Embodiment B82 The method of Embodiment B81, wherein the amplifying is isothermal.
  • Embodiment B83 The method of Embodiment B81, wherein the amplifying is not isothermal.
  • Embodiment B84 The method of any one of Embodiments B81-B83, wherein an amplifying product comprises (i) all or part of sequence of the ligation product specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof.
  • Embodiment B85 The method of any one of the preceding Embodiments, wherein the determining step comprises sequencing.
  • Embodiment B86 The method of Embodiment B85, wherein the sequencing step comprises in situ sequencing.
  • Embodiment B87 A kit comprising
  • a plurality of probes comprising a first probe and a second oligonucleotide, wherein the first probe and the second probe are substantially complementary to adjacent sequences of an analyte, wherein the second probe comprises (i) a capture probe capture domain that is capable of binding to a capture domain of the capture probe and (ii) a linker sequence;
  • Embodiment B88 A kit comprising
  • a plurality of probes comprising a first probe and a second oligonucleotide, wherein the first probe and the second probe are substantially complementary to adjacent sequences of an analyte, wherein the first probe includes a linker sequence, wherein the second probe comprises a capture probe capture domain that is capable of binding to a capture domain of the capture probe;
  • Embodiment B89 A kit comprising:
  • a spanning probe of the plurality of spanning probes comprises a first sequence, a linker sequence, and a second sequence, wherein the first sequence of the spanning probe and the first probe are substantially complementary to adjacent sequences of an analyte, wherein the second sequence of the spanning probe and the second probe are substantially complementary to adjacent sequences of the analyte;
  • Embodiment B90 The kit of any one of Embodiments B87-B89, wherein the ribonuclease is RNase H.
  • Embodiment B91 The kit of any one of Embodiments B87-B90, wherein the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase.
  • Embodiment B92 The kit of Embodiment B91, wherein the ligase is a T4 RNA ligase 2 (Rnl2) ligase.
  • the ligase is a T4 RNA ligase 2 (Rnl2) ligase.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US17/220,529 2019-12-23 2021-04-01 Methods for spatial analysis using RNA-templated ligation Active US11332790B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/220,529 US11332790B2 (en) 2019-12-23 2021-04-01 Methods for spatial analysis using RNA-templated ligation
US17/707,189 US11560593B2 (en) 2019-12-23 2022-03-29 Methods for spatial analysis using RNA-templated ligation
US18/100,133 US11981965B2 (en) 2019-12-23 2023-01-23 Methods for spatial analysis using RNA-templated ligation
US18/483,280 US20240124933A1 (en) 2019-12-23 2023-10-09 Methods for spatial analysis using rna-templated ligation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962952736P 2019-12-23 2019-12-23
US202062969458P 2020-02-03 2020-02-03
US202063087061P 2020-10-02 2020-10-02
US202063108088P 2020-10-30 2020-10-30
PCT/US2020/066720 WO2021133849A1 (en) 2019-12-23 2020-12-22 Methods for spatial analysis using rna-templated ligation
US17/220,529 US11332790B2 (en) 2019-12-23 2021-04-01 Methods for spatial analysis using RNA-templated ligation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/066720 Continuation WO2021133849A1 (en) 2019-12-23 2020-12-22 Methods for spatial analysis using rna-templated ligation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/707,189 Continuation US11560593B2 (en) 2019-12-23 2022-03-29 Methods for spatial analysis using RNA-templated ligation

Publications (2)

Publication Number Publication Date
US20210348221A1 US20210348221A1 (en) 2021-11-11
US11332790B2 true US11332790B2 (en) 2022-05-17

Family

ID=74191967

Family Applications (7)

Application Number Title Priority Date Filing Date
US17/220,529 Active US11332790B2 (en) 2019-12-23 2021-04-01 Methods for spatial analysis using RNA-templated ligation
US17/220,534 Active US11505828B2 (en) 2019-12-23 2021-04-01 Methods for spatial analysis using RNA-templated ligation
US17/707,189 Active US11560593B2 (en) 2019-12-23 2022-03-29 Methods for spatial analysis using RNA-templated ligation
US17/896,520 Active US11795507B2 (en) 2019-12-23 2022-08-26 Methods for spatial analysis using RNA-templated ligation
US18/100,133 Active US11981965B2 (en) 2019-12-23 2023-01-23 Methods for spatial analysis using RNA-templated ligation
US18/233,606 Pending US20230392204A1 (en) 2019-12-23 2023-08-14 Methods for spatial analysis using rna-templated ligation
US18/483,280 Pending US20240124933A1 (en) 2019-12-23 2023-10-09 Methods for spatial analysis using rna-templated ligation

Family Applications After (6)

Application Number Title Priority Date Filing Date
US17/220,534 Active US11505828B2 (en) 2019-12-23 2021-04-01 Methods for spatial analysis using RNA-templated ligation
US17/707,189 Active US11560593B2 (en) 2019-12-23 2022-03-29 Methods for spatial analysis using RNA-templated ligation
US17/896,520 Active US11795507B2 (en) 2019-12-23 2022-08-26 Methods for spatial analysis using RNA-templated ligation
US18/100,133 Active US11981965B2 (en) 2019-12-23 2023-01-23 Methods for spatial analysis using RNA-templated ligation
US18/233,606 Pending US20230392204A1 (en) 2019-12-23 2023-08-14 Methods for spatial analysis using rna-templated ligation
US18/483,280 Pending US20240124933A1 (en) 2019-12-23 2023-10-09 Methods for spatial analysis using rna-templated ligation

Country Status (9)

Country Link
US (7) US11332790B2 (da)
EP (2) EP4219754B1 (da)
CN (1) CN114885610A (da)
AU (1) AU2020412766A1 (da)
DK (1) DK3891300T3 (da)
ES (1) ES2946357T3 (da)
FI (1) FI3891300T3 (da)
SG (1) SG11202106899SA (da)
WO (1) WO2021133849A1 (da)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US20220282329A1 (en) * 2019-12-23 2022-09-08 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11512308B2 (en) 2020-06-02 2022-11-29 10X Genomics, Inc. Nucleic acid library methods
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US11592447B2 (en) 2019-11-08 2023-02-28 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11692218B2 (en) 2020-06-02 2023-07-04 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
WO2023150163A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from lymphatic tissue
WO2023150171A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from glioblastoma samples
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
WO2023159028A1 (en) 2022-02-15 2023-08-24 10X Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
US11739381B2 (en) 2021-03-18 2023-08-29 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
WO2023212532A1 (en) 2022-04-26 2023-11-02 10X Genomics, Inc. Systems and methods for evaluating biological samples
WO2023215552A1 (en) 2022-05-06 2023-11-09 10X Genomics, Inc. Molecular barcode readers for analyte detection
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
WO2023250077A1 (en) 2022-06-22 2023-12-28 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2024006827A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Methods and systems for light-controlled surface patterning using photomasks
WO2024006797A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Methods and compositions for refining feature boundaries in molecular arrays
WO2024006798A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. High definition molecular array feature generation using photoresist
WO2024006814A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Method of generating arrays using microfluidics and photolithography
WO2024006830A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Methods and compositions for patterned molecular array generation by directed bead delivery
WO2024006826A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Compositions and methods for generating molecular arrays using oligonucleotide printing and photolithography
WO2024006832A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Click chemistry-based dna photo-ligation for manufacturing of high-resolution dna arrays
WO2024006799A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Covalent attachment of splint oligonucleotides for molecular array generation using ligation
WO2024006816A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Compositions and methods for oligonucleotide inversion on arrays
WO2024015578A1 (en) 2022-07-15 2024-01-18 10X Genomics, Inc. Methods for determining a location of a target nucleic acid in a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
WO2024035844A1 (en) 2022-08-12 2024-02-15 10X Genomics, Inc. Methods for reducing capture of analytes
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11933957B1 (en) 2018-12-10 2024-03-19 10X Genomics, Inc. Imaging system hardware
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102834526B (zh) 2010-04-05 2015-12-02 普罗格诺西斯生物科学公司 空间编码的生物学测定
AU2022227563A1 (en) 2021-02-23 2023-08-24 10X Genomics, Inc. Probe-based analysis of nucleic acids and proteins
EP4305196A1 (en) 2021-04-14 2024-01-17 10X Genomics, Inc. Methods of measuring mislocalization of an analyte
WO2022226057A1 (en) 2021-04-20 2022-10-27 10X Genomics, Inc. Methods for assessing sample quality prior to spatial analysis using templated ligation
WO2023009988A1 (en) * 2021-07-26 2023-02-02 10X Genomics, Inc. Nucleic acid processing via circularization
EP4370675A1 (en) * 2021-08-12 2024-05-22 10X Genomics, Inc. Methods, compositions and systems for identifying antigen-binding molecules
US20230140008A1 (en) 2021-10-06 2023-05-04 10X Genomics, Inc. Systems and methods for evaluating biological samples
WO2023076345A1 (en) 2021-10-26 2023-05-04 10X Genomics, Inc. Methods for spatial analysis using targeted rna capture
WO2023102118A2 (en) 2021-12-01 2023-06-08 10X Genomics, Inc. Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
WO2023150098A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, kits, compositions, and systems for spatial analysis
WO2023172670A2 (en) 2022-03-11 2023-09-14 10X Genomics, Inc. Sample handling apparatus and fluid delivery methods
WO2024102809A1 (en) * 2022-11-09 2024-05-16 10X Genomics, Inc. Methods, compositions, and kits for determining the location of multiple analytes in a biological sample

Citations (430)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1989010977A1 (en) 1988-05-03 1989-11-16 Isis Innovation Limited Analysing polynucleotide sequences
US4883867A (en) 1985-11-01 1989-11-28 Becton, Dickinson And Company Detection of reticulocytes, RNA or DNA
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5002882A (en) 1989-04-27 1991-03-26 New England Biolabs, Inc. Method for producing the XmaI restriction endonuclease and methylase
WO1991006678A1 (en) 1989-10-26 1991-05-16 Sri International Dna sequencing
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5308751A (en) 1992-03-23 1994-05-03 General Atomics Method for sequencing double-stranded DNA
US5321130A (en) 1992-02-10 1994-06-14 Molecular Probes, Inc. Unsymmetrical cyanine dyes with a cationic side chain
US5410030A (en) 1993-04-05 1995-04-25 Molecular Probes, Inc. Dimers of unsymmetrical cyanine dyes containing pyridinium moieties
US5436134A (en) 1993-04-13 1995-07-25 Molecular Probes, Inc. Cyclic-substituted unsymmetrical cyanine dyes
WO1995023875A1 (en) 1994-03-02 1995-09-08 The Johns Hopkins University In vitro transposition of artificial transposons
WO1995025116A1 (en) 1994-03-16 1995-09-21 California Institute Of Technology Method and apparatus for performing multiple sequential reactions on a matrix
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
WO1995035505A1 (en) 1994-06-17 1995-12-28 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for fabricating microarrays of biological samples
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5512462A (en) 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5582977A (en) 1991-09-16 1996-12-10 Molecular Probes, Inc. Dimers of unsymmetrical cyanine dyes
US5599675A (en) 1994-04-04 1997-02-04 Spectragen, Inc. DNA sequencing by stepwise ligation and cleavage
US5641658A (en) 1994-08-03 1997-06-24 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid with two primers bound to a single solid support
US5648245A (en) 1995-05-09 1997-07-15 Carnegie Institution Of Washington Method for constructing an oligonucleotide concatamer library by rolling circle replication
US5658751A (en) 1993-04-13 1997-08-19 Molecular Probes, Inc. Substituted unsymmetrical cyanine dyes with selected permeability
WO1997031256A2 (en) 1996-02-09 1997-08-28 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US5763175A (en) 1995-11-17 1998-06-09 Lynx Therapeutics, Inc. Simultaneous sequencing of tagged polynucleotides
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5871921A (en) 1994-02-16 1999-02-16 Landegren; Ulf Circularizing nucleic acid probe able to interlock with a target sequence through catenation
US5912148A (en) 1994-08-19 1999-06-15 Perkin-Elmer Corporation Applied Biosystems Coupled amplification and ligation method
US5925545A (en) 1996-09-09 1999-07-20 Wisconsin Alumni Research Foundation System for in vitro transposition
US5958775A (en) 1997-07-25 1999-09-28 Thomas Jefferson University Composition and method for targeted integration into cells
US5965443A (en) 1996-09-09 1999-10-12 Wisconsin Alumni Research Foundation System for in vitro transposition
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6027889A (en) 1996-05-29 2000-02-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
WO2000017390A1 (en) 1998-09-18 2000-03-30 Micromet Ag Dna amplification of a single cell
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US6153389A (en) 1999-02-22 2000-11-28 Haarer; Brian K. DNA additives as a mechanism for unambiguously marking biological samples
US6159736A (en) 1998-09-23 2000-12-12 Wisconsin Alumni Research Foundation Method for making insertional mutations using a Tn5 synaptic complex
US6165714A (en) 1996-12-16 2000-12-26 Vysis, Inc. Devices and methods for detecting nucleic acid analytes in samples
US6172218B1 (en) 1994-10-13 2001-01-09 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
WO2001009363A1 (en) 1999-08-02 2001-02-08 Wisconsin Alumni Research Foundation Mutant tn5 transposase enzymes and method for their use
US6210891B1 (en) 1996-09-27 2001-04-03 Pyrosequencing Ab Method of sequencing DNA
US6210894B1 (en) 1991-09-04 2001-04-03 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6214587B1 (en) 1994-03-16 2001-04-10 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
WO2001042796A1 (en) 1999-12-13 2001-06-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health High-throughput tissue microarray technology and applications
US6258568B1 (en) 1996-12-23 2001-07-10 Pyrosequencing Ab Method of sequencing DNA based on the detection of the release of pyrophosphate and enzymatic nucleotide degradation
US6266459B1 (en) 1997-03-14 2001-07-24 Trustees Of Tufts College Fiber optic sensor with encoded microspheres
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US6291180B1 (en) 1999-09-29 2001-09-18 American Registry Of Pathology Ultrasound-mediated high-speed biological reaction and tissue processing
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US6309824B1 (en) 1997-01-16 2001-10-30 Hyseq, Inc. Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes
WO2001090415A2 (en) 2000-05-20 2001-11-29 The Regents Of The University Of Michigan Method of producing a dna library using positional amplification
WO2001096608A1 (en) 2000-06-15 2001-12-20 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US20010055764A1 (en) 1999-05-07 2001-12-27 Empedocles Stephen A. Microarray methods utilizing semiconductor nanocrystals
US6344316B1 (en) 1996-01-23 2002-02-05 Affymetrix, Inc. Nucleic acid analysis techniques
US6355431B1 (en) 1999-04-20 2002-03-12 Illumina, Inc. Detection of nucleic acid amplification reactions using bead arrays
US20020040275A1 (en) 2000-04-10 2002-04-04 The Scripps Research Institute Proteomic analysis
US6368801B1 (en) 2000-04-12 2002-04-09 Molecular Staging, Inc. Detection and amplification of RNA using target-mediated ligation of DNA by RNA ligase
US20020048766A1 (en) 2000-07-28 2002-04-25 Doyle Michael D. Method and system for the multidimensional morphological reconstruction of genome expression activity
US20020055100A1 (en) 1997-04-01 2002-05-09 Kawashima Eric H. Method of nucleic acid sequencing
US6404907B1 (en) 1998-06-26 2002-06-11 Visible Genetics Inc. Method for sequencing nucleic acids with reduced errors
US6401267B1 (en) 1993-09-27 2002-06-11 Radoje Drmanac Methods and compositions for efficient nucleic acid sequencing
WO2002059355A2 (en) 2001-01-25 2002-08-01 Tm Bioscience Corporation Polynucleotides for use as tags and tag complements, manufacture and use thereof
WO2002059364A1 (en) 2001-01-27 2002-08-01 Electron-Bio, Inc. Nucleic hybridization assay method and device using a cleavage technique responsive to the complementary double strand or the single strand of nucleic acids or oligonucleotides
US6432360B1 (en) 1997-10-10 2002-08-13 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
WO2002077283A1 (en) 2000-12-21 2002-10-03 Affymetrix, Inc. Methods for detecting transcripts
US20020164611A1 (en) 2000-11-15 2002-11-07 Bamdad R. Shoshana Oligonucleotide identifiers
US6503713B1 (en) 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
WO2003002979A2 (en) 2001-06-28 2003-01-09 Illumina, Inc. Multiplex decoding of array sensors with microspheres
US6506561B1 (en) 1999-01-27 2003-01-14 Commissariat A L'energie Atomique Method of obtaining a library of tags capable of defining a specific state of a biological sample
US20030022207A1 (en) 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
WO2003010176A2 (en) 2001-07-24 2003-02-06 Oxford Glycosciences (Uk) Ltd Protein-nucleic acid complexes
US20030064398A1 (en) 2000-02-02 2003-04-03 Solexa, Ltd. Synthesis of spatially addressed molecular arrays
US6544732B1 (en) 1999-05-20 2003-04-08 Illumina, Inc. Encoding and decoding of array sensors utilizing nanocrystals
US6579695B1 (en) 1995-10-13 2003-06-17 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US20030148335A1 (en) 2001-10-10 2003-08-07 Li Shen Detecting targets by unique identifier nucleotide tags
US20030162216A1 (en) 1997-12-15 2003-08-28 Somalogic, Inc. Nucleic acid ligand diagnostic biochip
US20030165948A1 (en) 2001-03-09 2003-09-04 Alsmadi Osama A. Method and compositions for efficient and specific rolling circle amplification
US6620584B1 (en) 1999-05-20 2003-09-16 Illumina Combinatorial decoding of random nucleic acid arrays
US6632641B1 (en) 1999-10-08 2003-10-14 Metrigen, Inc. Method and apparatus for performing large numbers of reactions using array assembly with releasable primers
US20030215936A1 (en) 2000-12-13 2003-11-20 Olli Kallioniemi High-throughput tissue microarray technology and applications
US20030224419A1 (en) 1997-05-23 2003-12-04 Lynx Therapeutics, Inc. Data analysis and display system for ligation-based DNA sequencing
US20030232348A1 (en) 2002-06-17 2003-12-18 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
US20040019005A1 (en) 2001-10-01 2004-01-29 Jeffrey Van Ness Methods for parallel measurement of genetic variations
WO2004015080A2 (en) 2002-08-09 2004-02-19 Illumina, Inc. Nucleic acid detection methods using universal priming
US20040033499A1 (en) 2002-08-16 2004-02-19 Ilsley Diane D. Method for synthesis of the second strand of cDNA
US20040067493A1 (en) 2001-07-25 2004-04-08 Affymetrix, Inc. Complexity management of genomic DNA
US20040067492A1 (en) 2002-10-04 2004-04-08 Allan Peng Reverse transcription on microarrays
US20040082059A1 (en) 1999-07-22 2004-04-29 Webb Peter G. Methods of fabricating an addressable array of biopolymer probes
US6737236B1 (en) 1997-01-08 2004-05-18 Proligo, Llc Bioconjugation of macromolecules
US20040096853A1 (en) 2000-12-08 2004-05-20 Pascal Mayer Isothermal amplification of nucleic acids on a solid support
US20040106110A1 (en) 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
US6770441B2 (en) 2000-02-10 2004-08-03 Illumina, Inc. Array compositions and methods of making same
US6773886B2 (en) 1999-08-13 2004-08-10 Yale University Binary encoded sequence tags
WO2004067759A2 (en) 2003-01-29 2004-08-12 Cranfield University Replication of nucleic acid arrays
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US6800453B2 (en) 2001-01-23 2004-10-05 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
US6812005B2 (en) 2000-02-07 2004-11-02 The Regents Of The University Of California Nucleic acid detection methods using universal priming
US20040224326A1 (en) 2003-01-03 2004-11-11 Young-A Kim Method of replicating nucleic acid array
US6828100B1 (en) 1999-01-22 2004-12-07 Biotage Ab Method of DNA sequencing
US20040248325A1 (en) 2001-07-19 2004-12-09 Cuneyt Bukusoglu Method for simultaneous multiple probes/multiple targets screening procedure
US6833246B2 (en) 1999-09-29 2004-12-21 Solexa, Ltd. Polynucleotide sequencing
US20040259105A1 (en) 2002-10-03 2004-12-23 Jian-Bing Fan Multiplex nucleic acid analysis using archived or fixed samples
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
WO2005007814A2 (en) 2003-07-03 2005-01-27 The Regents Of The University Of California Genome mapping of functional dna elements and cellular proteins
WO2005010145A2 (en) 2003-07-05 2005-02-03 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US20050037393A1 (en) 2003-06-20 2005-02-17 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US6859570B2 (en) 1997-03-14 2005-02-22 Trustees Of Tufts College, Tufts University Target analyte sensors utilizing microspheres
US6864052B1 (en) 1999-01-06 2005-03-08 Callida Genomics, Inc. Enhanced sequencing by hybridization using pools of probes
US6867028B2 (en) 2000-07-24 2005-03-15 Fermentas Ab Strand-specific polynucleotide nickases
US20050064460A1 (en) 2001-11-16 2005-03-24 Medical Research Council Emulsion compositions
WO2005026387A1 (en) 2003-09-18 2005-03-24 Nuevolution A/S A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
US6890741B2 (en) 2000-02-07 2005-05-10 Illumina, Inc. Multiplexed detection of analytes
WO2005042759A2 (en) 2003-09-10 2005-05-12 Althea Technologies, Inc. Expression profiling using microarrays
US20050100900A1 (en) 1997-04-01 2005-05-12 Manteia Sa Method of nucleic acid amplification
US6897023B2 (en) 2000-09-27 2005-05-24 The Molecular Sciences Institute, Inc. Method for determining relative abundance of nucleic acid sequences
US20050130173A1 (en) 2003-01-29 2005-06-16 Leamon John H. Methods of amplifying and sequencing nucleic acids
US20050130188A1 (en) 1997-03-14 2005-06-16 The Trustees Of Tufts College Methods for detecting target analytes and enzymatic reactions
US20050136414A1 (en) 2003-12-23 2005-06-23 Kevin Gunderson Methods and compositions for making locus-specific arrays
US20050164292A1 (en) 2001-10-24 2005-07-28 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
US20050191698A1 (en) 1999-04-20 2005-09-01 Illumina, Inc. Nucleic acid sequencing using microsphere arrays
US6942968B1 (en) 1999-08-30 2005-09-13 Illumina, Inc. Array compositions for improved signal detection
US20050202433A1 (en) 2002-06-03 2005-09-15 Van Beuningen Marinus Gerardus J. Novel high density arrays and methods for analyte analysis
CN1680604A (zh) 2004-04-10 2005-10-12 三星电子株式会社 具有微阵列识别信息的微阵列及其生产方法和使用方法
US20050260653A1 (en) 2004-04-14 2005-11-24 Joshua Labaer Nucleic-acid programmable protein arrays
WO2005113804A1 (en) 2004-05-20 2005-12-01 Trillion Genomics Limited Use of mass labelled probes to detect target nucleic acids using mass spectrometry
US20060046313A1 (en) 2004-08-26 2006-03-02 Intel Corporation Cellular analysis using Raman surface scanning
US20060105352A1 (en) 2004-11-15 2006-05-18 Eastman Kodak Company Method for sensitive detection of multiple biological analytes
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US7083980B2 (en) 2003-04-17 2006-08-01 Wisconsin Alumni Research Foundation Tn5 transposase mutants and the use thereof
US20060199183A1 (en) 2003-03-13 2006-09-07 Christophe Valat Probe biochips and methods for use thereof
US20060211001A1 (en) 2005-03-18 2006-09-21 Wisconsin Alumni Research Foundation Microdissection-based methods for determining genomic features of single chromosomes
US20060216775A1 (en) 2003-06-17 2006-09-28 The Regents Of The University Of Califoenia Compositions and methods for analysis and manipulation of enzymes in biosynthetic proteomes
US7115400B1 (en) 1998-09-30 2006-10-03 Solexa Ltd. Methods of nucleic acid amplification and sequencing
US7118883B2 (en) 2000-12-28 2006-10-10 Post Genome Institute Co., Ltd. Process for producing peptides by using in vitro transcription/translation system
US20060240439A1 (en) 2003-09-11 2006-10-26 Smith Geoffrey P Modified polymerases for improved incorporation of nucleotide analogues
US20060263789A1 (en) 2005-05-19 2006-11-23 Robert Kincaid Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using
WO2006124771A2 (en) 2005-05-12 2006-11-23 Panomics, Inc. Multiplex branched-chain dna assays
US20060281109A1 (en) 2005-05-10 2006-12-14 Barr Ost Tobias W Polymerases
JP2007014297A (ja) 2005-07-11 2007-01-25 Onchip Cellomics Consortium 細胞構成物質分取チップならびに細胞構成物質解析システム及びこれらを用いる細胞構成物質解析法
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
US20070020669A1 (en) 2005-07-08 2007-01-25 Olof Ericsson Regulation analysis by cis reactivity, RACR
US20070026430A1 (en) 2005-06-30 2007-02-01 Applera Corporation Proximity probing of target proteins comprising restriction and/or extension
US20070054288A1 (en) 2003-09-24 2007-03-08 Intel Corporation Programmable molecular barcodes
JP2007074967A (ja) 2005-09-13 2007-03-29 Canon Inc 識別子プローブ及びそれを用いた核酸増幅方法
WO2007041689A2 (en) 2005-10-04 2007-04-12 President And Fellows Of Harvard College Methods of site-specific labeling of molecules and molecules produced thereby
US7211414B2 (en) 2000-12-01 2007-05-01 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US20070099208A1 (en) 2005-06-15 2007-05-03 Radoje Drmanac Single molecule arrays for genetic and chemical analysis
EP1782737A1 (en) 2005-11-02 2007-05-09 BioPath Automation, L.L.C. Tissue cassette for transporting
WO2007060599A1 (en) 2005-11-25 2007-05-31 Koninklijke Philips Electronics N.V. Magnetic biosensor for determination of enzymic activity
US20070128656A1 (en) 2003-06-26 2007-06-07 University Of South Florida Direct Fluorescent Label Incorporation Via 1st Strand cDNA Synthesis
US20070128624A1 (en) 2005-11-01 2007-06-07 Gormley Niall A Method of preparing libraries of template polynucleotides
US20070134723A1 (en) 2005-12-09 2007-06-14 Illumina, Inc. Compositions and methods for detecting phosphomonoester
WO2007073171A2 (en) 2005-12-22 2007-06-28 Keygene N.V. Improved strategies for transcript profiling using high throughput sequencing technologies
WO2007076726A1 (en) 2006-01-04 2007-07-12 Si Lok Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities
US20070166705A1 (en) 2002-08-23 2007-07-19 John Milton Modified nucleotides
US20070172873A1 (en) 2006-01-23 2007-07-26 Sydney Brenner Molecular counting
US7255994B2 (en) 2003-06-10 2007-08-14 Applera Corporation Ligation assay
US7258976B2 (en) 1997-12-22 2007-08-21 Hitachi Chemical Co. Ltd. Method of preparing cell lysate
US20070207482A1 (en) 2004-08-04 2007-09-06 President And Fellows Of Harvard College Wobble sequencing
US7282328B2 (en) 2002-09-20 2007-10-16 New England Biolabs, Inc. Helicase dependent amplification of nucleic acids
US20070254305A1 (en) 2006-04-28 2007-11-01 Nsabp Foundation, Inc. Methods of whole genome or microarray expression profiling using nucleic acids prepared from formalin fixed paraffin embedded tissue
US7297518B2 (en) 2001-03-12 2007-11-20 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US20070269805A1 (en) 2003-09-02 2007-11-22 Keygene N.V. Ola-Based Methods for the Detection of Target Nucleic Avid Sequences
WO2007139766A2 (en) 2006-05-22 2007-12-06 Nanostring Technologies, Inc. Systems and methods for analyzing nanoreporters
WO2007145612A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
US20080009420A1 (en) 2006-03-17 2008-01-10 Schroth Gary P Isothermal methods for creating clonal single molecule arrays
US7329492B2 (en) 2000-07-07 2008-02-12 Visigen Biotechnologies, Inc. Methods for real-time single molecule sequence determination
WO2008022332A2 (en) 2006-08-18 2008-02-21 Board Of Regents, The University Of Texas System System, method and kit for replicating a dna array
EP1910562A1 (en) 2005-06-23 2008-04-16 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US20080108804A1 (en) 2006-11-02 2008-05-08 Kabushiki Kaisha Dnaform Method for modifying RNAS and preparing DNAS from RNAS
US20080108082A1 (en) 2006-10-23 2008-05-08 Pacific Biosciences Of California, Inc. Polymerase enzymes and reagents for enhanced nucleic acid sequencing
EP1923471A1 (en) 1999-04-20 2008-05-21 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US7378242B2 (en) 2004-03-18 2008-05-27 Atom Sciences, Inc. DNA sequence detection by limited primer extension
US20080132429A1 (en) 2006-05-23 2008-06-05 Uchicago Argonne Biological microarrays with enhanced signal yield
WO2008069906A2 (en) 2006-11-14 2008-06-12 The Regents Of The University Of California Digital expression of gene analysis
US20080153086A1 (en) 2003-08-08 2008-06-26 Wong Albert J Method For Rapid Identification of Alternative Splicing
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
CN101221182A (zh) 2007-01-08 2008-07-16 山东司马特生物芯片有限公司 一种荧光蛋白质芯片血清肿瘤系列诊断新方法
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US7407757B2 (en) 2005-02-10 2008-08-05 Population Genetics Technologies Genetic analysis by sequence-specific sorting
US20080220434A1 (en) 2007-02-07 2008-09-11 Perscitus Biosciences, Llc Detection Of Molecule Proximity
US20080261204A1 (en) 2004-01-23 2008-10-23 Lingvitae As Polynucleotide Ligation Reactions
EP2002017A2 (en) 2006-04-04 2008-12-17 Keygene N.V. High throughput detection of molecular markers based on restriction fragments
US20090006002A1 (en) 2007-04-13 2009-01-01 Sequenom, Inc. Comparative sequence analysis processes and systems
US20090005252A1 (en) 2006-02-24 2009-01-01 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US20090018024A1 (en) 2005-11-14 2009-01-15 President And Fellows Of Harvard College Nanogrid rolling circle dna sequencing
US20090026082A1 (en) 2006-12-14 2009-01-29 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes using large scale FET arrays
JP2009036694A (ja) 2007-08-03 2009-02-19 Tokyo Medical & Dental Univ 空間分布を保った細胞内生体物質の解析方法
WO2009032167A1 (en) 2007-08-29 2009-03-12 Illumina Cambridge Method for sequencing a polynucleotide template
US20090082212A1 (en) 1998-12-14 2009-03-26 Pacific Biosciences System and methods for nucleic acid sequencing of single molecules by polymerase synthesis
US20090099041A1 (en) 2006-02-07 2009-04-16 President And Fellows Of Harvard College Methods for making nucleotide probes for sequencing and synthesis
US20090105959A1 (en) 2007-06-01 2009-04-23 Braverman Michael S System and method for identification of individual samples from a multiplex mixture
US20090117573A1 (en) 2007-09-14 2009-05-07 Affymetrix, Inc. Locus specific amplification using array probes
US20090127589A1 (en) 2006-12-14 2009-05-21 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes using large scale FET arrays
US7544473B2 (en) 2006-01-23 2009-06-09 Population Genetics Technologies Ltd. Nucleic acid analysis using sequence tokens
US20090155781A1 (en) 2006-02-24 2009-06-18 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US20090170713A1 (en) 2005-09-29 2009-07-02 Keygene N.V. High throughput screening of mutagenized populations
US7579153B2 (en) 2005-01-25 2009-08-25 Population Genetics Technologies, Ltd. Isothermal DNA amplification
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
US20090233802A1 (en) 2007-02-02 2009-09-17 Helen Bignell Methods for indexing samples and sequencing multiple polynucleotide templates
US7601498B2 (en) 2005-03-17 2009-10-13 Biotium, Inc. Methods of using dyes in association with nucleic acid staining or detection and associated technology
US7608434B2 (en) 2004-08-04 2009-10-27 Wisconsin Alumni Research Foundation Mutated Tn5 transposase proteins and the use thereof
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
US20090283407A1 (en) 2008-05-15 2009-11-19 Gaurav Jitendra Shah Method for using magnetic particles in droplet microfluidics
US20090291854A1 (en) 2006-07-05 2009-11-26 Austrian Research Centers Gmbh - Arc Identification of Pathogens
DE102008025656A1 (de) 2008-05-28 2009-12-03 Genxpro Gmbh Verfahren zur quantitativen Analyse von Nikleinsäuren, Marker dafür und deren Verwendung
US20090312193A1 (en) 2008-01-23 2009-12-17 Samsung Electronics Co., Ltd. Microarray hybridization assay methods
US7635566B2 (en) 2007-06-29 2009-12-22 Population Genetics Technologies Ltd. Methods and compositions for isolating nucleic acid sequence variants
US20100035249A1 (en) 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
WO2010019826A1 (en) 2008-08-14 2010-02-18 Nanostring Technologies, Inc Stable nanoreporters
US7666612B2 (en) 2003-05-23 2010-02-23 Epfl-Ecole Polytechnique Federale De Lausanne Methods for protein labeling based on acyl carrier protein
US7674752B2 (en) 2000-08-15 2010-03-09 Discema Limited Functional protein arrays
WO2010027870A2 (en) 2008-08-26 2010-03-11 Fluidigm Corporation Assay methods for increased throughput of samples and/or targets
US20100069263A1 (en) 2008-09-12 2010-03-18 Washington, University Of Sequence tag directed subassembly of short sequencing reads into long sequencing reads
US7700286B2 (en) 2005-04-06 2010-04-20 Maurice Stroun Method for the detection of cancer
US20100105052A1 (en) 2007-10-29 2010-04-29 Complete Genomics, Inc. Nucleic acid sequencing and process
US7709198B2 (en) 2005-06-20 2010-05-04 Advanced Cell Diagnostics, Inc. Multiplex detection of nucleic acids
US20100120097A1 (en) 2008-05-30 2010-05-13 Board Of Regents, The University Of Texas System Methods and compositions for nucleic acid sequencing
US20100120098A1 (en) 2008-10-24 2010-05-13 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US20100120043A1 (en) 2006-11-16 2010-05-13 General Electric Company Sequential analysis of biological samples
US20100129874A1 (en) 2008-09-05 2010-05-27 The Washington University Method for multiplexed nucleic acid patch polymerase chain reaction
US20100145037A1 (en) 2001-11-13 2010-06-10 Rubicon Genomics, Inc. Dna amplification and sequencing using dna molecules generated by random fragmentation
US20100184618A1 (en) 2009-01-16 2010-07-22 Affymetrix, Inc. Dna ligation on rna template
US7776567B2 (en) 2005-03-17 2010-08-17 Biotium, Inc. Dimeric and trimeric nucleic acid dyes, and associated systems and methods
US20100210475A1 (en) 2009-02-11 2010-08-19 Samsung Electronics Co., Ltd. Microarray having bright fiducial mark and method of obtaining optical data from the mircoarray
US20100227329A1 (en) 2007-09-21 2010-09-09 Katholieke Universiteit Leuven K.U.Leuven R&D Tools and methods for genetic tests using next generation sequencing
WO2010126614A2 (en) 2009-04-30 2010-11-04 Good Start Genetics, Inc. Methods and compositions for evaluating genetic markers
US20110028685A1 (en) 2006-06-30 2011-02-03 Applera Corporation. Analyte Determination Utilizing Mass Tagging Reagents Comprising A Non-Encoded Detectable Label
US20110033854A1 (en) 2007-12-05 2011-02-10 Complete Genomics, Inc. Methods and compositions for long fragment read sequencing
US20110111409A1 (en) 2009-11-10 2011-05-12 Dominick Sinicropi Methods for depleting rna from nucleic acid samples
WO2011062933A2 (en) 2009-11-18 2011-05-26 Raybiotech, Inc. Array-based proximity ligation association assays
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
WO2011068088A1 (ja) 2009-12-04 2011-06-09 株式会社日立製作所 ２次元cDNAライブラリを用いた遺伝子発現解析方法
US20110245111A1 (en) 2010-04-05 2011-10-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20110245101A1 (en) 2010-04-05 2011-10-06 Prognosys Biosciences, Inc. Co-localization affinity assays
US8076063B2 (en) 2000-02-07 2011-12-13 Illumina, Inc. Multiplexed methylation detection methods
US8092784B2 (en) 2005-11-30 2012-01-10 Biotium, Inc. Enzyme substrate comprising a functional dye and associated technology and methods
US20120046175A1 (en) 2007-10-23 2012-02-23 Matthew Rodesch Methods and systems for solution based sequence enrichment
US20120046178A1 (en) 2008-10-30 2012-02-23 Sequenom, Inc. Products and processes for multiplex nucleic acid identification
US20120065081A1 (en) 2009-04-30 2012-03-15 Chee Mark S Nucleic acid constructs and methods of use
WO2012048341A1 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput single cell barcoding
WO2012049316A1 (en) 2010-10-15 2012-04-19 Olink Ab Dynamic range methods
WO2012071428A2 (en) 2010-11-22 2012-05-31 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for assays and detections
US20120202704A1 (en) 2009-12-07 2012-08-09 Illumina, Inc. Multi-sample indexing for multiplex genotyping
US20120258871A1 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
WO2012159089A1 (en) 2011-05-19 2012-11-22 Sequenom, Inc. Products and processes for multiplex nucleic acid identification
US20130005600A1 (en) 2010-02-03 2013-01-03 Sven Olek Assay for Determining the Type and/or Status of a Cell Based on the Epigenetic Pattern and the Chromatin Structure
US20130035239A1 (en) 2011-08-03 2013-02-07 Bio-Rad Laboratories Filtering small nucleic acids using permeabilized cells
US8383338B2 (en) 2006-04-24 2013-02-26 Roche Nimblegen, Inc. Methods and systems for uniform enrichment of genomic regions
US20130079232A1 (en) 2011-09-23 2013-03-28 Illumina, Inc. Methods and compositions for nucleic acid sequencing
US8460865B2 (en) 1998-06-24 2013-06-11 Illumina, Inc. Multiplex decoding of array sensors with microspheres
US20130171621A1 (en) 2010-01-29 2013-07-04 Advanced Cell Diagnostics Inc. Methods of in situ detection of nucleic acids
US8481292B2 (en) 2010-09-21 2013-07-09 Population Genetics Technologies Litd. Increasing confidence of allele calls with molecular counting
US8481257B2 (en) 2005-12-22 2013-07-09 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US8507204B2 (en) 2005-03-08 2013-08-13 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
WO2013123442A1 (en) 2012-02-17 2013-08-22 Fred Hutchinson Cancer Research Center Compositions and methods for accurately identifying mutations
WO2013138510A1 (en) 2012-03-13 2013-09-19 Patel Abhijit Ajit Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
WO2013142389A1 (en) 2012-03-20 2013-09-26 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
US20130261019A1 (en) 2010-10-29 2013-10-03 President And Fellows Of Harvard College Nucleic acid nanostructure barcode probes
US8551710B2 (en) 2011-02-15 2013-10-08 Leica Biosystems Newcastle Ltd. Methods for localized in situ detection of mRNA
WO2013150083A1 (en) 2012-04-03 2013-10-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Analysis of nucleic acid molecules distributed on a surface or within a layer by sequencing with position identification
US8603743B2 (en) 2009-04-03 2013-12-10 Timothy Z. Liu Multiplex nucleic acid detection methods and systems
US20140066318A1 (en) 2011-04-13 2014-03-06 Spatial Transcriptomics Ab Method and product for localized or spatial detection of nucleic acid in a tissue sample
WO2014044724A1 (en) 2012-09-18 2014-03-27 Qiagen Gmbh Method and kit for preparing a target rna depleted sample
US20140121118A1 (en) 2010-11-23 2014-05-01 Opx Biotechnologies, Inc. Methods, systems and compositions regarding multiplex construction protein amino-acid substitutions and identification of sequence-activity relationships, to provide gene replacement such as with tagged mutant genes, such as via efficient homologous recombination
US8741564B2 (en) 2011-05-04 2014-06-03 Htg Molecular Diagnostics, Inc. Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements
US8809238B2 (en) 2011-05-09 2014-08-19 Fluidigm Corporation Probe based nucleic acid detection
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US20140274731A1 (en) 2012-12-10 2014-09-18 Clearfork Bioscience, Inc. Methods for targeted genomic analysis
WO2014144713A2 (en) 2013-03-15 2014-09-18 Immumetrix, Inc. Methods of sequencing the immune repertoire
WO2014152397A2 (en) 2013-03-14 2014-09-25 The Broad Institute, Inc. Selective purification of rna and rna-bound molecular complexes
US20140323330A1 (en) 2013-04-25 2014-10-30 Vladislav B. Bergo Microarray compositions and methods of their use
US20140342921A1 (en) 2011-12-09 2014-11-20 Illumina, Inc. Expanded radix for polymeric tags
WO2014210223A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US20150000854A1 (en) 2013-06-27 2015-01-01 The Procter & Gamble Company Sheet products bearing designs that vary among successive sheets, and apparatus and methods for producing the same
US8951728B2 (en) 2004-11-22 2015-02-10 Chemgene Holding Aps Template directed split and mix synthesis of small molecule libraries
EP2881465A1 (en) 2012-07-30 2015-06-10 Hitachi, Ltd. Tag-sequence-attached two-dimensional cdna library device, and gene expression analysis method and gene expression analysis apparatus each utilizing same
US9080210B2 (en) 2010-06-09 2015-07-14 Keygene N.V. High throughput screening using combinatorial sequence barcodes
WO2015161173A1 (en) 2014-04-18 2015-10-22 William Marsh Rice University Competitive compositions of nucleic acid molecules for enrichment of rare-allele-bearing species
US20150376609A1 (en) 2014-06-26 2015-12-31 10X Genomics, Inc. Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations
US20160019337A1 (en) 2013-03-15 2016-01-21 Htg Molecular Diagnostics, Inc. Subtyping lung cancers
US20160108458A1 (en) 2014-10-06 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed detection and quantification of nucleic acids in single-cells
US20160122817A1 (en) 2014-10-29 2016-05-05 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US9416409B2 (en) 2009-07-31 2016-08-16 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
US20160253584A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
WO2016138500A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Methods and compositions for barcoding nucleic acids for sequencing
US20160289740A1 (en) 2015-03-30 2016-10-06 Cellular Research, Inc. Methods and compositions for combinatorial barcoding
WO2016168825A1 (en) 2015-04-17 2016-10-20 Centrillion Technology Holdings Corporation Methods for performing spatial profiling of biological molecules
WO2016166128A1 (en) 2015-04-14 2016-10-20 Koninklijke Philips N.V. Spatial mapping of molecular profiles of biological tissue samples
WO2016172362A1 (en) 2015-04-21 2016-10-27 General Automation Lab Technologies, Inc. High resolution systems, kits, apparatus, and methods for high throughput microbiology applications
US9506061B2 (en) 2004-11-12 2016-11-29 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US9512422B2 (en) 2013-02-26 2016-12-06 Illumina, Inc. Gel patterned surfaces
US20170016053A1 (en) 2015-07-17 2017-01-19 Nanostring Technologies, Inc. Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
WO2017019481A1 (en) 2015-07-24 2017-02-02 The Johns Hopkins University Compositions and methods of rna analysis
WO2017019456A2 (en) 2015-07-27 2017-02-02 Illumina, Inc. Spatial mapping of nucleic acid sequence information
US20170067096A1 (en) 2015-08-07 2017-03-09 Massachusetts Institute Of Technology Nanoscale Imaging of Proteins and Nucleic Acids via Expansion Microscopy
US9593365B2 (en) 2012-10-17 2017-03-14 Spatial Transcriptions Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US9598728B2 (en) 2012-02-14 2017-03-21 Cornell University Method for relative quantification of nucleic acid sequence, expression, or copy changes, using combined nuclease, ligation, and polymerase reactions
US20170089811A1 (en) 2015-08-07 2017-03-30 Massachusetts Institute Of Technology Protein Retention Expansion Microscopy
WO2017075265A1 (en) 2015-10-28 2017-05-04 The Broad Institute, Inc. Multiplex analysis of single cell constituents
WO2017075293A1 (en) 2015-10-28 2017-05-04 Silicon Valley Scientific, Inc. Method and apparatus for encoding cellular spatial position information
WO2017096158A1 (en) 2015-12-04 2017-06-08 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US20170220733A1 (en) 2014-07-30 2017-08-03 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
US20170233722A1 (en) 2016-02-12 2017-08-17 University Of Washington Combinatorial photo-controlled spatial sequencing and labeling
US20170241911A1 (en) 2016-02-22 2017-08-24 Miltenyi Biotec Gmbh Automated analysis tool for biological specimens
WO2017156336A1 (en) 2016-03-10 2017-09-14 The Board Of Trustees Of The Leland Stanford Junior University Transposase-mediated imaging of the accessible genome
US9783841B2 (en) 2012-10-04 2017-10-10 The Board Of Trustees Of The Leland Stanford Junior University Detection of target nucleic acids in a cellular sample
WO2017184984A1 (en) 2016-04-21 2017-10-26 Cell Data Sciences, Inc. Biomolecule processing from fixed biological samples
WO2017192633A1 (en) 2016-05-02 2017-11-09 Procure Life Sciences Inc. Macromolecule analysis employing nucleic acid encoding
US9816134B2 (en) 2010-05-27 2017-11-14 Affymetrix, Inc. Multiplex amplification methods
US20170335410A1 (en) 2016-05-17 2017-11-23 Shoreline Biome, Llc High Throughput Method for Identification and Sequencing of Unknown Microbial and Eukaryotic Genomes from Complex Mixtures
US9834814B2 (en) 2013-11-22 2017-12-05 Agilent Technologies, Inc. Spatial molecular barcoding of in situ nucleic acids
US20170349940A1 (en) 2014-09-26 2017-12-07 Two Pore Guys, Inc. Targeted Sequence Detection by Nanopore Sensing of Synthetic Probes
US9856521B2 (en) 2015-01-27 2018-01-02 BioSpyder Technologies, Inc. Ligation assays in liquid phase
WO2018023068A1 (en) 2016-07-29 2018-02-01 New England Biolabs, Inc. Methods and compositions for preventing concatemerization during template- switching
US20180051322A1 (en) 2013-03-12 2018-02-22 President And Fellows Of Harvard College Method for Generating A Three-Dimensional Nucleic Acid Containing Matrix
WO2018045181A1 (en) 2016-08-31 2018-03-08 President And Fellows Of Harvard College Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing
WO2018064640A1 (en) 2016-10-01 2018-04-05 Berkeley Lights, Inc. Dna barcode compositions and methods of in situ identification in a microfluidic device
US9938566B2 (en) 2014-09-08 2018-04-10 BioSpyder Technologies, Inc. Profiling expression at transcriptome scale
US20180105808A1 (en) 2016-10-19 2018-04-19 10X Genomics, Inc. Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations
US20180112209A1 (en) 2011-12-22 2018-04-26 Ibis Biosciences, Inc. Systems and methods for isolating nucleic acids
US9957550B2 (en) 2014-09-08 2018-05-01 BioSpyder Technologies, Inc. Attenuators
WO2018085599A2 (en) 2016-11-02 2018-05-11 ArcherDX, Inc. Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2018091676A1 (en) 2016-11-17 2018-05-24 Spatial Transcriptomics Ab Method for spatial tagging and analysing nucleic acids in a biological specimen
US20180163265A1 (en) 2014-12-19 2018-06-14 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
US20180179591A1 (en) 2016-12-22 2018-06-28 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20180201925A1 (en) 2014-06-30 2018-07-19 Illumina, Inc. Methods and compositions using one-sided transposition
WO2018136856A1 (en) 2017-01-23 2018-07-26 Massachusetts Institute Of Technology Multiplexed signal amplified fish via splinted ligation amplification and sequencing
US10041949B2 (en) 2013-09-13 2018-08-07 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed imaging of tissues using mass tags and secondary ion mass spectrometry
WO2018144582A1 (en) 2017-02-01 2018-08-09 Illumina, Inc. System and method with reflective fiducials
US20180237864A1 (en) 2015-01-27 2018-08-23 BioSpyder Technologies, Inc. Focal Gene Expression Profiling of Stained FFPE Tissues with Spatial Correlation to Morphology
US10059990B2 (en) 2015-04-14 2018-08-28 Massachusetts Institute Of Technology In situ nucleic acid sequencing of expanded biological samples
US10059989B2 (en) 2013-05-23 2018-08-28 The Board Of Trustees Of The Leland Stanford Junior University Transposition of native chromatin for personal epigenomics
US20180312822A1 (en) 2017-04-26 2018-11-01 10X Genomics, Inc. Mmlv reverse transcriptase variants
WO2018209398A1 (en) 2017-05-17 2018-11-22 Microbio Pty Ltd Biomarkers and uses thereof
US10144966B2 (en) 2008-01-17 2018-12-04 Sequenom, Inc. Methods of nucleic acid sequences analysis using solid supports containing identifier sequences
WO2019032760A1 (en) 2017-08-10 2019-02-14 Rootpath Genomics, Inc. IMPROVED METHOD OF ANALYZING NUCLEIC ACID CONTENT FROM MULTIPLE BIOLOGICAL PARTICLES
US10208982B2 (en) 2015-01-23 2019-02-19 Mestek, Inc. Airfoil blade and method of assembly
US20190055594A1 (en) 2016-02-26 2019-02-21 The Board Of Trustee Of The Leland Stanford Junior University Multiplexed single molecule rna visualization with a two-probe proximity ligation system
US20190085383A1 (en) 2014-07-11 2019-03-21 President And Fellows Of Harvard College Methods for High-Throughput Labelling and Detection of Biological Features In Situ Using Microscopy
WO2019068880A1 (en) 2017-10-06 2019-04-11 Cartana Ab RNA MATRIX LIGATION
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20190161796A1 (en) 2016-06-21 2019-05-30 Cartana Ab Nucleic acid sequencing
US20190177789A1 (en) 2012-08-14 2019-06-13 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
WO2019113457A1 (en) 2017-12-07 2019-06-13 Massachusetts Institute Of Technology Single cell analyses
US20190194709A1 (en) 2016-08-31 2019-06-27 President And Fellows Of Harvard College Methods of Combining the Detection of Biomolecules Into a Single Assay Using Fluorescent In Situ Sequencing
WO2019126313A1 (en) 2017-12-22 2019-06-27 The University Of Chicago Multiplex 5mc marker barcode counting for methylation detection in cell-free dna
US20190203275A1 (en) * 2015-04-10 2019-07-04 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20190218276A1 (en) 2016-03-21 2019-07-18 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics in single cells
WO2019140201A1 (en) 2018-01-12 2019-07-18 Claret Bioscience, Llc Methods and compositions for analyzing nucleic acid
WO2019165318A1 (en) 2018-02-22 2019-08-29 10X Genomics, Inc. Ligation mediated analysis of nucleic acids
US20190262831A1 (en) 2016-10-17 2019-08-29 Lociomics Corporation High resolution spatial genomic analysis of tissues and cell aggregates
US20190271031A1 (en) 2010-04-05 2019-09-05 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
WO2019213294A1 (en) 2018-05-03 2019-11-07 Becton, Dickinson And Company High throughput multiomics sample analysis
WO2019213254A1 (en) 2018-05-02 2019-11-07 The General Hospital Corporation High-resolution spatial macromolecule abundance assessment
US20190367969A1 (en) 2018-02-12 2019-12-05 10X Genomics, Inc. Methods and systems for analysis of chromatin
US20200010891A1 (en) 2014-11-21 2020-01-09 Nanostring Technologies, Inc. Enzyme- and amplification-free sequencing
US20200024641A1 (en) 2016-07-27 2020-01-23 The Board Of Trustees Of The Leland Stanford Junior University Highly-multiplexed fluorescent imaging
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2020028194A1 (en) 2018-07-30 2020-02-06 Readcoor, Inc. Methods and systems for sample processing or analysis
WO2020047010A2 (en) 2018-08-28 2020-03-05 10X Genomics, Inc. Increasing spatial array resolution
US20200080136A1 (en) 2016-09-22 2020-03-12 William Marsh Rice University Molecular hybridization probes for complex sequence capture and analysis
WO2020056381A1 (en) 2018-09-14 2020-03-19 Cold Spring Harbor Laboratory PROGRAMMABLE RNA-TEMPLATED SEQUENCING BY LIGATION (rSBL)
WO2020053655A1 (en) 2018-09-13 2020-03-19 Zenith Epigenetics Ltd. Combination therapy for the treatment of triple-negative breast cancer
WO2020061108A1 (en) 2018-09-17 2020-03-26 Schneider Electric Systems Usa, Inc. Industrial system event detection and corresponding response
WO2020061066A1 (en) 2018-09-17 2020-03-26 Computer World Services Corp. dba LabSavvy Systems and methods for automated reporting and education for laboratory test results
WO2020061064A1 (en) 2018-09-17 2020-03-26 Piggy Llc Systems, methods, and computer programs for providing users maximum benefit in electronic commerce
WO2020123318A1 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Resolving spatial arrays using deconvolution
US20200239946A1 (en) 2017-10-11 2020-07-30 Expansion Technologies Multiplexed in situ hybridization of tissue sections for spatially resolved transcriptomics with expansion microscopy
WO2020160044A1 (en) 2019-01-28 2020-08-06 The Broad Institute, Inc. In-situ spatial transcriptomics
US20200256867A1 (en) 2016-12-09 2020-08-13 Ultivue, Inc. Methods for Multiplex Imaging Using Labeled Nucleic Acid Imaging Agents
WO2020176788A1 (en) 2019-02-28 2020-09-03 10X Genomics, Inc. Profiling of biological analytes with spatially barcoded oligonucleotide arrays
WO2020190509A1 (en) 2019-03-15 2020-09-24 10X Genomics, Inc. Methods for using spatial arrays for single cell sequencing
WO2020219901A1 (en) 2019-04-26 2020-10-29 10X Genomics, Inc. Imaging support devices
US10829803B2 (en) 2006-05-10 2020-11-10 Dxterity Diagnostics Incorporated Detection of nucleic acid targets using chemically reactive oligonucleotide probes
US20200370095A1 (en) * 2019-05-24 2020-11-26 Takara Bio Usa, Inc. Spatial Analysis
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US20210095331A1 (en) 2019-09-30 2021-04-01 Yale University Deterministic barcoding for spatial omics sequencing
US20210140982A1 (en) 2019-10-18 2021-05-13 10X Genomics, Inc. Identification of spatial biomarkers of brain disorders and methods of using the same
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
WO2021091611A1 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US20210150707A1 (en) 2019-11-18 2021-05-20 10X Genomics, Inc. Systems and methods for binary tissue classification
WO2021097255A1 (en) 2019-11-13 2021-05-20 10X Genomics, Inc. Generating capture probes for spatial analysis
US20210158522A1 (en) 2019-11-22 2021-05-27 10X Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
US20210155982A1 (en) 2019-11-21 2021-05-27 10X Genomics, Inc. Pipeline for spatial analysis of analytes
WO2021119320A2 (en) 2019-12-11 2021-06-17 10X Genomics, Inc. Reverse transcriptase variants
US20210189475A1 (en) 2018-12-10 2021-06-24 10X Genomics, Inc. Imaging system hardware
US20210198741A1 (en) 2019-12-30 2021-07-01 10X Genomics, Inc. Identification of spatial biomarkers of heart disorders and methods of using the same
WO2021133849A1 (en) 2019-12-23 2021-07-01 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
US20210199660A1 (en) 2019-11-22 2021-07-01 10X Genomics, Inc. Biomarkers of breast cancer
US20210214785A1 (en) 2020-01-13 2021-07-15 Spatial Transcriptomics Ab Methods of decreasing background on a spatial array
US20210223227A1 (en) 2020-01-17 2021-07-22 Spatial Transcriptomics Ab Electrophoretic system and method for analyte capture
US20210222253A1 (en) 2020-01-21 2021-07-22 10X Genomics, Inc. Identification of biomarkers of glioblastoma and methods of using the same
US20210222242A1 (en) 2020-01-21 2021-07-22 10X Genomics, Inc. Spatial assays with perturbed cells
US20210222241A1 (en) 2020-01-21 2021-07-22 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US20210230681A1 (en) 2020-01-24 2021-07-29 10X Genomics, Inc. Methods for spatial analysis using proximity ligation
US20210230692A1 (en) 2018-10-10 2021-07-29 Readcoor, Llc Surface capture of targets
US20210238680A1 (en) 2020-02-03 2021-08-05 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US20210238664A1 (en) 2020-02-03 2021-08-05 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US20210238675A1 (en) 2020-02-05 2021-08-05 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US20210247316A1 (en) 2020-02-11 2021-08-12 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
WO2021168261A1 (en) 2020-02-21 2021-08-26 10X Genomics, Inc. Capturing genetic targets using a hybridization approach
US20210262019A1 (en) 2020-02-24 2021-08-26 10X Genomics, Inc. Methods of making gene expression libraries
WO2021168278A1 (en) 2020-02-20 2021-08-26 10X Genomics, Inc. METHODS TO COMBINE FIRST AND SECOND STRAND cDNA SYNTHESIS FOR SPATIAL ANALYSIS
US11118216B2 (en) 2015-09-08 2021-09-14 Affymetrix, Inc. Nucleic acid analysis by joining barcoded polynucleotide probes
US20210285036A1 (en) 2019-01-06 2021-09-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US20210317524A1 (en) 2018-08-28 2021-10-14 10X Genomics, Inc. Resolving spatial arrays
US20210324457A1 (en) 2018-08-28 2021-10-21 Eswar Prasad Ramachandran Iyer Methods for Generating Spatially Barcoded Arrays
WO2021216708A1 (en) 2020-04-22 2021-10-28 10X Genomics, Inc. Methods for spatial analysis using targeted rna depletion
WO2021225900A1 (en) 2020-05-04 2021-11-11 10X Genomics, Inc. Spatial transcriptomic transfer modes
WO2021237056A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Rna integrity analysis in a biological sample
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021236625A1 (en) 2020-05-19 2021-11-25 10X Genomics, Inc. Electrophoresis cassettes and instrumentation
WO2021237087A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Spatial analysis to detect sequence variants
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
WO2021247568A1 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Spatial trancriptomics for antigen-receptors
WO2021247543A2 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Nucleic acid library methods
WO2021252591A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
WO2021252576A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for spatial analysis using blocker oligonucleotides
WO2021263111A1 (en) 2020-06-25 2021-12-30 10X Genomics, Inc. Spatial analysis of dna methylation
US20220017951A1 (en) 2019-03-22 2022-01-20 10X Genomics, Inc. Three-dimensional spatial analysis

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4988617A (en) * 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1993004199A2 (en) 1991-08-20 1993-03-04 Scientific Generics Limited Methods of detecting or quantitating nucleic acids and of producing labelled immobilised nucleic acids
US6872816B1 (en) 1996-01-24 2005-03-29 Third Wave Technologies, Inc. Nucleic acid detection kits
US6759226B1 (en) 2000-05-24 2004-07-06 Third Wave Technologies, Inc. Enzymes for the detection of specific nucleic acid sequences
US6875572B2 (en) 1996-01-24 2005-04-05 Third Wave Technologies, Inc. Nucleic acid detection assays
US6913881B1 (en) 1996-01-24 2005-07-05 Third Wave Technologies, Inc. Methods and compositions for detecting target sequences
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
KR100471341B1 (ko) 1996-05-23 2005-07-21 제네시스 테크놀로지 가부시키가이샤 콘택트프로브및그것을구비한프로브장치
KR20010005544A (ko) * 1997-03-21 2001-01-15 그레그 펄쓰 Ｖｎｔｒ 대립 유전자의 추출 및 이용방법
AU8908198A (en) 1997-08-15 1999-03-08 Hyseq, Inc. Methods and compositions for detection or quantification of nucleic acid species
US6054274A (en) 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
AU2003200718B2 (en) 1997-12-15 2006-10-19 Somalogic, Inc. Nucleic acid ligand diagnostic biochip
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6830884B1 (en) 1998-12-15 2004-12-14 Molecular Staging Inc. Method of amplification
US20060275782A1 (en) * 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
WO2000065094A2 (en) 1999-04-22 2000-11-02 The Albert Einstein College Of Medicine Of Yeshiva University Assay of gene expression patterns by multi-fluor fish
EP1194592B1 (en) * 1999-07-14 2008-09-24 Packard Bioscience Company Derivative nucleic acids and uses thereof
ATE542916T1 (de) 1999-08-18 2012-02-15 Illumina Inc Methoden zur erzeugung von oligonukleotidlösungen
DK1218542T3 (da) 1999-09-13 2004-08-02 Nugen Technologies Inc Fremgangsmåder og sammensætninger til lineær isotermisk amplifikation af polynukleotidsekvenser
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US20010031468A1 (en) 2000-02-08 2001-10-18 Alex Chenchik Analyte assays employing universal arrays
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6511809B2 (en) 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
US6323009B1 (en) 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
WO2002040874A1 (en) 2000-11-16 2002-05-23 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
US7135296B2 (en) 2000-12-28 2006-11-14 Mds Inc. Elemental analysis of tagged biologically active materials
US6573755B2 (en) 2001-06-28 2003-06-03 Intel Corporation Symmetric differential domino “AND gate”
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US20040091857A1 (en) 2001-07-20 2004-05-13 Nallur Girish N. Gene expression profiling
US7499806B2 (en) 2002-02-14 2009-03-03 Illumina, Inc. Image processing in microsphere arrays
JP2005537030A (ja) 2002-05-09 2005-12-08 ユー．エス． ジェノミクス， インコーポレイテッド 核酸を分析する方法
US20050118616A1 (en) 2002-08-16 2005-06-02 Kawashima Tadashi R. Amplification of target nucleotide sequence without polymerase chain reaction
US7662594B2 (en) 2002-09-20 2010-02-16 New England Biolabs, Inc. Helicase-dependent amplification of RNA
CN103396933B (zh) 2003-02-26 2016-04-20 凯利达基因组股份有限公司 通过杂交进行的随机阵列dna分析
EP1604040B1 (en) 2003-03-07 2010-10-13 Rubicon Genomics, Inc. Amplification and analysis of whole genome and whole transcriptome libraries generated by a dna polymerization process
PL1601450T3 (pl) 2003-03-10 2014-03-31 Expression Pathology Inc Ciekły preparat tkankowy z próbek biologicznych, tkanek i komórek poddanych obróbce histopatologicznej
CN1300333C (zh) 2003-04-17 2007-02-14 中国人民解放军军事医学科学院放射与辐射医学研究所 炭疽菌诊断基因芯片的制备及应用
WO2005074417A2 (en) 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
US20050266417A1 (en) * 2003-09-12 2005-12-01 Francis Barany Methods for identifying target nucleic acid molecules
US20050147976A1 (en) 2003-12-29 2005-07-07 Xing Su Methods for determining nucleotide sequence information
JP4592060B2 (ja) 2004-04-26 2010-12-01 キヤノン株式会社 Ｐｃｒ増幅反応装置、ならびに、該装置を利用するｐｃｒ増幅反応方法
CN100396790C (zh) 2004-09-17 2008-06-25 北京大学 溶液识别、表面寻址蛋白质芯片及其制备和检测方法
US7527970B2 (en) 2004-10-15 2009-05-05 The United States Of America As Represented By The Department Of Health And Human Services Method of identifying active chromatin domains
WO2006084132A2 (en) 2005-02-01 2006-08-10 Agencourt Bioscience Corp. Reagents, methods, and libraries for bead-based squencing
GB0504774D0 (en) 2005-03-08 2005-04-13 Lingvitae As Method
US20070087360A1 (en) 2005-06-20 2007-04-19 Boyd Victoria L Methods and compositions for detecting nucleotides
CA2627967A1 (en) 2005-11-10 2007-05-24 Panomics, Inc. Detection of nucleic acids through amplification of surrogate nucleic acids
EP1969137B1 (en) * 2005-11-22 2011-10-05 Stichting Dienst Landbouwkundig Onderzoek Multiplex nucleic acid detection
DE102005060738A1 (de) 2005-12-16 2007-06-21 Qiagen Gmbh Verfahren zur Extraktion von Biomolekülen aus fixierten Geweben
AU2006330834B2 (en) 2005-12-23 2013-09-12 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
ES2374788T3 (es) 2005-12-23 2012-02-22 Nanostring Technologies, Inc. Nanoinformadores y métodos para su producción y uso.
DE102006002347A1 (de) 2006-01-18 2007-08-09 Busak + Shamban Deutschland Gmbh Lösbare Schutzlippe an Abstreifelement
GB0605584D0 (en) 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
US7858305B2 (en) 2006-06-30 2010-12-28 The Invention Science Fund I, Llc Method of combing a nucleic acid
CN101522915A (zh) 2006-08-02 2009-09-02 加州理工学院 用于检测和/或分选靶标的方法和系统
EP2076609A1 (en) 2006-10-10 2009-07-08 Illumina Inc. Compositions and methods for representational selection of nucleic acids fro complex mixtures using hybridization
WO2008151127A1 (en) 2007-06-04 2008-12-11 President And Fellows Of Harvard College Compounds and methods for chemical ligation
US9394567B2 (en) 2008-11-07 2016-07-19 Adaptive Biotechnologies Corporation Detection and quantification of sample contamination in immune repertoire analysis
US8288122B2 (en) 2008-12-03 2012-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Pressure-assisted molecular recovery (PAMR) of biomolecules, pressure-assisted antigen retrieval (PAAR), and pressure-assisted tissue histology (PATH)
US8481698B2 (en) 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
CA3018687C (en) 2009-04-02 2021-07-13 Fluidigm Corporation Multi-primer amplification method for barcoding of target nucleic acids
US8497071B2 (en) 2009-06-29 2013-07-30 California Institute Of Technology Isolation of unknown rearranged T-cell receptors from single cells
GB0912909D0 (en) * 2009-07-23 2009-08-26 Olink Genomics Ab Probes for specific analysis of nucleic acids
WO2011038403A1 (en) 2009-09-28 2011-03-31 Yuling Luo Methods of detecting nucleic acid sequences with high specificity
EP2488876B1 (en) 2009-10-13 2017-03-01 Nanostring Technologies, Inc Protein detection via nanoreporters
SG181543A1 (en) 2009-12-15 2012-07-30 Agency Science Tech & Res Processing of amplified dna fragments for sequencing
EP2516681B1 (en) 2010-02-11 2017-10-18 Nanostring Technologies, Inc Compositions and methods for the detection of preferably small rnas by bridge hybridisation and ligation
WO2011143556A1 (en) 2010-05-13 2011-11-17 Gen9, Inc. Methods for nucleotide sequencing and high fidelity polynucleotide synthesis
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
AU2011323107B2 (en) 2010-11-05 2015-09-10 Illumina, Inc. Linking sequence reads using paired code tags
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
WO2012129242A2 (en) 2011-03-23 2012-09-27 Pacific Biosciences Of California, Inc. Isolation of polymerase-nucleic acid complexes and loading onto substrates
US8946389B2 (en) 2011-04-25 2015-02-03 University Of Washington Compositions and methods for multiplex biomarker profiling
EP2710145B1 (en) 2011-05-17 2015-12-09 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
US9005935B2 (en) 2011-05-23 2015-04-14 Agilent Technologies, Inc. Methods and compositions for DNA fragmentation and tagging by transposases
GB201108678D0 (en) 2011-05-24 2011-07-06 Olink Ab Multiplexed proximity ligation assay
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP3604555A1 (en) 2011-10-14 2020-02-05 President and Fellows of Harvard College Sequencing by structure assembly
ES2953308T3 (es) 2011-12-22 2023-11-10 Harvard College Composiciones y métodos para la detección de analitos
NO2694769T3 (da) 2012-03-06 2018-03-03
US9914967B2 (en) 2012-06-05 2018-03-13 President And Fellows Of Harvard College Spatial sequencing of nucleic acids using DNA origami probes
US8895249B2 (en) 2012-06-15 2014-11-25 Illumina, Inc. Kinetic exclusion amplification of nucleic acid libraries
US9388465B2 (en) 2013-02-08 2016-07-12 10X Genomics, Inc. Polynucleotide barcode generation
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
WO2014071361A1 (en) 2012-11-05 2014-05-08 Rubicon Genomics Barcoding nucleic acids
WO2014076209A1 (en) 2012-11-14 2014-05-22 Olink Ab Localised rca-based amplification method
WO2014130576A1 (en) 2013-02-19 2014-08-28 Biodot, Inc. Automated fish analysis of tissue and cell samples using an isolating barrier for precise dispensing of probe and other reagents on regions of interest
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
US9330295B2 (en) 2013-03-15 2016-05-03 Brown University Spatial sequencing/gene expression camera
US10510435B2 (en) 2013-04-30 2019-12-17 California Institute Of Technology Error correction of multiplex imaging analysis by sequential hybridization
KR102436171B1 (ko) 2013-06-27 2022-08-24 10엑스 제노믹스, 인크. 샘플 처리를 위한 조성물 및 방법
SG10201806890VA (en) 2013-08-28 2018-09-27 Cellular Res Inc Massively parallel single cell analysis
JP6626830B2 (ja) 2013-11-07 2019-12-25 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． Ｄｎａ操作のための複数のトランスポザーゼアダプター
GB2520765A (en) 2013-12-02 2015-06-03 Vanadis Diagnostics Ab Multiplex detection of nucleic acids
GB201401885D0 (en) 2014-02-04 2014-03-19 Olink Ab Proximity assay with detection based on hybridisation chain reaction (HCR)
US10858698B2 (en) 2014-03-25 2020-12-08 President And Fellows Of Harvard College Barcoded protein array for multiplex single-molecule interaction profiling
WO2015157567A1 (en) 2014-04-10 2015-10-15 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
EP3845640A3 (en) 2014-04-15 2021-09-01 Illumina, Inc. Modified tranposases for improved insertion sequence bias and increased dna input tolerence
US9909167B2 (en) 2014-06-23 2018-03-06 The Board Of Trustees Of The Leland Stanford Junior University On-slide staining by primer extension
US20170212101A1 (en) 2014-07-18 2017-07-27 Cdi Laboratories, Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties
AU2015305570C1 (en) 2014-08-19 2020-07-23 President And Fellows Of Harvard College RNA-guided systems for probing and mapping of nucleic acids
WO2016044313A1 (en) 2014-09-16 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the removal of aldehyde adducts and crosslinks from biomolecules
CA2967036A1 (en) 2014-11-13 2016-05-19 The Board Of Trustees Of The University Of Illinois Bio-engineered hyper-functional "super" helicases
EP4095261A1 (en) * 2015-01-06 2022-11-30 Molecular Loop Biosciences, Inc. Screening for structural variants
US11046952B2 (en) 2015-03-16 2021-06-29 The Broad Institute, Inc. Encoding of DNA vector identity via iterative hybridization detection of a barcode transcript
US11408890B2 (en) 2015-04-14 2022-08-09 Massachusetts Institute Of Technology Iterative expansion microscopy
US10767220B2 (en) 2015-05-21 2020-09-08 Becton, Dickinson And Company Methods of amplifying nucleic acids and compositions for practicing the same
WO2017015097A1 (en) 2015-07-17 2017-01-26 Nanostring Technologies, Inc. Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
WO2017139501A1 (en) 2016-02-10 2017-08-17 The Board Of Trustees Of The Leland Stanford Junior University Rna fixation and detection in clarity-based hydrogel tissue
WO2017143155A2 (en) 2016-02-18 2017-08-24 President And Fellows Of Harvard College Multiplex alteration of cells using a pooled nucleic acid library and analysis thereof
WO2017161251A1 (en) 2016-03-17 2017-09-21 President And Fellows Of Harvard College Methods for detecting and identifying genomic nucleic acids
CA3022290A1 (en) 2016-04-25 2017-11-02 President And Fellows Of Harvard College Hybridization chain reaction methods for in situ molecular detection
CA3023566A1 (en) 2016-05-16 2017-11-23 Nanostring Technologies, Inc. Methods for detecting target nucleic acids in a sample
US10495554B2 (en) 2016-05-25 2019-12-03 The Board Of Trustees Of The Leland Stanford Junior University Method and system for imaging and analysis of a biological specimen
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
DK3481843T3 (en) 2016-07-05 2022-02-07 California Inst Of Techn Fractional initiator hybridization chain reaction
JP6747894B2 (ja) 2016-07-08 2020-08-26 ファナック株式会社 ネットワークを利用した診断サービスシステム及び診断方法
EP3491151A4 (en) 2016-08-01 2020-07-29 California Institute of Technology SEQUENTIAL SURVEY OF MOLECULAR TARGETS BASED ON PSEUDO-COLORED BAR CODES PRESENTING AN INTEGRATED ERROR CORRECTION MECHANISM
US20210017587A1 (en) 2016-08-01 2021-01-21 California Institute Of Technology Sequential probing of molecular targets based on pseudo-color barcodes with embedded error correction mechanism
CA3034617A1 (en) 2016-08-30 2018-03-08 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
CA3043489A1 (en) 2016-11-21 2018-05-24 Nanostring Technologies, Inc. Chemical compositions and methods of using same
US20190177800A1 (en) 2017-12-08 2019-06-13 10X Genomics, Inc. Methods and compositions for labeling cells
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11492661B2 (en) 2017-01-10 2022-11-08 President And Fellows Of Harvard College Multiplexed signal amplification
US10711269B2 (en) 2017-01-18 2020-07-14 Agilent Technologies, Inc. Method for making an asymmetrically-tagged sequencing library
EP4029939B1 (en) 2017-01-30 2023-06-28 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
JP7248368B2 (ja) 2017-03-01 2023-03-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高度に特異的な環状近接ライゲーションアッセイ
WO2018175779A1 (en) 2017-03-22 2018-09-27 The Board Of Trustees Of The Leland Stanford Junior University Molecular profiling using proximity ligation-in situ hybridization
JP2020523992A (ja) 2017-06-16 2020-08-13 ザ ジョンズ ホプキンス ユニバーシティ Ｇタンパク質共役受容体媒介症状を治療するための組成物および方法
US11180804B2 (en) 2017-07-25 2021-11-23 Massachusetts Institute Of Technology In situ ATAC sequencing
US20190064173A1 (en) 2017-08-22 2019-02-28 10X Genomics, Inc. Methods of producing droplets including a particle and an analyte
US10837047B2 (en) 2017-10-04 2020-11-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US10590244B2 (en) 2017-10-04 2020-03-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
EP3625361A1 (en) 2017-11-15 2020-03-25 10X Genomics, Inc. Functionalized gel beads
AU2018375160A1 (en) * 2017-11-29 2020-05-28 Xgenomes Corp. Sequencing of nucleic acids by emergence
EP3720972A1 (en) 2017-12-08 2020-10-14 California Institute of Technology Multiplex labeling of molecules by sequential hybridization barcoding with rapid switching and rehybridzation of probes
WO2019195166A1 (en) 2018-04-06 2019-10-10 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US20190360043A1 (en) 2018-05-23 2019-11-28 Pacific Biosciences Of California, Inc. Enrichment of dna comprising target sequence of interest
US20210254134A1 (en) 2018-06-12 2021-08-19 Accuragen Holdings Limited Methods and compositions for forming ligation products
CN108949924B (zh) 2018-06-27 2021-10-08 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 基因缺失突变的荧光检测试剂盒和荧光检测方法
KR101981301B1 (ko) 2018-08-10 2019-05-22 대신아이브(주) 화재진압용 비행기
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US20230147726A1 (en) 2018-09-28 2023-05-11 Danmarks Tekniske Universitet High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
WO2020082087A1 (en) 2018-10-19 2020-04-23 Akoya Biosciences, Inc. Detection of co-occurring receptor-coding nucleic acid segments
GB201818742D0 (en) 2018-11-16 2019-01-02 Cartana Ab Method for detection of RNA
US20220195504A1 (en) 2018-11-30 2022-06-23 Illumina, Inc. Analysis of multiple analytes using a single assay
CN113227395A (zh) 2018-12-04 2021-08-06 豪夫迈·罗氏有限公司 细胞靶标的空间上定向的量子条形编码
US20230242976A1 (en) 2018-12-10 2023-08-03 10X Genomics, Inc. Imaging system hardware
US20220049293A1 (en) 2018-12-10 2022-02-17 10X Genomics, Inc. Methods for determining a location of a biological analyte in a biological sample
DE102018132378A1 (de) 2018-12-17 2020-06-18 Hamm Ag Bodenbearbeitungsmaschine
US20200199565A1 (en) 2018-12-20 2020-06-25 New England Biolabs, Inc. Proteinases with Improved Properties
MX2021003712A (es) 2018-12-21 2021-07-16 Illumina Inc Reducción de arn basada en nucleasa.
US20220267844A1 (en) 2019-11-27 2022-08-25 10X Genomics, Inc. Methods for determining a location of a biological analyte in a biological sample
WO2020167862A1 (en) 2019-02-12 2020-08-20 10X Genomics, Inc. Systems and methods for transfer of reagents between droplets
CN113747974A (zh) 2019-02-28 2021-12-03 10X基因组学有限公司 用于提高液滴形成效率的装置、系统和方法
US20230143569A1 (en) 2019-02-28 2023-05-11 10X Genomics, Inc. Profiling of biological analytes with spatially barcoded oligonucleotide arrays
US20220145361A1 (en) 2019-03-15 2022-05-12 10X Genomics, Inc. Methods for using spatial arrays for single cell sequencing
EP3887542A1 (en) 2019-03-22 2021-10-06 10X Genomics, Inc. Three-dimensional spatial analysis
EP3947727A4 (en) 2019-04-05 2023-01-04 Board of Regents, The University of Texas System METHODS AND APPLICATIONS OF CELL BARCODING
CA3139791A1 (en) 2019-05-31 2020-12-03 10X Genomics, Inc. Method of detecting target nucleic acid molecules
EP3754028A1 (en) 2019-06-18 2020-12-23 Apollo Life Sciences GmbH Method of signal encoding of analytes in a sample
CN114761992B (zh) 2019-10-01 2023-08-08 10X基因组学有限公司 用于识别组织样品中的形态学模式的系统和方法
GB201918340D0 (en) 2019-12-12 2020-01-29 Cambridge Entpr Ltd Spatial barcoding
US20210190770A1 (en) 2019-12-23 2021-06-24 10X Genomics, Inc. Compositions and methods for using fixed biological samples in partition-based assays
CN115135984A (zh) 2019-12-23 2022-09-30 10X基因组学有限公司 可逆固定试剂及其使用方法
EP4087945B1 (en) 2020-01-10 2024-03-06 10X Genomics, Inc. Methods for determining a location of a target nucleic acid in a biological sample
US20220348992A1 (en) 2020-01-10 2022-11-03 10X Genomics, Inc. Methods for determining a location of a target nucleic acid in a biological sample
US20210237022A1 (en) 2020-01-31 2021-08-05 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
WO2021158925A1 (en) 2020-02-07 2021-08-12 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
CA3168202A1 (en) 2020-02-21 2021-08-26 Felice Alessio BAVA Methods and compositions for integrated in situ spatial assay
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
WO2021207610A1 (en) 2020-04-10 2021-10-14 10X Genomics, Inc. Cold protease treatment method for preparing biological samples
WO2021212042A1 (en) 2020-04-16 2021-10-21 10X Genomics, Inc. Compositions and methods for use with fixed samples
EP4164796A4 (en) 2020-06-10 2024-03-06 10X Genomics Inc FLUID DISTRIBUTION PROCESSES
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
CN116323968A (zh) 2020-07-31 2023-06-23 10X基因组学有限公司 用于空间分析的去交联化合物和使用方法
WO2022060798A1 (en) 2020-09-15 2022-03-24 10X Genomics, Inc. Methods of releasing an extended capture probe from a substrate and uses of the same
WO2022060953A1 (en) 2020-09-16 2022-03-24 10X Genomics, Inc. Methods of determining the location of an analyte in a biological sample using a plurality of wells
EP4213993A2 (en) 2020-09-18 2023-07-26 10X Genomics, Inc. Sample handling apparatus and fluid delivery methods
EP4214330A1 (en) 2020-10-22 2023-07-26 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification
CN116829733A (zh) 2020-11-06 2023-09-29 10X基因组学有限公司 用于将分析物结合至捕获探针的组合物和方法
WO2022098810A1 (en) 2020-11-06 2022-05-12 10X Genomics, Inc. Assay support devices
EP4244379A1 (en) 2020-11-13 2023-09-20 10X Genomics, Inc. Nano-partitions (encapsulated nucleic acid processing enzymes) for cell-lysis and multiple reactions in partition-based assays
US20230407404A1 (en) 2020-11-18 2023-12-21 10X Genomics, Inc. Methods and compositions for analyzing immune infiltration in cancer stroma to predict clinical outcome
EP4121555A1 (en) 2020-12-21 2023-01-25 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US20240076723A1 (en) 2020-12-30 2024-03-07 10X Genomics, Inc. Cleavage of capture probes for spatial analysis
US20240068017A1 (en) 2020-12-30 2024-02-29 10X Genomics, Inc. Methods for analyte capture determination
WO2022164615A1 (en) 2021-01-29 2022-08-04 10X Genomics, Inc. Method for transposase mediated spatial tagging and analyzing genomic dna in a biological sample
WO2022178267A2 (en) 2021-02-19 2022-08-25 10X Genomics, Inc. Modular assay support devices
EP4301870A1 (en) 2021-03-18 2024-01-10 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
IL307195A (en) 2021-03-29 2023-11-01 Illumina Inc Improved methods of library preparation
EP4305196A1 (en) 2021-04-14 2024-01-17 10X Genomics, Inc. Methods of measuring mislocalization of an analyte
WO2022226057A1 (en) 2021-04-20 2022-10-27 10X Genomics, Inc. Methods for assessing sample quality prior to spatial analysis using templated ligation
US20220333192A1 (en) 2021-04-20 2022-10-20 10X Genomics, Inc. Methods and devices for spatial assessment of rna quality
WO2022236054A1 (en) 2021-05-06 2022-11-10 10X Genomics, Inc. Methods for increasing resolution of spatial analysis
WO2022256503A1 (en) 2021-06-03 2022-12-08 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
WO2022271820A1 (en) 2021-06-22 2022-12-29 10X Genomics, Inc. Spatial detection of sars-cov-2 using templated ligation
EP4352252A1 (en) 2021-07-13 2024-04-17 10X Genomics, Inc. Methods for spatial analysis using targeted probe silencing
US20230014008A1 (en) 2021-07-13 2023-01-19 10X Genomics, Inc. Methods for improving spatial performance
US20230034216A1 (en) 2021-07-28 2023-02-02 10X Genomics, Inc. Multiplexed spatial capture of analytes
US20230034039A1 (en) 2021-08-02 2023-02-02 10X Genomics, Inc. Methods of preserving a biological sample
US20230042817A1 (en) 2021-08-04 2023-02-09 10X Genomics, Inc. Analyte capture from an embedded biological sample
EP4370675A1 (en) 2021-08-12 2024-05-22 10X Genomics, Inc. Methods, compositions and systems for identifying antigen-binding molecules
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023076345A1 (en) 2021-10-26 2023-05-04 10X Genomics, Inc. Methods for spatial analysis using targeted rna capture
US20230135010A1 (en) 2021-11-03 2023-05-04 10X Genomics, Inc. Sequential analyte capture
WO2023086880A1 (en) 2021-11-10 2023-05-19 10X Genomics, Inc. Methods, compositions, and kits for determining the location of an analyte in a biological sample
WO2023102118A2 (en) 2021-12-01 2023-06-08 10X Genomics, Inc. Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
US20230175045A1 (en) 2021-12-03 2023-06-08 10X Genomics, Inc. Method for transposase mediated spatial tagging and analyzing genomic dna in a biological sample
WO2023150163A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from lymphatic tissue
WO2023150098A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, kits, compositions, and systems for spatial analysis
WO2023150171A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from glioblastoma samples

Patent Citations (619)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (da) 1985-03-28 1990-11-27 Cetus Corp
US4883867A (en) 1985-11-01 1989-11-28 Becton, Dickinson And Company Detection of reticulocytes, RNA or DNA
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (da) 1986-01-30 1990-11-27 Cetus Corp
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
WO1989010977A1 (en) 1988-05-03 1989-11-16 Isis Innovation Limited Analysing polynucleotide sequences
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5002882A (en) 1989-04-27 1991-03-26 New England Biolabs, Inc. Method for producing the XmaI restriction endonuclease and methylase
WO1991006678A1 (en) 1989-10-26 1991-05-16 Sri International Dna sequencing
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5830711A (en) 1990-05-03 1998-11-03 Cornell Research Foundation, Inc. Thermostable ligase mediated DNA amplification system for the detection of genetic diseases
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US6210894B1 (en) 1991-09-04 2001-04-03 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5582977A (en) 1991-09-16 1996-12-10 Molecular Probes, Inc. Dimers of unsymmetrical cyanine dyes
US5321130A (en) 1992-02-10 1994-06-14 Molecular Probes, Inc. Unsymmetrical cyanine dyes with a cationic side chain
US5308751A (en) 1992-03-23 1994-05-03 General Atomics Method for sequencing double-stranded DNA
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5410030A (en) 1993-04-05 1995-04-25 Molecular Probes, Inc. Dimers of unsymmetrical cyanine dyes containing pyridinium moieties
US5658751A (en) 1993-04-13 1997-08-19 Molecular Probes, Inc. Substituted unsymmetrical cyanine dyes with selected permeability
US5436134A (en) 1993-04-13 1995-07-25 Molecular Probes, Inc. Cyclic-substituted unsymmetrical cyanine dyes
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6401267B1 (en) 1993-09-27 2002-06-11 Radoje Drmanac Methods and compositions for efficient nucleic acid sequencing
US5871921A (en) 1994-02-16 1999-02-16 Landegren; Ulf Circularizing nucleic acid probe able to interlock with a target sequence through catenation
US5512462A (en) 1994-02-25 1996-04-30 Hoffmann-La Roche Inc. Methods and reagents for the polymerase chain reaction amplification of long DNA sequences
WO1995023875A1 (en) 1994-03-02 1995-09-08 The Johns Hopkins University In vitro transposition of artificial transposons
US6214587B1 (en) 1994-03-16 2001-04-10 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
WO1995025116A1 (en) 1994-03-16 1995-09-21 California Institute Of Technology Method and apparatus for performing multiple sequential reactions on a matrix
US5599675A (en) 1994-04-04 1997-02-04 Spectragen, Inc. DNA sequencing by stepwise ligation and cleavage
WO1995035505A1 (en) 1994-06-17 1995-12-28 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for fabricating microarrays of biological samples
US5641658A (en) 1994-08-03 1997-06-24 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid with two primers bound to a single solid support
US6130073A (en) 1994-08-19 2000-10-10 Perkin-Elmer Corp., Applied Biosystems Division Coupled amplification and ligation method
US5912148A (en) 1994-08-19 1999-06-15 Perkin-Elmer Corporation Applied Biosystems Coupled amplification and ligation method
US6172218B1 (en) 1994-10-13 2001-01-09 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US5863753A (en) 1994-10-27 1999-01-26 Molecular Probes, Inc. Chemically reactive unsymmetrical cyanine dyes and their conjugates
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US5648245A (en) 1995-05-09 1997-07-15 Carnegie Institution Of Washington Method for constructing an oligonucleotide concatamer library by rolling circle replication
US7192735B2 (en) 1995-10-13 2007-03-20 President & Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US20030138879A1 (en) 1995-10-13 2003-07-24 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US6579695B1 (en) 1995-10-13 2003-06-17 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5763175A (en) 1995-11-17 1998-06-09 Lynx Therapeutics, Inc. Simultaneous sequencing of tagged polynucleotides
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US6344316B1 (en) 1996-01-23 2002-02-05 Affymetrix, Inc. Nucleic acid analysis techniques
US7892747B2 (en) 1996-02-09 2011-02-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
WO1997031256A2 (en) 1996-02-09 1997-08-28 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7888009B2 (en) 1996-02-09 2011-02-15 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US8624016B2 (en) 1996-02-09 2014-01-07 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7914981B2 (en) 1996-02-09 2011-03-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6027889A (en) 1996-05-29 2000-02-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6797470B2 (en) 1996-05-29 2004-09-28 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US8597891B2 (en) 1996-05-29 2013-12-03 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6268148B1 (en) 1996-05-29 2001-07-31 Francis Barany Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US5925545A (en) 1996-09-09 1999-07-20 Wisconsin Alumni Research Foundation System for in vitro transposition
US5965443A (en) 1996-09-09 1999-10-12 Wisconsin Alumni Research Foundation System for in vitro transposition
US6210891B1 (en) 1996-09-27 2001-04-03 Pyrosequencing Ab Method of sequencing DNA
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6165714A (en) 1996-12-16 2000-12-26 Vysis, Inc. Devices and methods for detecting nucleic acid analytes in samples
US6258568B1 (en) 1996-12-23 2001-07-10 Pyrosequencing Ab Method of sequencing DNA based on the detection of the release of pyrophosphate and enzymatic nucleotide degradation
US6737236B1 (en) 1997-01-08 2004-05-18 Proligo, Llc Bioconjugation of macromolecules
US6309824B1 (en) 1997-01-16 2001-10-30 Hyseq, Inc. Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes
US6859570B2 (en) 1997-03-14 2005-02-22 Trustees Of Tufts College, Tufts University Target analyte sensors utilizing microspheres
US20050130188A1 (en) 1997-03-14 2005-06-16 The Trustees Of Tufts College Methods for detecting target analytes and enzymatic reactions
US6266459B1 (en) 1997-03-14 2001-07-24 Trustees Of Tufts College Fiber optic sensor with encoded microspheres
US20080286795A1 (en) 1997-04-01 2008-11-20 Solexa Limited Method of nucleic acid amplification
US20020055100A1 (en) 1997-04-01 2002-05-09 Kawashima Eric H. Method of nucleic acid sequencing
US20050100900A1 (en) 1997-04-01 2005-05-12 Manteia Sa Method of nucleic acid amplification
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US20030224419A1 (en) 1997-05-23 2003-12-04 Lynx Therapeutics, Inc. Data analysis and display system for ligation-based DNA sequencing
US5958775A (en) 1997-07-25 1999-09-28 Thomas Jefferson University Composition and method for targeted integration into cells
US6432360B1 (en) 1997-10-10 2002-08-13 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US20030162216A1 (en) 1997-12-15 2003-08-28 Somalogic, Inc. Nucleic acid ligand diagnostic biochip
US7258976B2 (en) 1997-12-22 2007-08-21 Hitachi Chemical Co. Ltd. Method of preparing cell lysate
US8460865B2 (en) 1998-06-24 2013-06-11 Illumina, Inc. Multiplex decoding of array sensors with microspheres
US6404907B1 (en) 1998-06-26 2002-06-11 Visible Genetics Inc. Method for sequencing nucleic acids with reduced errors
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US20040106110A1 (en) 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
WO2000017390A1 (en) 1998-09-18 2000-03-30 Micromet Ag Dna amplification of a single cell
US6159736A (en) 1998-09-23 2000-12-12 Wisconsin Alumni Research Foundation Method for making insertional mutations using a Tn5 synaptic complex
US20080160580A1 (en) 1998-09-30 2008-07-03 Solexa, Inc Methods of nucleic acid amplification and sequencing
US7115400B1 (en) 1998-09-30 2006-10-03 Solexa Ltd. Methods of nucleic acid amplification and sequencing
US20030022207A1 (en) 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US20090082212A1 (en) 1998-12-14 2009-03-26 Pacific Biosciences System and methods for nucleic acid sequencing of single molecules by polymerase synthesis
US20050191656A1 (en) 1999-01-06 2005-09-01 Callida Genomics, Inc. Enhanced sequencing by hybridization using pools of probes
US6864052B1 (en) 1999-01-06 2005-03-08 Callida Genomics, Inc. Enhanced sequencing by hybridization using pools of probes
US6828100B1 (en) 1999-01-22 2004-12-07 Biotage Ab Method of DNA sequencing
US6506561B1 (en) 1999-01-27 2003-01-14 Commissariat A L'energie Atomique Method of obtaining a library of tags capable of defining a specific state of a biological sample
US6153389A (en) 1999-02-22 2000-11-28 Haarer; Brian K. DNA additives as a mechanism for unambiguously marking biological samples
US6355431B1 (en) 1999-04-20 2002-03-12 Illumina, Inc. Detection of nucleic acid amplification reactions using bead arrays
US20050191698A1 (en) 1999-04-20 2005-09-01 Illumina, Inc. Nucleic acid sequencing using microsphere arrays
EP1923471A1 (en) 1999-04-20 2008-05-21 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US20010055764A1 (en) 1999-05-07 2001-12-27 Empedocles Stephen A. Microarray methods utilizing semiconductor nanocrystals
US6544732B1 (en) 1999-05-20 2003-04-08 Illumina, Inc. Encoding and decoding of array sensors utilizing nanocrystals
US8206917B2 (en) 1999-05-20 2012-06-26 Illumina, Inc. Combinatorial decoding of random nucleic acid arrays
US7563576B2 (en) 1999-05-20 2009-07-21 Illumina, Inc. Combinatorial decoding of random nucleic acid arrays
US7166431B2 (en) 1999-05-20 2007-01-23 Illumina, Inc. Combinatorial decoding of random nucleic acid arrays
US6620584B1 (en) 1999-05-20 2003-09-16 Illumina Combinatorial decoding of random nucleic acid arrays
US7960119B2 (en) 1999-05-20 2011-06-14 Illumina, Inc. Combinatorial decoding of random nucleic acid arrays
US20040082059A1 (en) 1999-07-22 2004-04-29 Webb Peter G. Methods of fabricating an addressable array of biopolymer probes
WO2001009363A1 (en) 1999-08-02 2001-02-08 Wisconsin Alumni Research Foundation Mutant tn5 transposase enzymes and method for their use
US6773886B2 (en) 1999-08-13 2004-08-10 Yale University Binary encoded sequence tags
US6942968B1 (en) 1999-08-30 2005-09-13 Illumina, Inc. Array compositions for improved signal detection
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US6833246B2 (en) 1999-09-29 2004-12-21 Solexa, Ltd. Polynucleotide sequencing
US6291180B1 (en) 1999-09-29 2001-09-18 American Registry Of Pathology Ultrasound-mediated high-speed biological reaction and tissue processing
US6503713B1 (en) 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6632641B1 (en) 1999-10-08 2003-10-14 Metrigen, Inc. Method and apparatus for performing large numbers of reactions using array assembly with releasable primers
US20030232382A1 (en) 1999-10-08 2003-12-18 Brennan Thomas M. Method and apparatus for performing large numbers of reactions using array assembly
WO2001042796A1 (en) 1999-12-13 2001-06-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health High-throughput tissue microarray technology and applications
US20030064398A1 (en) 2000-02-02 2003-04-03 Solexa, Ltd. Synthesis of spatially addressed molecular arrays
US6812005B2 (en) 2000-02-07 2004-11-02 The Regents Of The University Of California Nucleic acid detection methods using universal priming
US8076063B2 (en) 2000-02-07 2011-12-13 Illumina, Inc. Multiplexed methylation detection methods
US8906626B2 (en) 2000-02-07 2014-12-09 Illumina, Inc. Multiplex nucleic acid reactions
US7361488B2 (en) 2000-02-07 2008-04-22 Illumina, Inc. Nucleic acid detection methods using universal priming
US6890741B2 (en) 2000-02-07 2005-05-10 Illumina, Inc. Multiplexed detection of analytes
US20180094316A1 (en) 2000-02-07 2018-04-05 Illumina, Inc. Multiplex nucleic acid reactions
US9850536B2 (en) 2000-02-07 2017-12-26 Illumina, Inc. Multiplex nucleic acid reactions
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
US8003354B2 (en) 2000-02-07 2011-08-23 Illumina, Inc. Multiplex nucleic acid reactions
US8288103B2 (en) 2000-02-07 2012-10-16 Illumina, Inc. Multiplex nucleic acid reactions
US6770441B2 (en) 2000-02-10 2004-08-03 Illumina, Inc. Array compositions and methods of making same
US20020040275A1 (en) 2000-04-10 2002-04-04 The Scripps Research Institute Proteomic analysis
US6368801B1 (en) 2000-04-12 2002-04-09 Molecular Staging, Inc. Detection and amplification of RNA using target-mediated ligation of DNA by RNA ligase
WO2001090415A2 (en) 2000-05-20 2001-11-29 The Regents Of The University Of Michigan Method of producing a dna library using positional amplification
WO2001096608A1 (en) 2000-06-15 2001-12-20 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US20110059436A1 (en) 2000-07-07 2011-03-10 Life Technologies Corporation Methods for sequence determination
US7329492B2 (en) 2000-07-07 2008-02-12 Visigen Biotechnologies, Inc. Methods for real-time single molecule sequence determination
US6867028B2 (en) 2000-07-24 2005-03-15 Fermentas Ab Strand-specific polynucleotide nickases
US20020048766A1 (en) 2000-07-28 2002-04-25 Doyle Michael D. Method and system for the multidimensional morphological reconstruction of genome expression activity
US7674752B2 (en) 2000-08-15 2010-03-09 Discema Limited Functional protein arrays
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US6897023B2 (en) 2000-09-27 2005-05-24 The Molecular Sciences Institute, Inc. Method for determining relative abundance of nucleic acid sequences
US20020164611A1 (en) 2000-11-15 2002-11-07 Bamdad R. Shoshana Oligonucleotide identifiers
US7211414B2 (en) 2000-12-01 2007-05-01 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US20040096853A1 (en) 2000-12-08 2004-05-20 Pascal Mayer Isothermal amplification of nucleic acids on a solid support
US20030215936A1 (en) 2000-12-13 2003-11-20 Olli Kallioniemi High-throughput tissue microarray technology and applications
US20030017451A1 (en) 2000-12-21 2003-01-23 Hui Wang Methods for detecting transcripts
WO2002077283A1 (en) 2000-12-21 2002-10-03 Affymetrix, Inc. Methods for detecting transcripts
US7118883B2 (en) 2000-12-28 2006-10-10 Post Genome Institute Co., Ltd. Process for producing peptides by using in vitro transcription/translation system
US20050048580A1 (en) 2001-01-23 2005-03-03 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
US6800453B2 (en) 2001-01-23 2004-10-05 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
WO2002059355A2 (en) 2001-01-25 2002-08-01 Tm Bioscience Corporation Polynucleotides for use as tags and tag complements, manufacture and use thereof
WO2002059364A1 (en) 2001-01-27 2002-08-01 Electron-Bio, Inc. Nucleic hybridization assay method and device using a cleavage technique responsive to the complementary double strand or the single strand of nucleic acids or oligonucleotides
US20030165948A1 (en) 2001-03-09 2003-09-04 Alsmadi Osama A. Method and compositions for efficient and specific rolling circle amplification
US7297518B2 (en) 2001-03-12 2007-11-20 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
WO2003002979A2 (en) 2001-06-28 2003-01-09 Illumina, Inc. Multiplex decoding of array sensors with microspheres
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
US20040248325A1 (en) 2001-07-19 2004-12-09 Cuneyt Bukusoglu Method for simultaneous multiple probes/multiple targets screening procedure
WO2003010176A2 (en) 2001-07-24 2003-02-06 Oxford Glycosciences (Uk) Ltd Protein-nucleic acid complexes
US20040067493A1 (en) 2001-07-25 2004-04-08 Affymetrix, Inc. Complexity management of genomic DNA
US20040019005A1 (en) 2001-10-01 2004-01-29 Jeffrey Van Ness Methods for parallel measurement of genetic variations
US20030148335A1 (en) 2001-10-10 2003-08-07 Li Shen Detecting targets by unique identifier nucleotide tags
US20050164292A1 (en) 2001-10-24 2005-07-28 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
US20100145037A1 (en) 2001-11-13 2010-06-10 Rubicon Genomics, Inc. Dna amplification and sequencing using dna molecules generated by random fragmentation
US20050064460A1 (en) 2001-11-16 2005-03-24 Medical Research Council Emulsion compositions
US20060188901A1 (en) 2001-12-04 2006-08-24 Solexa Limited Labelled nucleotides
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20050202433A1 (en) 2002-06-03 2005-09-15 Van Beuningen Marinus Gerardus J. Novel high density arrays and methods for analyte analysis
US20030232348A1 (en) 2002-06-17 2003-12-18 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
WO2004015080A2 (en) 2002-08-09 2004-02-19 Illumina, Inc. Nucleic acid detection methods using universal priming
US20040033499A1 (en) 2002-08-16 2004-02-19 Ilsley Diane D. Method for synthesis of the second strand of cDNA
US20070166705A1 (en) 2002-08-23 2007-07-19 John Milton Modified nucleotides
US7282328B2 (en) 2002-09-20 2007-10-16 New England Biolabs, Inc. Helicase dependent amplification of nucleic acids
US20110152111A1 (en) 2002-10-03 2011-06-23 Illumina, Inc. Multiplex nucleic acid analysis using archived or fixed samples
US20040259105A1 (en) 2002-10-03 2004-12-23 Jian-Bing Fan Multiplex nucleic acid analysis using archived or fixed samples
US20040067492A1 (en) 2002-10-04 2004-04-08 Allan Peng Reverse transcription on microarrays
US20040224326A1 (en) 2003-01-03 2004-11-11 Young-A Kim Method of replicating nucleic acid array
US20050130173A1 (en) 2003-01-29 2005-06-16 Leamon John H. Methods of amplifying and sequencing nucleic acids
WO2004067759A2 (en) 2003-01-29 2004-08-12 Cranfield University Replication of nucleic acid arrays
US20060199183A1 (en) 2003-03-13 2006-09-07 Christophe Valat Probe biochips and methods for use thereof
US7083980B2 (en) 2003-04-17 2006-08-01 Wisconsin Alumni Research Foundation Tn5 transposase mutants and the use thereof
US20100173384A1 (en) 2003-05-23 2010-07-08 Kai Johnsson Methods for protein labeling based on acyl carrier protein
US7666612B2 (en) 2003-05-23 2010-02-23 Epfl-Ecole Polytechnique Federale De Lausanne Methods for protein labeling based on acyl carrier protein
US7255994B2 (en) 2003-06-10 2007-08-14 Applera Corporation Ligation assay
US20060216775A1 (en) 2003-06-17 2006-09-28 The Regents Of The University Of Califoenia Compositions and methods for analysis and manipulation of enzymes in biosynthetic proteomes
US20050037393A1 (en) 2003-06-20 2005-02-17 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US20070128656A1 (en) 2003-06-26 2007-06-07 University Of South Florida Direct Fluorescent Label Incorporation Via 1st Strand cDNA Synthesis
WO2005007814A2 (en) 2003-07-03 2005-01-27 The Regents Of The University Of California Genome mapping of functional dna elements and cellular proteins
US7601492B2 (en) 2003-07-03 2009-10-13 The Regents Of The University Of California Genome mapping of functional DNA elements and cellular proteins
WO2005010145A2 (en) 2003-07-05 2005-02-03 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
US20080153086A1 (en) 2003-08-08 2008-06-26 Wong Albert J Method For Rapid Identification of Alternative Splicing
US20070269805A1 (en) 2003-09-02 2007-11-22 Keygene N.V. Ola-Based Methods for the Detection of Target Nucleic Avid Sequences
WO2005042759A2 (en) 2003-09-10 2005-05-12 Althea Technologies, Inc. Expression profiling using microarrays
US20060240439A1 (en) 2003-09-11 2006-10-26 Smith Geoffrey P Modified polymerases for improved incorporation of nucleotide analogues
WO2005026387A1 (en) 2003-09-18 2005-03-24 Nuevolution A/S A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
US20070054288A1 (en) 2003-09-24 2007-03-08 Intel Corporation Programmable molecular barcodes
US20050136414A1 (en) 2003-12-23 2005-06-23 Kevin Gunderson Methods and compositions for making locus-specific arrays
US20080261204A1 (en) 2004-01-23 2008-10-23 Lingvitae As Polynucleotide Ligation Reactions
US7378242B2 (en) 2004-03-18 2008-05-27 Atom Sciences, Inc. DNA sequence detection by limited primer extension
CN1680604A (zh) 2004-04-10 2005-10-12 三星电子株式会社 具有微阵列识别信息的微阵列及其生产方法和使用方法
US20050227271A1 (en) 2004-04-10 2005-10-13 Kwon Tae-Joon Microarray having microarray identification information stored in the form of a spot, method of producing the microarray and method of using the microarray
US20050260653A1 (en) 2004-04-14 2005-11-24 Joshua Labaer Nucleic-acid programmable protein arrays
WO2005113804A1 (en) 2004-05-20 2005-12-01 Trillion Genomics Limited Use of mass labelled probes to detect target nucleic acids using mass spectrometry
US20070207482A1 (en) 2004-08-04 2007-09-06 President And Fellows Of Harvard College Wobble sequencing
US7608434B2 (en) 2004-08-04 2009-10-27 Wisconsin Alumni Research Foundation Mutated Tn5 transposase proteins and the use thereof
US7776547B2 (en) 2004-08-26 2010-08-17 Intel Corporation Cellular analysis using Raman surface scanning
US20060046313A1 (en) 2004-08-26 2006-03-02 Intel Corporation Cellular analysis using Raman surface scanning
US9506061B2 (en) 2004-11-12 2016-11-29 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20060105352A1 (en) 2004-11-15 2006-05-18 Eastman Kodak Company Method for sensitive detection of multiple biological analytes
US8951728B2 (en) 2004-11-22 2015-02-10 Chemgene Holding Aps Template directed split and mix synthesis of small molecule libraries
US7579153B2 (en) 2005-01-25 2009-08-25 Population Genetics Technologies, Ltd. Isothermal DNA amplification
US7407757B2 (en) 2005-02-10 2008-08-05 Population Genetics Technologies Genetic analysis by sequence-specific sorting
US9194001B2 (en) 2005-02-10 2015-11-24 Population Genetics Technologies Ltd. Methods and compositions for tagging and identifying polynucleotides
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US8148068B2 (en) 2005-02-10 2012-04-03 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US8507204B2 (en) 2005-03-08 2013-08-13 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
US7601498B2 (en) 2005-03-17 2009-10-13 Biotium, Inc. Methods of using dyes in association with nucleic acid staining or detection and associated technology
US7776567B2 (en) 2005-03-17 2010-08-17 Biotium, Inc. Dimeric and trimeric nucleic acid dyes, and associated systems and methods
US7803943B2 (en) 2005-03-17 2010-09-28 Biotium, Inc. Methods of using dyes in association with nucleic acid staining or detection and associated technology
US20060211001A1 (en) 2005-03-18 2006-09-21 Wisconsin Alumni Research Foundation Microdissection-based methods for determining genomic features of single chromosomes
US7700286B2 (en) 2005-04-06 2010-04-20 Maurice Stroun Method for the detection of cancer
US20060281109A1 (en) 2005-05-10 2006-12-14 Barr Ost Tobias W Polymerases
WO2006124771A2 (en) 2005-05-12 2006-11-23 Panomics, Inc. Multiplex branched-chain dna assays
US20060263789A1 (en) 2005-05-19 2006-11-23 Robert Kincaid Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using
WO2007145612A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
US20070099208A1 (en) 2005-06-15 2007-05-03 Radoje Drmanac Single molecule arrays for genetic and chemical analysis
US8951726B2 (en) 2005-06-20 2015-02-10 Advanced Cell Diagnostics, Inc. Multiplex detection of nucleic acids
US8604182B2 (en) 2005-06-20 2013-12-10 Advanced Cell Diagnostics, Inc. Multiplex detection of nucleic acids
US7709198B2 (en) 2005-06-20 2010-05-04 Advanced Cell Diagnostics, Inc. Multiplex detection of nucleic acids
EP2292788A1 (en) 2005-06-23 2011-03-09 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9898577B2 (en) 2005-06-23 2018-02-20 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9447459B2 (en) 2005-06-23 2016-09-20 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US20180247017A1 (en) 2005-06-23 2018-08-30 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9898576B2 (en) 2005-06-23 2018-02-20 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US8785353B2 (en) 2005-06-23 2014-07-22 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9376716B2 (en) 2005-06-23 2016-06-28 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
EP1910562A1 (en) 2005-06-23 2008-04-16 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9493820B2 (en) 2005-06-23 2016-11-15 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US8685889B2 (en) 2005-06-23 2014-04-01 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US10095832B2 (en) 2005-06-23 2018-10-09 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9453256B2 (en) 2005-06-23 2016-09-27 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US9023768B2 (en) 2005-06-23 2015-05-05 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
EP2302070A2 (en) 2005-06-23 2011-03-30 Keygene N.V. Strategies for high throughput identification and detection fo polymorpisms
US9896721B2 (en) 2005-06-23 2018-02-20 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US20090036323A1 (en) 2005-06-23 2009-02-05 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
US20070026430A1 (en) 2005-06-30 2007-02-01 Applera Corporation Proximity probing of target proteins comprising restriction and/or extension
US20070020669A1 (en) 2005-07-08 2007-01-25 Olof Ericsson Regulation analysis by cis reactivity, RACR
JP2007014297A (ja) 2005-07-11 2007-01-25 Onchip Cellomics Consortium 細胞構成物質分取チップならびに細胞構成物質解析システム及びこれらを用いる細胞構成物質解析法
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
JP2007074967A (ja) 2005-09-13 2007-03-29 Canon Inc 識別子プローブ及びそれを用いた核酸増幅方法
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US8614073B2 (en) 2005-09-29 2013-12-24 Keygene N.V. High throughput screening of mutagenized populations
US9670542B2 (en) 2005-09-29 2017-06-06 Keygene N.V. High throughput screening of populations carrying naturally occurring mutations
US9657335B2 (en) 2005-09-29 2017-05-23 Keygene N.V. High throughput screening of populations carrying naturally occurring mutations
US9574230B2 (en) 2005-09-29 2017-02-21 Keygene N.V. High throughput screening of populations carrying naturally occuring mutations
US20090170713A1 (en) 2005-09-29 2009-07-02 Keygene N.V. High throughput screening of mutagenized populations
US9376719B2 (en) 2005-09-29 2016-06-28 Keygene N.V. High throughput screening of mutagenized populations
US20170166962A1 (en) 2005-09-29 2017-06-15 Keygene N.V. High throughput screening of populations carrying naturally occurring mutations
US9745627B2 (en) 2005-09-29 2017-08-29 Keygene N.V. High throughput screening of populations carrying naturally occurring mutations
WO2007041689A2 (en) 2005-10-04 2007-04-12 President And Fellows Of Harvard College Methods of site-specific labeling of molecules and molecules produced thereby
US20070128624A1 (en) 2005-11-01 2007-06-07 Gormley Niall A Method of preparing libraries of template polynucleotides
EP1782737A1 (en) 2005-11-02 2007-05-09 BioPath Automation, L.L.C. Tissue cassette for transporting
US20090018024A1 (en) 2005-11-14 2009-01-15 President And Fellows Of Harvard College Nanogrid rolling circle dna sequencing
WO2007060599A1 (en) 2005-11-25 2007-05-31 Koninklijke Philips Electronics N.V. Magnetic biosensor for determination of enzymic activity
US8092784B2 (en) 2005-11-30 2012-01-10 Biotium, Inc. Enzyme substrate comprising a functional dye and associated technology and methods
US20070134723A1 (en) 2005-12-09 2007-06-14 Illumina, Inc. Compositions and methods for detecting phosphomonoester
US9702004B2 (en) 2005-12-22 2017-07-11 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US9062348B1 (en) 2005-12-22 2015-06-23 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
WO2007073171A2 (en) 2005-12-22 2007-06-28 Keygene N.V. Improved strategies for transcript profiling using high throughput sequencing technologies
US8815512B2 (en) 2005-12-22 2014-08-26 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US8481257B2 (en) 2005-12-22 2013-07-09 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US9328383B2 (en) 2005-12-22 2016-05-03 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US9777324B2 (en) 2005-12-22 2017-10-03 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US8911945B2 (en) 2005-12-22 2014-12-16 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
US9334536B2 (en) 2005-12-22 2016-05-10 Keygene N.V. Method for high-throughput AFLP-based polymorphism detection
WO2007076726A1 (en) 2006-01-04 2007-07-12 Si Lok Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities
US20070172873A1 (en) 2006-01-23 2007-07-26 Sydney Brenner Molecular counting
US7544473B2 (en) 2006-01-23 2009-06-09 Population Genetics Technologies Ltd. Nucleic acid analysis using sequence tokens
US7537897B2 (en) 2006-01-23 2009-05-26 Population Genetics Technologies, Ltd. Molecular counting
US20090099041A1 (en) 2006-02-07 2009-04-16 President And Fellows Of Harvard College Methods for making nucleotide probes for sequencing and synthesis
US20090005252A1 (en) 2006-02-24 2009-01-01 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US20090155781A1 (en) 2006-02-24 2009-06-18 Complete Genomics, Inc. High throughput genome sequencing on DNA arrays
US20080009420A1 (en) 2006-03-17 2008-01-10 Schroth Gary P Isothermal methods for creating clonal single molecule arrays
US20180291439A1 (en) 2006-04-04 2018-10-11 Keygene N.V. High throughput detection of molecular markers based on aflp and high through-put sequencing
US10023907B2 (en) 2006-04-04 2018-07-17 Keygene N.V. High throughput detection of molecular markers based on AFLP and high through-put sequencing
EP2002017A2 (en) 2006-04-04 2008-12-17 Keygene N.V. High throughput detection of molecular markers based on restriction fragments
US20090253581A1 (en) 2006-04-04 2009-10-08 Keygene N.V. High Throughput Detection of Molecular Markers Based on AFLP and High Throughput Sequencing
US20120202698A1 (en) 2006-04-04 2012-08-09 Keygene N.V. High throughput detection of molecular markers based on aflp and high through-put sequencing
US20120135871A1 (en) 2006-04-04 2012-05-31 Keygene N.V. High throughput detection of molecular markers based on aflp and high through-put sequencing
US8383338B2 (en) 2006-04-24 2013-02-26 Roche Nimblegen, Inc. Methods and systems for uniform enrichment of genomic regions
US20070254305A1 (en) 2006-04-28 2007-11-01 Nsabp Foundation, Inc. Methods of whole genome or microarray expression profiling using nucleic acids prepared from formalin fixed paraffin embedded tissue
US10829803B2 (en) 2006-05-10 2020-11-10 Dxterity Diagnostics Incorporated Detection of nucleic acid targets using chemically reactive oligonucleotide probes
WO2007139766A2 (en) 2006-05-22 2007-12-06 Nanostring Technologies, Inc. Systems and methods for analyzing nanoreporters
US20080132429A1 (en) 2006-05-23 2008-06-05 Uchicago Argonne Biological microarrays with enhanced signal yield
US20110028685A1 (en) 2006-06-30 2011-02-03 Applera Corporation. Analyte Determination Utilizing Mass Tagging Reagents Comprising A Non-Encoded Detectable Label
US20090291854A1 (en) 2006-07-05 2009-11-26 Austrian Research Centers Gmbh - Arc Identification of Pathogens
WO2008022332A2 (en) 2006-08-18 2008-02-21 Board Of Regents, The University Of Texas System System, method and kit for replicating a dna array
US20080108082A1 (en) 2006-10-23 2008-05-08 Pacific Biosciences Of California, Inc. Polymerase enzymes and reagents for enhanced nucleic acid sequencing
US20080108804A1 (en) 2006-11-02 2008-05-08 Kabushiki Kaisha Dnaform Method for modifying RNAS and preparing DNAS from RNAS
US20110045462A1 (en) 2006-11-14 2011-02-24 The Regents Of The University Of California Digital analysis of gene expression
WO2008069906A2 (en) 2006-11-14 2008-06-12 The Regents Of The University Of California Digital expression of gene analysis
US20100120043A1 (en) 2006-11-16 2010-05-13 General Electric Company Sequential analysis of biological samples
US20090026082A1 (en) 2006-12-14 2009-01-29 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes using large scale FET arrays
US20090127589A1 (en) 2006-12-14 2009-05-21 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes using large scale FET arrays
CN101221182A (zh) 2007-01-08 2008-07-16 山东司马特生物芯片有限公司 一种荧光蛋白质芯片血清肿瘤系列诊断新方法
US20090233802A1 (en) 2007-02-02 2009-09-17 Helen Bignell Methods for indexing samples and sequencing multiple polynucleotide templates
US20080220434A1 (en) 2007-02-07 2008-09-11 Perscitus Biosciences, Llc Detection Of Molecule Proximity
US20090006002A1 (en) 2007-04-13 2009-01-01 Sequenom, Inc. Comparative sequence analysis processes and systems
US20090105959A1 (en) 2007-06-01 2009-04-23 Braverman Michael S System and method for identification of individual samples from a multiplex mixture
US7635566B2 (en) 2007-06-29 2009-12-22 Population Genetics Technologies Ltd. Methods and compositions for isolating nucleic acid sequence variants
JP2009036694A (ja) 2007-08-03 2009-02-19 Tokyo Medical & Dental Univ 空間分布を保った細胞内生体物質の解析方法
WO2009032167A1 (en) 2007-08-29 2009-03-12 Illumina Cambridge Method for sequencing a polynucleotide template
US20090117573A1 (en) 2007-09-14 2009-05-07 Affymetrix, Inc. Locus specific amplification using array probes
US20100227329A1 (en) 2007-09-21 2010-09-09 Katholieke Universiteit Leuven K.U.Leuven R&D Tools and methods for genetic tests using next generation sequencing
US20120046175A1 (en) 2007-10-23 2012-02-23 Matthew Rodesch Methods and systems for solution based sequence enrichment
US20100105052A1 (en) 2007-10-29 2010-04-29 Complete Genomics, Inc. Nucleic acid sequencing and process
US20110033854A1 (en) 2007-12-05 2011-02-10 Complete Genomics, Inc. Methods and compositions for long fragment read sequencing
US10144966B2 (en) 2008-01-17 2018-12-04 Sequenom, Inc. Methods of nucleic acid sequences analysis using solid supports containing identifier sequences
US20090312193A1 (en) 2008-01-23 2009-12-17 Samsung Electronics Co., Ltd. Microarray hybridization assay methods
US20090283407A1 (en) 2008-05-15 2009-11-19 Gaurav Jitendra Shah Method for using magnetic particles in droplet microfluidics
WO2009152928A2 (de) 2008-05-28 2009-12-23 Genxpro Gmbh Verfahren zur quantitativen analyse von nukleinsäuren, marker dafür und deren verwendung
DE102008025656A1 (de) 2008-05-28 2009-12-03 Genxpro Gmbh Verfahren zur quantitativen Analyse von Nikleinsäuren, Marker dafür und deren Verwendung
US20100120097A1 (en) 2008-05-30 2010-05-13 Board Of Regents, The University Of Texas System Methods and compositions for nucleic acid sequencing
US20100035249A1 (en) 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
WO2010019826A1 (en) 2008-08-14 2010-02-18 Nanostring Technologies, Inc Stable nanoreporters
WO2010027870A2 (en) 2008-08-26 2010-03-11 Fluidigm Corporation Assay methods for increased throughput of samples and/or targets
US8586310B2 (en) 2008-09-05 2013-11-19 Washington University Method for multiplexed nucleic acid patch polymerase chain reaction
US20100129874A1 (en) 2008-09-05 2010-05-27 The Washington University Method for multiplexed nucleic acid patch polymerase chain reaction
US8936912B2 (en) 2008-09-05 2015-01-20 Washington University Method for multiplexed nucleic acid patch polymerase chain reaction
US20120289414A1 (en) 2008-09-05 2012-11-15 The Washington University Method for multiplexed nucleic acid patch polymerase chain reaction
US8865410B2 (en) 2008-09-12 2014-10-21 University Of Washington Error detection in sequence tag directed subassemblies of short sequencing reads
US20100069263A1 (en) 2008-09-12 2010-03-18 Washington, University Of Sequence tag directed subassembly of short sequencing reads into long sequencing reads
US20100120098A1 (en) 2008-10-24 2010-05-13 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US20110287435A1 (en) 2008-10-24 2011-11-24 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US20120046178A1 (en) 2008-10-30 2012-02-23 Sequenom, Inc. Products and processes for multiplex nucleic acid identification
US20100184618A1 (en) 2009-01-16 2010-07-22 Affymetrix, Inc. Dna ligation on rna template
US8790873B2 (en) 2009-01-16 2014-07-29 Affymetrix, Inc. DNA ligation on RNA template
US20100210475A1 (en) 2009-02-11 2010-08-19 Samsung Electronics Co., Ltd. Microarray having bright fiducial mark and method of obtaining optical data from the mircoarray
US8603743B2 (en) 2009-04-03 2013-12-10 Timothy Z. Liu Multiplex nucleic acid detection methods and systems
US20170058345A1 (en) 2009-04-30 2017-03-02 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20120065081A1 (en) 2009-04-30 2012-03-15 Chee Mark S Nucleic acid constructs and methods of use
WO2010126614A2 (en) 2009-04-30 2010-11-04 Good Start Genetics, Inc. Methods and compositions for evaluating genetic markers
US20170058340A1 (en) 2009-04-30 2017-03-02 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20160024576A1 (en) 2009-04-30 2016-01-28 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20170058339A1 (en) 2009-04-30 2017-03-02 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20170088881A1 (en) 2009-04-30 2017-03-30 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20160333403A1 (en) 2009-04-30 2016-11-17 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US9416409B2 (en) 2009-07-31 2016-08-16 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
US20110111409A1 (en) 2009-11-10 2011-05-12 Dominick Sinicropi Methods for depleting rna from nucleic acid samples
WO2011062933A2 (en) 2009-11-18 2011-05-26 Raybiotech, Inc. Array-based proximity ligation association assays
WO2011068088A1 (ja) 2009-12-04 2011-06-09 株式会社日立製作所 ２次元cDNAライブラリを用いた遺伝子発現解析方法
US20120202704A1 (en) 2009-12-07 2012-08-09 Illumina, Inc. Multi-sample indexing for multiplex genotyping
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US9290809B2 (en) 2009-12-15 2016-03-22 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US9290808B2 (en) 2009-12-15 2016-03-22 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US20130171621A1 (en) 2010-01-29 2013-07-04 Advanced Cell Diagnostics Inc. Methods of in situ detection of nucleic acids
US20130005600A1 (en) 2010-02-03 2013-01-03 Sven Olek Assay for Determining the Type and/or Status of a Cell Based on the Epigenetic Pattern and the Chromatin Structure
US10472669B2 (en) 2010-04-05 2019-11-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190271031A1 (en) 2010-04-05 2019-09-05 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20200325531A1 (en) 2010-04-05 2020-10-15 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20200299757A1 (en) 2010-04-05 2020-09-24 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20110245111A1 (en) 2010-04-05 2011-10-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20200063195A1 (en) 2010-04-05 2020-02-27 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20200063196A1 (en) 2010-04-05 2020-02-27 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10914730B2 (en) 2010-04-05 2021-02-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20200048690A1 (en) 2010-04-05 2020-02-13 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10494667B2 (en) 2010-04-05 2019-12-03 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9371598B2 (en) 2010-04-05 2016-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11008607B2 (en) 2010-04-05 2021-05-18 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20210207202A1 (en) 2010-04-05 2021-07-08 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US11067567B2 (en) 2010-04-05 2021-07-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10480022B2 (en) 2010-04-05 2019-11-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20110245101A1 (en) 2010-04-05 2011-10-06 Prognosys Biosciences, Inc. Co-localization affinity assays
US20190323071A1 (en) 2010-04-05 2019-10-24 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20210222235A1 (en) 2010-04-05 2021-07-22 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20210255175A1 (en) 2010-04-05 2021-08-19 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190309355A1 (en) 2010-04-05 2019-10-10 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20160298180A1 (en) 2010-04-05 2016-10-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190309353A1 (en) 2010-04-05 2019-10-10 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190309354A1 (en) 2010-04-05 2019-10-10 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190300943A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20210269864A1 (en) 2010-04-05 2021-09-02 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20210270822A1 (en) 2010-04-05 2021-09-02 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20220003755A1 (en) 2010-04-05 2022-01-06 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190300944A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190271030A1 (en) 2010-04-05 2019-09-05 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190177777A1 (en) 2010-04-05 2019-06-13 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US20190177778A1 (en) 2010-04-05 2019-06-13 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US9816134B2 (en) 2010-05-27 2017-11-14 Affymetrix, Inc. Multiplex amplification methods
US9080210B2 (en) 2010-06-09 2015-07-14 Keygene N.V. High throughput screening using combinatorial sequence barcodes
US8481292B2 (en) 2010-09-21 2013-07-09 Population Genetics Technologies Litd. Increasing confidence of allele calls with molecular counting
US8741606B2 (en) 2010-09-21 2014-06-03 Population Genetics Technologies Ltd. Method of tagging using a split DBR
WO2012048341A1 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput single cell barcoding
WO2012049316A1 (en) 2010-10-15 2012-04-19 Olink Ab Dynamic range methods
US20130261019A1 (en) 2010-10-29 2013-10-03 President And Fellows Of Harvard College Nucleic acid nanostructure barcode probes
WO2012071428A2 (en) 2010-11-22 2012-05-31 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for assays and detections
US20140121118A1 (en) 2010-11-23 2014-05-01 Opx Biotechnologies, Inc. Methods, systems and compositions regarding multiplex construction protein amino-acid substitutions and identification of sequence-activity relationships, to provide gene replacement such as with tagged mutant genes, such as via efficient homologous recombination
US8551710B2 (en) 2011-02-15 2013-10-08 Leica Biosystems Newcastle Ltd. Methods for localized in situ detection of mRNA
US20120258871A1 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
US20140066318A1 (en) 2011-04-13 2014-03-06 Spatial Transcriptomics Ab Method and product for localized or spatial detection of nucleic acid in a tissue sample
US10030261B2 (en) 2011-04-13 2018-07-24 Spatial Transcriptomics Ab Method and product for localized or spatial detection of nucleic acid in a tissue sample
US20190264268A1 (en) 2011-04-13 2019-08-29 Spatial Transcriptions Ab Methods of Detecting Analytes
US8741564B2 (en) 2011-05-04 2014-06-03 Htg Molecular Diagnostics, Inc. Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements
US8809238B2 (en) 2011-05-09 2014-08-19 Fluidigm Corporation Probe based nucleic acid detection
WO2012159089A1 (en) 2011-05-19 2012-11-22 Sequenom, Inc. Products and processes for multiplex nucleic acid identification
US20130035239A1 (en) 2011-08-03 2013-02-07 Bio-Rad Laboratories Filtering small nucleic acids using permeabilized cells
US20130079232A1 (en) 2011-09-23 2013-03-28 Illumina, Inc. Methods and compositions for nucleic acid sequencing
US20140342921A1 (en) 2011-12-09 2014-11-20 Illumina, Inc. Expanded radix for polymeric tags
US20180112209A1 (en) 2011-12-22 2018-04-26 Ibis Biosciences, Inc. Systems and methods for isolating nucleic acids
US9598728B2 (en) 2012-02-14 2017-03-21 Cornell University Method for relative quantification of nucleic acid sequence, expression, or copy changes, using combined nuclease, ligation, and polymerase reactions
WO2013123442A1 (en) 2012-02-17 2013-08-22 Fred Hutchinson Cancer Research Center Compositions and methods for accurately identifying mutations
WO2013138510A1 (en) 2012-03-13 2013-09-19 Patel Abhijit Ajit Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
WO2013142389A1 (en) 2012-03-20 2013-09-26 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
WO2013150083A1 (en) 2012-04-03 2013-10-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Analysis of nucleic acid molecules distributed on a surface or within a layer by sequencing with position identification
EP2881465A1 (en) 2012-07-30 2015-06-10 Hitachi, Ltd. Tag-sequence-attached two-dimensional cdna library device, and gene expression analysis method and gene expression analysis apparatus each utilizing same
US20190177789A1 (en) 2012-08-14 2019-06-13 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2014044724A1 (en) 2012-09-18 2014-03-27 Qiagen Gmbh Method and kit for preparing a target rna depleted sample
US9783841B2 (en) 2012-10-04 2017-10-10 The Board Of Trustees Of The Leland Stanford Junior University Detection of target nucleic acids in a cellular sample
US9593365B2 (en) 2012-10-17 2017-03-14 Spatial Transcriptions Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
EP3511423A1 (en) 2012-10-17 2019-07-17 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US20140274731A1 (en) 2012-12-10 2014-09-18 Clearfork Bioscience, Inc. Methods for targeted genomic analysis
US9512422B2 (en) 2013-02-26 2016-12-06 Illumina, Inc. Gel patterned surfaces
US20180051322A1 (en) 2013-03-12 2018-02-22 President And Fellows Of Harvard College Method for Generating A Three-Dimensional Nucleic Acid Containing Matrix
WO2014152397A2 (en) 2013-03-14 2014-09-25 The Broad Institute, Inc. Selective purification of rna and rna-bound molecular complexes
WO2014144713A2 (en) 2013-03-15 2014-09-18 Immumetrix, Inc. Methods of sequencing the immune repertoire
US20160019337A1 (en) 2013-03-15 2016-01-21 Htg Molecular Diagnostics, Inc. Subtyping lung cancers
US20140323330A1 (en) 2013-04-25 2014-10-30 Vladislav B. Bergo Microarray compositions and methods of their use
US10059989B2 (en) 2013-05-23 2018-08-28 The Board Of Trustees Of The Leland Stanford Junior University Transposition of native chromatin for personal epigenomics
EP3013984A1 (en) 2013-06-25 2016-05-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20180201980A1 (en) 2013-06-25 2018-07-19 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20210010068A1 (en) 2013-06-25 2021-01-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20210317510A1 (en) 2013-06-25 2021-10-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20200109443A1 (en) 2013-06-25 2020-04-09 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
WO2014210223A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US20160145677A1 (en) 2013-06-25 2016-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US11046996B1 (en) 2013-06-25 2021-06-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10774372B2 (en) 2013-06-25 2020-09-15 Prognosy s Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20160138091A1 (en) 2013-06-25 2016-05-19 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20210172007A1 (en) 2013-06-25 2021-06-10 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
WO2014210225A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US9868979B2 (en) 2013-06-25 2018-01-16 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
US10927403B2 (en) 2013-06-25 2021-02-23 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20150000854A1 (en) 2013-06-27 2015-01-01 The Procter & Gamble Company Sheet products bearing designs that vary among successive sheets, and apparatus and methods for producing the same
US10041949B2 (en) 2013-09-13 2018-08-07 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed imaging of tissues using mass tags and secondary ion mass spectrometry
US9834814B2 (en) 2013-11-22 2017-12-05 Agilent Technologies, Inc. Spatial molecular barcoding of in situ nucleic acids
WO2015161173A1 (en) 2014-04-18 2015-10-22 William Marsh Rice University Competitive compositions of nucleic acid molecules for enrichment of rare-allele-bearing species
US20170029875A1 (en) 2014-04-18 2017-02-02 William Marsh Rice University Competitive compositions of nucleic acid molecules for enrichment of rare-allele-bearing species
US20150376609A1 (en) 2014-06-26 2015-12-31 10X Genomics, Inc. Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations
US20180201925A1 (en) 2014-06-30 2018-07-19 Illumina, Inc. Methods and compositions using one-sided transposition
US20190085383A1 (en) 2014-07-11 2019-03-21 President And Fellows Of Harvard College Methods for High-Throughput Labelling and Detection of Biological Features In Situ Using Microscopy
US20170220733A1 (en) 2014-07-30 2017-08-03 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
US9957550B2 (en) 2014-09-08 2018-05-01 BioSpyder Technologies, Inc. Attenuators
US9938566B2 (en) 2014-09-08 2018-04-10 BioSpyder Technologies, Inc. Profiling expression at transcriptome scale
US20170349940A1 (en) 2014-09-26 2017-12-07 Two Pore Guys, Inc. Targeted Sequence Detection by Nanopore Sensing of Synthetic Probes
US20160108458A1 (en) 2014-10-06 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed detection and quantification of nucleic acids in single-cells
US20160122817A1 (en) 2014-10-29 2016-05-05 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US20200010891A1 (en) 2014-11-21 2020-01-09 Nanostring Technologies, Inc. Enzyme- and amplification-free sequencing
US20180163265A1 (en) 2014-12-19 2018-06-14 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
US10208982B2 (en) 2015-01-23 2019-02-19 Mestek, Inc. Airfoil blade and method of assembly
US20180237864A1 (en) 2015-01-27 2018-08-23 BioSpyder Technologies, Inc. Focal Gene Expression Profiling of Stained FFPE Tissues with Spatial Correlation to Morphology
US9856521B2 (en) 2015-01-27 2018-01-02 BioSpyder Technologies, Inc. Ligation assays in liquid phase
US9727810B2 (en) 2015-02-27 2017-08-08 Cellular Research, Inc. Spatially addressable molecular barcoding
US10002316B2 (en) 2015-02-27 2018-06-19 Cellular Research, Inc. Spatially addressable molecular barcoding
US20160253584A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
WO2016138500A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Methods and compositions for barcoding nucleic acids for sequencing
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
US20160289740A1 (en) 2015-03-30 2016-10-06 Cellular Research, Inc. Methods and compositions for combinatorial barcoding
US20210292822A1 (en) 2015-04-10 2021-09-23 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20220002791A1 (en) 2015-04-10 2022-01-06 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20210292748A1 (en) 2015-04-10 2021-09-23 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20190203275A1 (en) * 2015-04-10 2019-07-04 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US20200399687A1 (en) 2015-04-10 2020-12-24 Spatial Transcriptomics Ab Spatially Distinguished, Multiplex Nucleic Acid Analysis of Biological Specimens
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10724078B2 (en) 2015-04-14 2020-07-28 Koninklijke Philips N.V. Spatial mapping of molecular profiles of biological tissue samples
US10059990B2 (en) 2015-04-14 2018-08-28 Massachusetts Institute Of Technology In situ nucleic acid sequencing of expanded biological samples
US20180112261A1 (en) 2015-04-14 2018-04-26 Koninklijke Philips N.V. Spatial mapping of molecular profiles of biological tissue samples
WO2016166128A1 (en) 2015-04-14 2016-10-20 Koninklijke Philips N.V. Spatial mapping of molecular profiles of biological tissue samples
US20180057873A1 (en) * 2015-04-17 2018-03-01 Centrillion Technology Holdings Corporation Methods for performing spatial profiling of biological materials
WO2016168825A1 (en) 2015-04-17 2016-10-20 Centrillion Technology Holdings Corporation Methods for performing spatial profiling of biological molecules
WO2016172362A1 (en) 2015-04-21 2016-10-27 General Automation Lab Technologies, Inc. High resolution systems, kits, apparatus, and methods for high throughput microbiology applications
US20170016053A1 (en) 2015-07-17 2017-01-19 Nanostring Technologies, Inc. Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
WO2017019481A1 (en) 2015-07-24 2017-02-02 The Johns Hopkins University Compositions and methods of rna analysis
US20180208967A1 (en) * 2015-07-24 2018-07-26 The Johns Hopkins University Compositions and methods of rna analysis
US20180245142A1 (en) 2015-07-27 2018-08-30 Illumina, Inc. Spatial mapping of nucleic acid sequence information
US10913975B2 (en) 2015-07-27 2021-02-09 Illumina, Inc. Spatial mapping of nucleic acid sequence information
WO2017019456A2 (en) 2015-07-27 2017-02-02 Illumina, Inc. Spatial mapping of nucleic acid sequence information
US20170089811A1 (en) 2015-08-07 2017-03-30 Massachusetts Institute Of Technology Protein Retention Expansion Microscopy
US20170067096A1 (en) 2015-08-07 2017-03-09 Massachusetts Institute Of Technology Nanoscale Imaging of Proteins and Nucleic Acids via Expansion Microscopy
US11118216B2 (en) 2015-09-08 2021-09-14 Affymetrix, Inc. Nucleic acid analysis by joining barcoded polynucleotide probes
WO2017075293A1 (en) 2015-10-28 2017-05-04 Silicon Valley Scientific, Inc. Method and apparatus for encoding cellular spatial position information
WO2017075265A1 (en) 2015-10-28 2017-05-04 The Broad Institute, Inc. Multiplex analysis of single cell constituents
WO2017096158A1 (en) 2015-12-04 2017-06-08 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US20170233722A1 (en) 2016-02-12 2017-08-17 University Of Washington Combinatorial photo-controlled spatial sequencing and labeling
US20170241911A1 (en) 2016-02-22 2017-08-24 Miltenyi Biotec Gmbh Automated analysis tool for biological specimens
US20190055594A1 (en) 2016-02-26 2019-02-21 The Board Of Trustee Of The Leland Stanford Junior University Multiplexed single molecule rna visualization with a two-probe proximity ligation system
WO2017156336A1 (en) 2016-03-10 2017-09-14 The Board Of Trustees Of The Leland Stanford Junior University Transposase-mediated imaging of the accessible genome
US20190218276A1 (en) 2016-03-21 2019-07-18 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics in single cells
WO2017184984A1 (en) 2016-04-21 2017-10-26 Cell Data Sciences, Inc. Biomolecule processing from fixed biological samples
WO2017192633A1 (en) 2016-05-02 2017-11-09 Procure Life Sciences Inc. Macromolecule analysis employing nucleic acid encoding
US20190145982A1 (en) 2016-05-02 2019-05-16 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US20170335410A1 (en) 2016-05-17 2017-11-23 Shoreline Biome, Llc High Throughput Method for Identification and Sequencing of Unknown Microbial and Eukaryotic Genomes from Complex Mixtures
US20190161796A1 (en) 2016-06-21 2019-05-30 Cartana Ab Nucleic acid sequencing
US20200024641A1 (en) 2016-07-27 2020-01-23 The Board Of Trustees Of The Leland Stanford Junior University Highly-multiplexed fluorescent imaging
WO2018023068A1 (en) 2016-07-29 2018-02-01 New England Biolabs, Inc. Methods and compositions for preventing concatemerization during template- switching
WO2018045181A1 (en) 2016-08-31 2018-03-08 President And Fellows Of Harvard College Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing
US20190194709A1 (en) 2016-08-31 2019-06-27 President And Fellows Of Harvard College Methods of Combining the Detection of Biomolecules Into a Single Assay Using Fluorescent In Situ Sequencing
US20190330617A1 (en) 2016-08-31 2019-10-31 President And Fellows Of Harvard College Methods of Generating Libraries of Nucleic Acid Sequences for Detection via Fluorescent in Situ Sequ
US20200080136A1 (en) 2016-09-22 2020-03-12 William Marsh Rice University Molecular hybridization probes for complex sequence capture and analysis
WO2018064640A1 (en) 2016-10-01 2018-04-05 Berkeley Lights, Inc. Dna barcode compositions and methods of in situ identification in a microfluidic device
US20190262831A1 (en) 2016-10-17 2019-08-29 Lociomics Corporation High resolution spatial genomic analysis of tissues and cell aggregates
US20180105808A1 (en) 2016-10-19 2018-04-19 10X Genomics, Inc. Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations
WO2018085599A2 (en) 2016-11-02 2018-05-11 ArcherDX, Inc. Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2018091676A1 (en) 2016-11-17 2018-05-24 Spatial Transcriptomics Ab Method for spatial tagging and analysing nucleic acids in a biological specimen
EP3541956A1 (en) 2016-11-17 2019-09-25 Spatial Transcriptomics AB Method for spatial tagging and analysing nucleic acids in a biological specimen
US20200256867A1 (en) 2016-12-09 2020-08-13 Ultivue, Inc. Methods for Multiplex Imaging Using Labeled Nucleic Acid Imaging Agents
US20180179591A1 (en) 2016-12-22 2018-06-28 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20180216161A1 (en) 2017-01-23 2018-08-02 Massachusetts Institute Of Technology Multiplexed Signal Amplified FISH via Splinted Ligation Amplification and Sequencing
WO2018136856A1 (en) 2017-01-23 2018-07-26 Massachusetts Institute Of Technology Multiplexed signal amplified fish via splinted ligation amplification and sequencing
WO2018144582A1 (en) 2017-02-01 2018-08-09 Illumina, Inc. System and method with reflective fiducials
US20180312822A1 (en) 2017-04-26 2018-11-01 10X Genomics, Inc. Mmlv reverse transcriptase variants
WO2018209398A1 (en) 2017-05-17 2018-11-22 Microbio Pty Ltd Biomarkers and uses thereof
WO2019032760A1 (en) 2017-08-10 2019-02-14 Rootpath Genomics, Inc. IMPROVED METHOD OF ANALYZING NUCLEIC ACID CONTENT FROM MULTIPLE BIOLOGICAL PARTICLES
US20200224244A1 (en) 2017-10-06 2020-07-16 Cartana Ab Rna templated ligation
WO2019068880A1 (en) 2017-10-06 2019-04-11 Cartana Ab RNA MATRIX LIGATION
US20200239946A1 (en) 2017-10-11 2020-07-30 Expansion Technologies Multiplexed in situ hybridization of tissue sections for spatially resolved transcriptomics with expansion microscopy
WO2019113457A1 (en) 2017-12-07 2019-06-13 Massachusetts Institute Of Technology Single cell analyses
WO2019126313A1 (en) 2017-12-22 2019-06-27 The University Of Chicago Multiplex 5mc marker barcode counting for methylation detection in cell-free dna
WO2019140201A1 (en) 2018-01-12 2019-07-18 Claret Bioscience, Llc Methods and compositions for analyzing nucleic acid
US20190367969A1 (en) 2018-02-12 2019-12-05 10X Genomics, Inc. Methods and systems for analysis of chromatin
US20200239874A1 (en) 2018-02-22 2020-07-30 10X Genomics, Inc. Ligation mediated analysis of nucleic acids
WO2021041974A1 (en) 2018-02-22 2021-03-04 10X Genomics, Inc. Ligation mediated analysis of nucleic acids
US20210230584A1 (en) 2018-02-22 2021-07-29 10X Genomics, Inc. Ligation mediated analysis of nucleic acids
WO2019165318A1 (en) 2018-02-22 2019-08-29 10X Genomics, Inc. Ligation mediated analysis of nucleic acids
WO2019213254A1 (en) 2018-05-02 2019-11-07 The General Hospital Corporation High-resolution spatial macromolecule abundance assessment
US20210123040A1 (en) 2018-05-02 2021-04-29 The General Hospital Corporation High-resolution spatial macromolecule abundance assessment
WO2019213294A1 (en) 2018-05-03 2019-11-07 Becton, Dickinson And Company High throughput multiomics sample analysis
WO2020028194A1 (en) 2018-07-30 2020-02-06 Readcoor, Inc. Methods and systems for sample processing or analysis
WO2020047002A1 (en) 2018-08-28 2020-03-05 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic dna in a biological sample
US20200407781A1 (en) * 2018-08-28 2020-12-31 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic dna in a biological sample
US20210324457A1 (en) 2018-08-28 2021-10-21 Eswar Prasad Ramachandran Iyer Methods for Generating Spatially Barcoded Arrays
US20210010070A1 (en) 2018-08-28 2021-01-14 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic dna in a biological sample
US20210332424A1 (en) 2018-08-28 2021-10-28 10X Genomics, Inc. Methods of generating an array
US20210332425A1 (en) 2018-08-28 2021-10-28 Rajiv Bharadwaj Increasing spatial array resolution
US20210317524A1 (en) 2018-08-28 2021-10-14 10X Genomics, Inc. Resolving spatial arrays
WO2020047010A2 (en) 2018-08-28 2020-03-05 10X Genomics, Inc. Increasing spatial array resolution
WO2020053655A1 (en) 2018-09-13 2020-03-19 Zenith Epigenetics Ltd. Combination therapy for the treatment of triple-negative breast cancer
WO2020056381A1 (en) 2018-09-14 2020-03-19 Cold Spring Harbor Laboratory PROGRAMMABLE RNA-TEMPLATED SEQUENCING BY LIGATION (rSBL)
WO2020061064A1 (en) 2018-09-17 2020-03-26 Piggy Llc Systems, methods, and computer programs for providing users maximum benefit in electronic commerce
WO2020061066A1 (en) 2018-09-17 2020-03-26 Computer World Services Corp. dba LabSavvy Systems and methods for automated reporting and education for laboratory test results
WO2020061108A1 (en) 2018-09-17 2020-03-26 Schneider Electric Systems Usa, Inc. Industrial system event detection and corresponding response
US20210230692A1 (en) 2018-10-10 2021-07-29 Readcoor, Llc Surface capture of targets
WO2020123320A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Imaging system hardware
WO2020123311A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Resolving spatial arrays using deconvolution
WO2020123301A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Generating spatial arrays with gradients
WO2020123318A1 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Resolving spatial arrays using deconvolution
US20210189475A1 (en) 2018-12-10 2021-06-24 10X Genomics, Inc. Imaging system hardware
WO2020123319A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Methods of using master / copy arrays for spatial detection
US20200277664A1 (en) 2018-12-10 2020-09-03 10X Genomics, Inc. Methods for determining a location of a biological analyte in a biological sample
US20200277663A1 (en) 2018-12-10 2020-09-03 10X Genomics, Inc. Methods for determining a location of a biological analyte in a biological sample
WO2020123317A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc Three-dimensional spatial analysis
US20220025446A1 (en) 2018-12-10 2022-01-27 10X Genomics, Inc. Methods of using master / copy arrays for spatial detection
WO2020123305A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Generating capture probes for spatial analysis
US20220025447A1 (en) 2018-12-10 2022-01-27 10X Genomics, Inc. Generating spatial arrays with gradients
US20220033888A1 (en) 2018-12-10 2022-02-03 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2020123316A2 (en) 2018-12-10 2020-06-18 10X Genomics, Inc. Methods for determining a location of a biological analyte in a biological sample
US20210285036A1 (en) 2019-01-06 2021-09-16 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2020160044A1 (en) 2019-01-28 2020-08-06 The Broad Institute, Inc. In-situ spatial transcriptomics
WO2020176788A1 (en) 2019-02-28 2020-09-03 10X Genomics, Inc. Profiling of biological analytes with spatially barcoded oligonucleotide arrays
US20220010367A1 (en) 2019-02-28 2022-01-13 10X Genomics, Inc. Profiling of biological analytes with spatially barcoded oligonucleotide arrays
WO2020190509A1 (en) 2019-03-15 2020-09-24 10X Genomics, Inc. Methods for using spatial arrays for single cell sequencing
US20220017951A1 (en) 2019-03-22 2022-01-20 10X Genomics, Inc. Three-dimensional spatial analysis
WO2020219901A1 (en) 2019-04-26 2020-10-29 10X Genomics, Inc. Imaging support devices
US20200370095A1 (en) * 2019-05-24 2020-11-26 Takara Bio Usa, Inc. Spatial Analysis
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
WO2021067246A1 (en) 2019-09-30 2021-04-08 Yale University Deterministic barcoding for spatial omics sequencing
US20210095331A1 (en) 2019-09-30 2021-04-01 Yale University Deterministic barcoding for spatial omics sequencing
US20210140982A1 (en) 2019-10-18 2021-05-13 10X Genomics, Inc. Identification of spatial biomarkers of brain disorders and methods of using the same
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
WO2021091611A1 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
WO2021097255A1 (en) 2019-11-13 2021-05-20 10X Genomics, Inc. Generating capture probes for spatial analysis
US20210150707A1 (en) 2019-11-18 2021-05-20 10X Genomics, Inc. Systems and methods for binary tissue classification
US20210155982A1 (en) 2019-11-21 2021-05-27 10X Genomics, Inc. Pipeline for spatial analysis of analytes
US20210199660A1 (en) 2019-11-22 2021-07-01 10X Genomics, Inc. Biomarkers of breast cancer
US20210158522A1 (en) 2019-11-22 2021-05-27 10X Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
WO2021119320A2 (en) 2019-12-11 2021-06-17 10X Genomics, Inc. Reverse transcriptase variants
US20210285046A1 (en) 2019-12-23 2021-09-16 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
WO2021133849A1 (en) 2019-12-23 2021-07-01 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
US20210198741A1 (en) 2019-12-30 2021-07-01 10X Genomics, Inc. Identification of spatial biomarkers of heart disorders and methods of using the same
US20210214785A1 (en) 2020-01-13 2021-07-15 Spatial Transcriptomics Ab Methods of decreasing background on a spatial array
US20210223227A1 (en) 2020-01-17 2021-07-22 Spatial Transcriptomics Ab Electrophoretic system and method for analyte capture
US20210222241A1 (en) 2020-01-21 2021-07-22 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US20210222242A1 (en) 2020-01-21 2021-07-22 10X Genomics, Inc. Spatial assays with perturbed cells
US20210222253A1 (en) 2020-01-21 2021-07-22 10X Genomics, Inc. Identification of biomarkers of glioblastoma and methods of using the same
US20210230681A1 (en) 2020-01-24 2021-07-29 10X Genomics, Inc. Methods for spatial analysis using proximity ligation
US20210238680A1 (en) 2020-02-03 2021-08-05 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US20210238664A1 (en) 2020-02-03 2021-08-05 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US20210238675A1 (en) 2020-02-05 2021-08-05 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US20210247316A1 (en) 2020-02-11 2021-08-12 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
WO2021168278A1 (en) 2020-02-20 2021-08-26 10X Genomics, Inc. METHODS TO COMBINE FIRST AND SECOND STRAND cDNA SYNTHESIS FOR SPATIAL ANALYSIS
WO2021168261A1 (en) 2020-02-21 2021-08-26 10X Genomics, Inc. Capturing genetic targets using a hybridization approach
US20210262019A1 (en) 2020-02-24 2021-08-26 10X Genomics, Inc. Methods of making gene expression libraries
WO2021216708A1 (en) 2020-04-22 2021-10-28 10X Genomics, Inc. Methods for spatial analysis using targeted rna depletion
WO2021225900A1 (en) 2020-05-04 2021-11-11 10X Genomics, Inc. Spatial transcriptomic transfer modes
WO2021236625A1 (en) 2020-05-19 2021-11-25 10X Genomics, Inc. Electrophoresis cassettes and instrumentation
WO2021237056A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Rna integrity analysis in a biological sample
WO2021237087A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Spatial analysis to detect sequence variants
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
WO2021247543A2 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Nucleic acid library methods
WO2021247568A1 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Spatial trancriptomics for antigen-receptors
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
WO2021252576A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for spatial analysis using blocker oligonucleotides
WO2021252591A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021263111A1 (en) 2020-06-25 2021-12-30 10X Genomics, Inc. Spatial analysis of dna methylation

Non-Patent Citations (291)

* Cited by examiner, † Cited by third party
Title
[No Author Listed], "Chromium Next GEM Single Cell 3' Reagent Kits v.3.1 (Dual Index)—User Guide," 10x Genomics, Mar. 2021, Document No. CG000315, 61 pages.
[No Author Listed], "Chromium Next GEM Single Cell 3' Reagent Kits v.3.1," User Guide, Document No. CG000204, 10x Genomics, Nov. 2019, 58 pages.
[No Author Listed], "HuSNP Mapping Assay User's Manual," Affymetrix Part No. 90094 (Affymetrix, Santa Clara, Calif.), GeneChip, 2000, 104 pages.
[No Author Listed], "Microarray technologies have excellent possibilities in genomics-related researches," Science Tools From Amersham Pharmacia Biotech. 1998. 3(4): 8 pages (with English Translation).
[No Author Listed], "Proseek® Multiplex 96×96 User Manual." Olink Proteomics, Olink Bioscience, Uppsala, Sweden, 2017. 20 pages.
10xGenomics.com, [online], "Visium Spatial Gene Expression Reagent Kits—Tissue Optimization," Nov. 2019, retrieved on Jan. 25, 2022, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/4q03w6959AJFxffSw51ee9/6a2ac61cf4388a72564eeb96bc2949673CG000238_VisiumSpatialTissueOptimizationUserGuide_Rev_A.pdf>, 46 pages.
10xGenomics.com, [online], "Visium Spatial Gene Expression Reagent Kits—Tissue Optimization," Oct. 2020, retrieved on Dec. 28, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/5UJrN0cH17rEk0UXwdl9It/e54d99fb08a8f1500aba503005a04a56/CG000238_VisiumSpatialTissueOptimizationUserGuide_RevD.pdf>, 43 pages.
10xGenomics.com, [online], "Visium Spatial Gene Expression Reagent Kits—User Guide," Jun. 2020, retrieved on May 25, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/3GGIfH3RWpd1bFVha1pexR/8baa08d9007I57592b65b2cdc7130990/CG000239_VisiumSpatialGeneExpression_UserGuide_RevD.pdf>, 70 pages.
10xGenomics.com, [online], "Visium Spatial Gene Expression Reagent Kits—User Guide," Oct. 2020, retrieved on Dec. 28, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/3GGIfH3RWpdlbFVhalpexR/8baa08d9007157592b65b2cdc7130990/CG000239_VisiumSpatialGeneExpiession_UserGuide_RevD.pdf>, 70 pages.
10xGenomics.com. [online],"Visium Spatial Gene Expression Reagent Kits—Tissue Optimization—User Guide," Jul. 2020, retrieved on May 25, 2021, retrieved from URL<https://assets.ctfassets.net/an68im79xiti/5UJrN0cH17rEk0UXwdl9It/e54d99fb08a8f1500aba503005a04a56/CG000238_VisiumSpatialTissueOptimizationUserGuide_RevD.pdf>, 43 pages.
Adessi et al., "Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms," Nucl. Acids Res., 2000, 28(20):E87, 8 pages.
Adiconis et al., "Comparative analysis of RNA sequencing methods for degraded or low-input samples," Nat Methods, Jul. 2013, 10(7):623-9.
Affymetrix, "GeneChip Human Genome U133 Set," retrieved from the Internet: on the World Wide Web at affymetrix.com/support/technical/datasheets/hgul33_datasheet.pdf, retrieved on Feb. 26, 2003, 2 pages.
Affymetrix, "Human Genome U95Av2," Internet Citation, retrieved from the internet: on the World Wide Web affymetrix.com, retrieved on Oct. 2, 2002, 1 page.
Alam, "Proximity Ligation Assay (PLA)," Curr Protoc Immunol., Nov. 2018, 123(1):e58, 8 pages.
Albretsen et al., "Applications of magnetic beads with covalently attached oligonucleotides in hybridization: Isolation and detection of specific measles virus mRNA from a crude cell lysate," Anal. Biochem, 1990, 189(1)40-50.
Allawi et al., "Thermodynamics and NMR of Internal GâT Mismatches in DNA," Biochemistry, 1996, 36(34):10581-10594.
Andresen et al., "Helicase-dependent amplification: use in OnChip amplification and potential for point-of-care diagnostics," Expert Rev Mol Diagn, Oct. 2009. 9(7):645-650.
Aran et al., "xCell: digitally portraying the tissue cellular heterogeneity landscape," Genome Biol., Nov. 2017, 18(1):220, 14 pages.
Archer et al., "Selective and flexible depletion of problematic sequences from RNA-seq libraries at the cDNA stage," BMC Genomics. May 2014, 15(1):401, 9 pages.
Armani et al, "2D-PCR: a method of mapping DNA in tissue sections," Lab Chip, 2009, 9(24):3526-34.
Atkinson et al., "An Updated Protocol for High Throughput Plant Tissue Sectioning," Front Plant Sci, 2017, 8:1721, 8 pages.
Atkinson, "Overview of Translation: Lecture Manuscript," U of Texas, 2000, DD, p. 6.1-6.8.
Bains et al., "A novel method for nucleic acid sequence determination," Journal of Theoretical Biology, 1988, 135(3), 303-7.
Barnes, "PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates," Proc. Natl. Acad. Sci USA, 1994, 91(6):2216-2220.
Barnett et al., "ATAC-Me Captures Prolonged DNA Methylation of Dynamic Chromatin Accessibility Loci during Cell Fate Transitions," Mol Cell., Mar. 2020, 77(6):1350-1364.e6.
Bartosovic et al., "Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues," Nat Biotechnol., Jul. 2021, 39(7):825-835, Abstract.
Baugh et al., "Quantitative analysis of mRNA amplification by in vitro transcription," Nucleic Acids Res., 2001, 29(5):e29, 9 pages.
Beattie et al., "Advances in genosensor research." Clin Chem., May 1995. 41(5):700-6.
Beechem et al., "High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research," Methods Mol Biol, 2020, Chapter 25, 2055:563-583.
Bell, "A simple way to treat PCR products prior to sequencing using ExoSAP-IT," Biotechniques, 2008, 44(6):834, 1 page.
Bentley et al., "Accurate whole human genome sequencing using reversible terminator chemistry," Nature, 2008, 456(7218):53-59.
Birney et al., "Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project," Nature, 2007, 447(7146):799-816.
Blanchard et al., "High-density oligonucleotide arrays," Biosensors & Bioelectronics, 1996, 11(6-7):687-690.
Blanco et al., "A practical approach to FRET-based PNA fluorescence in situ hybridization," Methods, Dec. 2010, 52(4):343-51.
Blokzijl et al., "Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine," J Intern. Med., 2010, 268(3):232-245.
Blow, "Tissue Issues," Nature, 2007, 448(7156):959-962.
Bolognesi et al., "Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections," J. Histochem. Cytochem., Aug. 2017, 65(8):431-444.
Brandon et al., "Mitochondrial mutations in cancer," Oncogene, 2006, 25(34)4647-4662.
Brenner et al., "Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays," Nat. Biotech., 2000, 18(6):630-634.
Brenner et al., "In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs," Proc. Natl. Acad. Sci. USA, 2000, 97(4):1665-1670.
Brow, "35—The Cleavase I enzyme for mutation and polymorphism scanning," PCR Applications Protocols for Functional Genomics, 1999, pp. 537-550.
Brown et al., "Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein," Proc Natl Acad Sci USA, Apr. 1989, 86(8):2525-9.
Buenrostro et al., "Transposition of native chromatin for multimodal regulatory analysis and personal epigenomics," Nat Methods, Dec. 2013, 10(12):1213-1218.
Bullard et al., "Direct comparison of nick-joining activity of the nucleic acid ligases from bacteriophage T4," Biochem. J. 2006, 398(1):135-144.
Burgess, "A space for transcriptomics," Nature Reviews Genetics, 2016, 17(8):436-7.
Burgess, "Finding structure in gene expression," Nature Reviews Genetics, 2018, 19(5):249, 1 page.
Burton et al., "Coverslip Mounted-Immersion Cycled in Situ RT-PCR for the Localization of mRNA in Tissue Sections," Biotechniques, 1998, 24(1):92-100.
Cha et al., "Specificity, efficiency, and fidelity of PCR," Genome Res., 1993, 3(3):S18-29.
Chandra et al., "Cell-free synthesis-based protein microarrays and their applications," Proteomics, 2009, 5(6):717-30.
Chatterjee et al., "Mitochondrial DNA mutations in human cancer. Oncogene," 2006, 25(34):4663-4674.
Chen et al., "DNA hybridization detection in a microfluidic Channel using two fluorescently labelled nucleic acid probes," Biosensors and Bioelectronics, 2008, 23(12):1878-1882.
Chen et al., "Expansion microscopy," Science, 2015, 347(6221):543-548.
Chen et al., "Nanoscale imaging of RNA with expansion microscopy." Nat Methods, Aug. 2016. 13(8):679-84.
Chen et al., "RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells," Science, Apr. 2015, 348(6233):aaa6090, 21 pages.
Chen et al., "Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease," Cell, Aug. 2020, 182(4):976-991.
Chen et al., "Spatially resolved, highly multiplexed RNA profiling in single cells," Science, 2015, 348(6233):aaa6090, 21 pages.
Chen et al.. "μCB-seq: microfluidic cell barcoding and sequencing for high-resolution imaging and sequencing of single cells," Lab Chip, Nov. 2020. 20(21):3899-3913.
Chrisey et al., "Covalent attachment of synthetic DNA to self-assembled monolayer films," Nucleic Acids Res., Aug. 1996, 24(15):3031-9.
Constantine et al., "Use of genechip high-density oligonucleotide arrays for gene expression monitoring," Life Sceience News, Amersham Life Science, 1998, pp. 11-14.
Corces et al., "An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues," Nat. Methods, 2017, 14(10):959-962.
Credle et al., "Multiplexed analysis of fixed tissue RNA using Ligation in situ Hybridization," Nucleic Acids Research, 2017, 45(14):e128, 9 pages.
Crosetto et al., "Spatially resolved transcriptomics and beyond," Nature Review Genetics, 2015, 16(1):57-66.
Cruz et al., "Methylation in cell-free DNA for early cancer detection," Ann Oncol., Jun. 2018, 29(6):1351-1353.
Cujec et al., "Selection of v-abl tyrosine kinase substrate sequences from randomized peptide and cellular proteomic libraries using mRNA display," Chemistry and Biology, 2002, 9(2):253-264.
Czarnik, "Encoding methods for combinatorial chemistry," Curr Opin Chem Biol., Jun. 1997, 1(1):60-6.
Dahl et al., "Circle-to-circle amplification for precise and sensitive DNA analysis," Proc. Natl. Acad. Sci., 2004, 101(13):4548-4553.
Darmanis et al.,"ProteinSeq: High-Performance Proteomic Analyses by Proximity, Ligation and Next Generation Sequencing," PLos One, 2011, 6(9):e25583, 10 pages.
Daubendiek et al., "Rolling-Circle RNA Synthesis: Circular Oligonucleotides as Efficient Substrates for T7 RNA Polymerase," J. Am. Chem. Soc., 1995, 117(29):7818-7819.
Davies et al., "How best to identify chromosomal interactions: a comparison of approaches," Nat. Methods, 2017, 14(2):125-134.
Deamer et al.. "Characterization of nucleic acids by nanopore analysis," Acc ChemRes., Oct. 2002, 35(10):817-25.
Dean et al., "Comprehensive human genome amplification using multiple displacement amplification," Proc Natl. Acad. Sci. USA, 2002, 99(8):5261-66.
Deng et al., "Spatial Epigenome Sequencing at Tissue Scale and Cellular Level," BioRxiv, Mar. 2021, 40 pages.
Dressman et al., "Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations," Proc. Natl. Acad. Sci. USA, 2003, 100(15):8817-8822.
Drmanac et al., "CoolMPS™: Advanced massively parallel sequencing using antibodies specific to each natural nucleobase," BioRxiv, 2020, 19 pages.
Druley et al., "Quantification of rare allelic variants from pooled genomic DNA," Nat. Methods, 2009, 6(4):263-65.
Duncan et al., "Affinity chromatography of a sequence-specific DNA binding protein using Teflon-linked oligonucleotides," Anal. Biochem., 1988, 169(1):104-108.
Eberwine, "Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA," BioTechniques, 1996, 20(4):584-91.
Eguiluz et al., "Multitissue array review: a chronological description of tissue array techniques, applications and procedures," Pathology Research and Practice, 2006, 202(8):561-568.
Eldridge et al., "An in vitro selection strategy for conferring protease resistance to ligand binding peptides," Protein Eng Des Sel., 2009, 22(11):691-698.
Ellington et al., "Antibody-based protein multiplex platforms: technical and operational challenges," Clin Chem, 2010, 56(2):186-193.
Eng et al., "Profiling the transcriptome with RNA SPOTs," Nat Methods., 2017, 14(12):1153-1155.
Fire et al., "Rolling replication of short DNA circles," Proc. Natl. Acad. Sci., 1995, 92(10):4641-4645.
Flanigon et al., "Multiplex protein detection with DNA readout via mass spectrometry," N. Biotechnol., 2013, 30(2):153-158.
Fluidigm, "Equivalence of Imaging Mass Cytometry and Immunofluorescence on FFPE Tissue Sections," White Paper, 2017, 12 pages.
Fodor et al., "Light-directed, spatially addressable parallel chemical synthesis," Science, 1995, 251(4995):767-773.
Forster et al., "A human gut bacterial genome and culture collection for improved metagenomic analyses," Nature Biotechnology, Feb. 2019, 37(2):186-192.
Frese et al., "Formylglycine aldehyde Tag—protein engineering through a novel post-translational modification," ChemBioChem., 2009, 10(3):425-27.
Fu el al., "Repeat subtraction-mediated sequence capture from a complex genome," Plant J., Jun. 2010, 62(5):898-909.
Fu et al., "Continuous Polony Gels for Tissue Mapping with High Resolution and RNA Capture Efficiency," bioRxiv, 2021, 20 pages.
Fu et al., "Counting individual DNA molecules by the stochastic attachment of diverse labels," PNAS, 2011, 108(22):9026-9031.
Fullwood et al., "Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses," Genome Res., 2009, 19(4):521-532.
Ganguli et al., "Pixelated spatial gene expression analysis from tissue," Nat Commun., Jan. 2018, 9(1):202, 9 pages.
Gao et al., "Q&A: Expansion microscopy", BMC Biology, 15: 50, 9 pages, 2017.
Gene@arrays[online], BeadArray Technology, available on or before Feb. 14, 2015, via Internet Archive: Wayback Machine URL <https://web.archive.org/web/20150214084616/http://genearrays.com/services/microarrays/illumina/beadarray-technology/>, [retrieved on Jan. 30, 2020], 3 pages.
Gill et al., "Nucleic acid isothermal amplification technologies: a review," Nucleosides Nucleotides Nucleic Acids, Mar. 2008, 27(3):224-43.
Glass et al., "SIMPLE: a sequential immunoperoxidase labeling and erasing method," J. Histochem. Cytochem, Oct. 2009, 57(10):899-905.
Gloor, "Gene targeting in Drosophila," Methods Mol Biol., 2004, 260:97-114.
Gnanapragasam, "Unlocking the molecular archive: the emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer," BJU International, 2009, 105(2):274-278.
Goldkorn et al., "A simple and efficient enzymatic method for covalent attachment of DNA to cellulose. Application for hybridization-restriction analysis and for in vitro synthesis of DNA probes," Nucleic Acids Res., 1986, 14(22):9171-9191.
Goryshin et al., "Tn5 in vitro transposition," J Biol Chem., Mar. 1998, 273(13):7367-74.
Gracia Villacampa et al., "Genome-wide Spatial Expression Profiling in FFPE Tissues," bioRxiv, 2020, pp. 38 pages.
Grokhovsky, "Specificity of DNA cleavage by ultrasound," Molecular Biology. 2006. 40(2):276-283.
Gu et al., "Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation," N Biotechnol., 2013, 30(2):144-152.
Gunderson et al., "Decoding randomly ordered DNA arrays," Genome Research, 2004, 14(5):870-877.
Guo et al., "Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports," Nucleic Acids Res., Dec. 1994, 22(24):5456-65.
Gupta et al., "Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells." Nature Biotechnol., Oct. 2018. 36:1197-1202.
Hahnke el al., "Striptease on glass: validation of an improved stripping procedure for in situ microarrays," J Biotechnol., Jan. 2007, 128(1):1-13.
Hamaguchi et al., "Direct reverse transcription-PCR on oligo(dT)-immobilized polvpropvlene microplates after capturing total mRNA from crude cell lysates," Clin Chem., Nov. 1998, 44(11):2256-63.
Hardenbol et al., "Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay," Genome Res., Feb. 2005, 15(2):269-75.
Hardenbol et al., "Multiplexed genotyping with sequence-tagged molecular inversion probes," Nature Biotechnol., Jun. 2003, 21(6):673-678.
Hayes et al., "Electrophoresis of proteins and nucleic acids: I-Theory," BMJ, Sep. 1989, 299(6703):843-6.
He et al., "In situ synthesis of protein arrays," Current Opinion in Biotechnology, 2008, 19(1):4-9.
He et al., "Printing protein arrays from DNA arrays," Nature Methods, 2008, 5(2):175-77.
He, "Cell-free protein synthesis: applications in proteomics and biotechnology," New Biotechnology, 2008, 25(2-3):126-132.
Healy, "Nanopore-based single-molecule DNA analysis," Nanomedicine (Lond), Aug. 2007, 2(4):459-81.
Hejatko et al., "In situ hybridization technique for mRNA detection in whole mount Arabidopsis samples," Nature Protocols, 2006, 1(4):1939-1946.
Hiatt et al., "Parallel, tag-directed assembly of locally derived short sequence reads," Nature Methods, 2010, 7(2):119-25.
Ho et al., "Bacteriophage T4 RNA ligase 2 (gp24.1) exemplifies a family of RNA ligases found in all phylogenetic domains," PNAS, Oct. 2002, 99(20):12709-14.
Hu et al., "High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays," Biotechniques, Jan. 2005, 38(1):121-4.
Hycultbiotech.com, [online], "Immunohistochemisty, Paraffin" April 2010, retrieved on Apr. 16, 2020, retrieved from URL<https://www.hycultbiotech.com/media/wysiwyg/Protocol_Immunohistochemistry_Paraffin_2.pdf>, 3 pages.
Ichikawa et al., "In vitro transposition of transposon Tn3," J Biol. Chem., Nov. 1990, 265(31):18829-32, Abstract.
Jamur et al., "Permeabilization of cell membranes.," Method Mol. Biol., 2010, 588:63-66.
Jemt et al., "An automated approach to prepare tissue-derived spatially barcoded RNA-sequencing libraries," Scientific Reports, 2016, 6:37137, 10 pages.
Kalinka et al., "Comparison of ethylene carbonate and formamide as components of the hybridization mixture in FISH," Scientia Agricola, 2021, 78(4):e20190315, 5 pages.
Kap et al., "Histological assessment of PAXgene tissue fixation and stabilization reagents," PLoS One, 2011,6:e27704, 10 pages.
Kapteyn et al., "Incorporation of non-natural nucleotides into template-switching oligonucleotides reduces background and improves cDNA synthesis from very small RNA samples," BMC Genomics, Jul. 2010, 11:413, 9 pages.
Karmakar et al., "Organocatalytic removal of formaldehyde adducts from RNA and DNA bases," Nature Chemistry, Aug. 3, 2015, 7(9):752-758.
Kaya-Okur et al., "CUT&Tag for efficient epigenomic profiling of small samples and single cells," Apr. 2019, 10(1):1930, 10 pages.
Ke et al., "In situ sequencing for RNA analysis in preserved tissue and cells," Nat Methods., Sep. 2013, Supplementary Materials, 29 pages.
Kennedy-Darling et al., "Measuring the Formaldehyde Protein-DNA Cross-Link Reversal Rate," Analytical Chemistry, 2014, 86(12):5678-5681.
Kent et al., "Polymerase θ is a robust terminal transferase that oscillates between three different mechanisms during end-joining" Elife, Jun. 2016, 5:e13740, 25 pages.
Kirby et al., "Cryptic plasmids of Mycobacterium avium: Tn552 to the rescue," Mol Microbiol., Jan. 2002, 43(1):173-86.
Kleckner et al., "Tn10 and IS10 transposition and chromosome rearrangements: mechanism and regulation in vivo and in vitro." Curr Top Microbiol Immunol., 1996, 204:49-82.
Korbel et al., "Paired-end mapping reveals extensive structural variation in the human genome," Science, 2007, 318(5849):420-426.
Kozlov et al., "A highly scalable peptide-based assay system for proteomics," PLoS ONE, 2012, 7(6):e37441, 10 pages.
Kozlov et al., "A method for rapid protease substrate evaluation and optimization," Comb Chem High Throughput Screen, 2006, 9(6):481-87.
Kristensen et al., "High-Throughput Methods for Detection of Genetic Variation," BioTechniques. Feb. 2001, 30(2):318-332.
Kurz et al., "cDNA—protein fusions: covalent protein—gene conjugates for the in vitro selection of peptides and proteins," ChemBioChem., 2001, 2(9):666-72.
Kwok, "High-throughput genotyping assay approaches," Pharmocogenomics, Feb. 2000, 1(1):95-100.
Lage et al., "Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH," Genome Research, 2003, 13(2):294-307.
Lampe et al., "A purified mariner transposase is sufficient to mediate transposition in vitro," EMBO J., Oct. 1996, 15(19):5470-9.
Landegren et al., "Reading bits of genetic information: methods for single-nucleotide polymorphism analysis," Genome Res., Aug. 1998, 8(8):769-76.
Langdale et al., "A rapid method of gene detection using DNA bound to Sephacryl," Gene, 1985, 36(3):201-210.
Larman et al., "Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay," Nucleic Acids Research, 2014, 42(14):9146-9157.
Lee et al., "Fluorescent: in situ sequencing (FISSEQ) of RNA for gene expression profiting in intact cells and tissues," Nature Protocols, 2015, 10(3):442-458.
Lee et al., "Improving the efficiency of genomic loci capture using oligonucleotide arrays for high throughput resequencing," BMC Genomics, Dec. 2009, 10:646, 12 pages.
Leriche et al., "Cleavable linkers in chemical biology," Bioorganic & Medicinal Chemistry, 2012, 20:571-582.
Li et al., "A photocleavable fluorescent nucleotide for DNA sequencing and analysis," Proc. Natl. Acad. Sci., 2003, 100(2):414-419.
Li et al., "An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells," Nat Commun, Nov. 2017, 8(1):1775, 12 pages.
Li et al., "RASL-seq for Massively Parallel and Quantitative Analysis of Gene Expression," Curr Protoc Mol Biol., Apr. 2012, 4(13):1-10.
Li et al., "Review: a comprehensive summary of a decade development of the recombinase polymerase amplification," Analyst, Dec. 2018, 144(1):31-67.
Lin et al., "Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method," Nat Commun., Sep. 2015, 6:8390, 7 pages.
Linnarsson, "Recent advances in DNA sequencing methods—general principles of sample preparation," Experimental Cell Research, 2010, 316(8):1339-1343.
Liu et al., "High-Spatial-Resolution Multi-Omics Atlas Sequencing of Mouse Embryos via Deterministic Barcoding in Tissue," BioRxiv, Oct. 2019, 55 pages.
Lizardi et al., "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," Nat. Genet., 1998, 19(3):225-232.
Lovatt et al., "Transcriptome in vivo analysis (TIVA) of spatially defined single cells in live tissue," Nature Methods, 2013, 11(2):190-196.
Lund et al., "Assessment of methods for covalent binding of nucleic acids to magnetic beads, Dynabeads, and the characteristics of the bound nucleic acids in hybridization reactions," Nucleic Acids Res., 1988, 16(22):10861-80.
Lundberg et al., "High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus," Gene, 1991, 108(1):1-6.
Lundberg et al., "Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood," Nucleic Acids Res., 2011, 39(15):e102, 8 pages.
Lundberg et al., "Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material," Mol Cell Proteomics, 2011, 10(4):M110.004978, 11 pages.
Lundin et al., "Increased throughput by parallelization of library preparation for massive sequencing," PLoS One, Apr. 2010, 5(4):e10029, 7 pages.
Lyck et al., "Immunohistochemical markers for quantitative studies of neurons and glia in human neocortex," J Histochem Cytochem, 2008, 56(3):201-21.
MacBeath et al., "Printing proteins as microarrays for high-throughput function determination," Science, Sep. 2000, 289(5485):1760-1763.
MacIntyre, "Unmasking antigens for immunohistochemistry.," Br J Biomed Sci., 2001, 58(3):190-6.
Macosko et al., "Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets," Cell, 2015, 161:1202-1214.
Marx, "Method of the Year: spatially resolved transcriptomics," Nature Methods, 2021, 18(1):9-14.
McCloskey et al., "Encoding PCR products with batch-stamps and barcodes," Biochem. Genet., 2007, 45(11-12):761-767.
Meers et al., "Improved CUT&RUN chromatin profiling tools," Elife, Jun. 2019, 8:e46314, 16 pages.
Merritt, et al., "Multiplex digital spatial profilin gof proteins and RNA in fixed tissue," Nat Biotechnol, May 2020, 38(5):586-599.
Metzker, "Sequencing technologies—the next generation," Nature Reviews Genetics, 2010, 11(1):31-46.
Miele et al., "Mapping cis- and trans-chromatin interaction networks using chromosome conformation capture (3C)," Methods Mol Biol., 2009, 464:105-21.
Miller et al., "Basic concepts of microarrays and potential applications in clinical microbiology," Clinical Microbiology Reviews, 2009, 22(4):611-633.
Miner et al.,, "Molecular barcodes detect redundancv and contamination in hairpin-bisulfite PCR," Nucleic Acids Res., Sep. 2004, 32(17):e135, 4 pages.
Mishra et al., "Three-dimensional genome architecture and emerging technologies: looping in disease," Genome Medicine, 2017, 9(1):87, 14 pages.
Mitra et al., "Digital genotyping and haplotyping with polymerase colonies," Proc. Natl. Acad. Sci. USA, May 2003, 100(10):5926-5931.
Mizusawa et al., "A bacteriophage lambda vector for cloning with BamHI and Sau3A," Gene, 1982, 20(3):317-322.
Morian et al., "Selective depletion of rRNA enables whole transcriptome profiling of archival fixed tissue," PLoS One, Aug. 2012, 7(8):e42882, 8 pages.
Motea et al., "Terminal deoxynucleotidyl transferase: the story of a misguided DNA polymerase." Biochim Brophys Acta., May 2010, 1804(5):1151-66.
Nandakumar et al., "How an RNA Ligase Discriminates RNA versus DNA Damage," Molecular Cell, 2004, 16:211-221.
Ncbi.nlm.nih.gov. [online], "Molecular Inversion Probe Assay," available on or before Oct. 14, 2014, via Internet Archive: Wayback Marchine URL<https://web.archive.org/web/20141014124037/https://www.ncbi.nlm.nih.gov/probe/docs/techmip/>, retrieved on Jun. 16, 2021, retrieved from URL<https://www.ncbi.nlm.nih.gov/probe/docs/techmip/>, 2 pages.
Ng et al., "Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation," Nature Methods, 2005, 2(2):105-111.
Nichols et al., "RNA Ligases," Curr Protoc Mol Biol., Oct. 2008, 84(1):3.15.1-3.15.4.
Nikiforov et al., "The use of 96-well polystyrene plates for DNA hybridization-based assays: an evaluation of different approaches to oligonucleotide immobilization," Anal Biochem, May 1995, 227(1):201-9.
Niklas et al., "Selective permeabilization for the high-throughput measurement of compartmented enzyme activities in mammalian cells." Anal Biochem, Sep. 2011, 416(2):218-27.
Nowak et al., "Entering the Postgenome Era," Science, 1995, 270(5235):368-71.
Ohtsubo et al., "Bacterial insertion sequences." Curr Top Microbiol Immunol., 1996, 204:1-26.
Pandey et al., "Inhibition of terminal deoxvnucleotidvl transferase by adenine dinucleotides. Unique iniiibitory action of Ap5A," FEBS Lett., Mar. 1987, 213(1):204-8.
Park et al., "Single cell trapping in larger microwells capable of supporting cell spreading and proliferation," Microfluid Nanofluid, 2010, 8:263-268.
PCT International Preliminary Report on Patentability in International Appln. No. PCT/EP2016/057355, dated Oct. 10, 2017, 7 pages.
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/048425, dated Mar. 2, 2021, 9 pages .
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/048434, dated Mar. 2, 2021, 15 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/066681, dated Apr. 14, 2021, 17 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/066720, dated Mar. 22, 2021, 13 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2021/012659, dated Apr. 16, 2021, 15 pages.
Pellestor et al., "The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics," Eur J Hum Genet., Sep. 2004, 12(9):694-700.
Pemov et al., "DNA analysis with multiplex microarray-enhanced PCR," Nucl. Acids Res., Jan. 2005, 33(2):e11, 9 pages.
Perler et al., "Intervening sequences in an Archaea DNA polymerase gen," Proc Natl Acad Sci USA, Jun. 1992, 89(12):5577-5581.
Petterson et al., "Generations of sequencing technologies," Genomics, 2009, 93(2):105-111.
Picelli et al., "Tn5 transposase and tagmentation procedures for massively scaled sequencing projects," Genome Res., Dec. 2014, 24(12):2033-40.
Pipenburg et al., "DNA detection using recombination proteins," PLoS Biol., Jul. 2006, 4(7):e204, 7 pages.
Pirici et al., "Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtypem." J. Histochem. Cytochem., Jun. 2009, 57(6):567-75.
Plasterk, "The Tcl/mariner transposon family," Curr Top Microbiol Immunol., 1996, 204:125-43.
Plongthongkum et al., "Advances in the profiling of DNA modifications: cytosine methylation and beyond," Nature Reviews Genetics, Aug. 2014, 15(10):647-661.
Polsky-Cynkin et al., "Use of DNA immobilized on plastic and agarose supports to detect DNA by sandwich hybridization," Clin. Chem., 1985, 31(9):1438-1443.
Punwaney et al., "Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction," Head & Neck, Jan. 1999, 21(1):21-29.
Raab et al., "Human tRNA genes function as chromatin insulators," EMBO J., Jan. 2012, 31(2):330-50.
Ranki et al., "Sandwich hybridization as a convenient method for the detection of nucleic acids in crude samples," Gene, 1983, 21(1-2):77-85.
Reinartz et al., "Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms." Brief Funct Genomic Proteomic, Feb. 2002. 1(1):95-104.
Reznikoff. "Tn5 as a model for understanding DNA transposition," Mol Microbiol., Mar. 2003, 47(5): 1199-206.
Ristic et al., "Detection of Protein-Protein Interactions and Posttranslational Modifications Using the Proximity Ligation Assay: Application to the Study of the SUMO Pathway," Methods Mol. Biol., 2016, 1449:279-90.
Rodriguez et al., "APPRIS 2017: principal isoforms for multiple gene sets," Nucleic Acids Research, Jan. 2018, 46(D1):D213-217.
Rodriques et al., "Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution," Science, Mar. 2019, 363(6434):1463-1467.
Ronaghi et al., "A sequencing method based on real-time pyrophosphate," Science, Jul. 1998, 281(5375):363-365.
Ronaghi et al., "Real-time DNA sequencing using detection of pyrophosphate release," Analytical Biochemistry, Nov. 1996, 242(1):84-89.
Ronaghi, "Pyrosequencing sheds light on DNA sequencing," Genome Res, Jan. 2001, 11(1):3-11.
Roy et al., "Assessing long-distance RNA sequence connectivity via RNA-templated DNA-DNA ligation," eLife, 2015, 4:e03700, 21 pages.
Salmén et al., "Barcoded solid-phase RNA capture for Spatial Transcriptomics profiling in mammalian tissue sections," Nature Protocols, Oct. 2018, 13(11):2501-2534.
Saxonov et al.," 10x Genomics, Mastering Biology to Advance Human Health," PowerPoint, 10x, 2020, 41 pages.
Schena et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," Science, Oct. 1995, 270(5235):467-470.
Schweitzer et al., "Multiplexed protein profiling on microarrays by rolling-circle amplification." Nature Biotechnology, Apr. 2002, 20(4):359-365.
Shalon et al., "A DNA microarrav system for analyzing complex DNA samples using two-color fluorescent probe hybridization," Genome Res., Jul. 1996, 6(7):639-45.
Shelbourne et al., "Fast copper-free click DNA ligation by the ring-strain promoted alkyne-azide cycloaddition reaction," Chem. Commun., 2011, 47(22):6257-6259.
Shendure et al., "Accurate multiplex polony sequencing of an evolved bacterial genome," Science, 2005, 309(5741):1728-1732.
Simonis et al., "Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C)," Nat Genet., Nov. 2006, 38(11):1348-54.
Skene et al., "An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites," Elife, Jan. 2017, 6:e21856, 35 pages.
Spitale et al., "Structural imprints in vivo decode RNA regulatory mechanisms," Nature, 2015, 519(7544):486-90.
Stahl et al., "Visualization and analysis of gene expression in tissue sections by spatial transcriptomics," Science, Jun. 2016, 353(6294):78-82.
Stahl et al., "Visualization and analysis of gene expression in tissue sections by spatial transcriptomics," Supplementary Materials, Science, Jul. 2016, 353(6294):78-82, 41 pages.
Stimpson et al., "Real-time detection of DNA hybridization and melting on oligonucleotide arrays bv using optical wave guides," Proc Natl Acad Sci USA, Jul. 1995, 92(14):6379-83.
Stoddart et al., "Single-nucleotide discrimination in immobilized DNA oligonucleotides with a biological nanopore," PNAS USA., May 2009, 106(19):7702-7707.
Strell et al., "Placing RNA in context and space—methods for spatially resolved transcriptomics," The FEBS Journal, Apr. 2019, 286(8):1468-1481.
Stroh et al., "Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo." Nat Med., Jun. 2005, 11(6):678-82.
Taylor et al., "Mitochondrial DNA mutations in human disease," Nature Reviews Genetics, May 2005, 6(5):389-402.
Tentori et al., "Detection of Isoforms Differing by a Single Charge Unit in Individual Cells," Chem. Int. Ed., 2016, 55(40):12431-5.
Tian et al., "Antigen peptide-based immunosensors for rapid detection of antibodies and antigens," Anal Chem, 2009, 81(13):5218-5225.
Tijssen et al., "Overview of principles of hybridization and the strategy of nucleic acid assays" in Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes, 1993, 24(Chapter 2), 65 pages.
Tolbert et al., "New methods for proteomic research: preparation of proteins with N-terminal cysteines for labeling and conjugation," Angewandte Chemie International Edition, Jun. 2002, 41(12):2171-4.
Trejo et al., "Extraction-free whole transcriptome gene expression analysis of FFPE sections and histology-directed subareas of tissue." PLoS ONE, Feb. 2019, 14(2):e0212031, 22 pages.
Twyman et al., "Techniques Patents for SNP Genotyping," Pharmacogenomics, Jan. 2003, 4(1):67-79.
U.S. Appl. No. 16/876,682, US-2020-0407781-A1, filed May 18, 2020, Michael Schnall-Levin.
U.S. Appl. No. 16/876,709, US-2021-0010070-A1, filed May 18, 2020, Michael Schnall-Levin.
U.S. Appl. No. 16/876,913, US-2020-0277663-A1, filed May 18, 2020, Eswar Prasad Ramachandran Iyer.
U.S. Appl. No. 16/876,947, US-2020-0277664-A1, filed May 18, 2020, Lucas Frenz.
U.S. Appl. No. 17/073,242, US-2021-0140982-A1, filed Oct. 16, 2020, Cedric Uytingco.
U.S. Appl. No. 17/100,106, US-2021-0199660-A1, filed Nov. 20, 2020, Stephen R. Williams.
U.S. Appl. No. 17/172,926, US-2021-0189475-A1, filed Feb. 10, 2021, Augusto Manuel Tentori.
U.S. Appl. No. 17/212,681, filed Mar. 25, 2021, Yifeng Yin.
U.S. Appl. No. 17/220,534, filed Apr. 1, 2021, James Michael Chell.
U.S. Appl. No. 17/312,247, filed Jun. 9, 2021, Michael Schnall-Levin.
U.S. Appl. No. 17/312,375, filed Jun. 9, 2021, Cedric Uytingco.
U.S. Appl. No. 60/416,118 Fan et al., Multiplex Nucleic Acid Analysis Using Archived or Fixed Samples, filed Oct. 3, 2002, 22 pages.
U.S. Appl. No. 60/416,118, filed Oct. 3, 2002, Fan et al.
U.S. Appl. No. 61/267,363, filed Dec. 7, 2009, 33 pages.
U.S. Appl. No. 61/267,363, filed Dec. 7, 2009, Fan et al.
Van Gelder et al., "Amplified RNA synthesized from limited quantities of heterogeneous cDNA," Proc. Natl. Acad. Sci. USA, 1990, 87(5):1663-1667.
Vandernoot et al., "cDNA normalization by hvdroxvapatite chromatography to enrich transcriptome diversity in RNA-seq applications." Biotechniques, Dec. 2012, 53(6):373-80.
Vasiliskov et al., "Fabrication of microarray of gel-immobilized compounds on a chip by copolymerization," Biotechniques, Sep. 1999, 27(3):592-606.
Velculescu et al., "Serial analysis of gene expression," Science, Oct. 1995, 270(5235):484-7.
Vickovic et al., "High-definition spatial transcriptomics for in situ tissue profiling," Nat Methods, Oct. 2019, 16(10):987-990.
Vickovic et al.. "High-definition spatial transcriptomics for in situ tissue profiling." Nature Methods, 2019, 9 pages.
Vincent et al., "Helicase-dependent isothermal DNA amplification," EMBO Rep., Aug. 2004, 5(8):795-800.
Viollet et al., "T4 RNA ligase 2 truncated active site mutants: improved tools for RNA analysis," BMC Biotechnol., Jul. 2011, 11:72, 14 pages.
Vlassakis et al., "Effect of Polymer Hydration State on In-Gel Immunoassays," Anal Chem., Nov. 2015, 87(21):11030-8.
Vogelstein et al., "Digital PCR," Proceedings of the National Academy of Sciences, Aug. 1999, 96(16):9236-9241.
Waichman et al., "Functional immobilization and patterning of proteins by an enzymatic transfer reaction," Analytical chemistiy, 2010, 82(4):1478-85.
Walker et al., "Strand displacement amplification—an isothermal, in vitro DNA amplification technique," Nucleic Acids Research, 1992, 20(7):1691-1696.
Wang et al., "Concentration gradient generation methods based on microfluidic systems," RSC Adv., 2017, 7:29966-29984.
Wang et al., "High-fidelity mRNA amplification for gene profiling," Nature Biotechnology, Apr. 2000, 18(4):457-459.
Wang et al., "Imaging-based pooled CRISPR screening reveals regulators of IncRNA localization," Proc Natl Acad Sci USA, May 2019, 116(22):10842-10851.
Wang et al., "Tagmentation-based whole-genome bisulfite sequencing," Nature Protocols, Oct. 2013, 8(10):2022-2032.
Wang, "RNA amplification for successful gene profiling analysis," J Transl Med., Jul. 2005, 3:28, 11 pages.
Weinreich et al., "Evidence that the cis Preference of the Tn5 Transposase is Caused bv Nonproductive Multimerization," Genes and Development, Oct. 1994, 8(19):2363-2374.
Wiedmann et al. PCR Methods and Applications 3:551-564 (Year: 1994). *
Wilson et al., "New transposon delivery plasmids for insertional mutagenesis in Bacillus anthracis," J Microbiol Methods, Dec. 2007, 71(3):332-5.
Wolf et al., "Rapid hybridization kinetics of DNA attached to submicron latex particles," Nucleic Acids Res, 1987, 15(7):2911-2926.
Wong et al., "Direct Site-Selective Covalent Protein Immobilization Catalyzed by a Phosphopantetheinyl Transferase," J. Am. Chem Soc., 2008, 130(37):42456-64.
Worthington et al., "Cloning of random oligonucleotides to create single-insert plasmid libraries," Anal Biochem, 2001, 294(2):169-175.
Wu et al., "Detection DNA Point Mutation with Rolling-Circle Amplification Chip," IEEE, 2010 4th International Conference on Bioinformatics and Biomedical Engineering. Jun. 2010, 4 pages.
Yeakley et al., "A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling," 11 PLoS One. May 2017. 12(5):e0178302, 22 pages.
Yeakley et al., "Profiling alternative splicing on fiber-optic arrays," Nature biotechnology, 2002, 20:353-358.
Yershov et al., "DNA analysis and diagnostics on oligonucleotide microchips," Proc. Natl. Acad. Sci. USA, May 1996, 93(10):4913-4918.
Yin et al., "Genetically encoded short peptide tag for versatile protein labeling by Sfp phosphopantetheinyl transferase," PNAS, 2005, 102(44):15815-20.
Zhang et al., "Archaeal RNA ligase from thermoccocus kodakarensis for template dependent ligation," RNA Biol., Jan. 2017, 14(1):36-44.
Zhang et al., "Assembling DNA through Affinity Binding to Achieve Ultrasensitive Protein Detection," Angew Chem Int Ed Engl., 2013, 52(41):10698-705.
Zhang et al., "Binding-induced DNA assembly and its application to yoctomole detection of proteins," Anal Chem, 2012, 84(2):877-884.
Zhang et al., "Multiplex ligation-dependent probe amplification (MLPA) for ultrasensitive multiplexed microRNA detection using ribonucleotide-modified DNA probes†," Chem. Commun., 2013, 49:10013-10015.
Zheng et al., "Origins of human mitochondrial point mutations as DNA polymerase gamma-mediated errors," Mutat. Res., 2006, 599(1-2):11-20.
Zhou et al., "Genetically encoded short peptide tags for orthogonal protein labeling by Sfp and AcpS phosphopantetheinyl transferases," ACS Chemical Biol., 2007, 2(5):337-346.
Zhu et al., "Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction," Biotechniques, Apr. 2001, 30(4):892-897.
Zieba et al., "Bright-field microscopy visualization of proteins and protein complexes by situ proximity ligation with peroxidase detection," Clin Chem, Jan. 2010, 56(1):99-110.

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11767550B2 (en) 2010-04-05 2023-09-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11634756B2 (en) 2010-04-05 2023-04-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11866770B2 (en) 2010-04-05 2024-01-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11761030B2 (en) 2010-04-05 2023-09-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732292B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays correlating target nucleic acid to tissue section location
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11479810B1 (en) 2010-04-05 2022-10-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11560587B2 (en) 2010-04-05 2023-01-24 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11549138B2 (en) 2010-04-05 2023-01-10 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11542543B2 (en) 2010-04-05 2023-01-03 Prognosys Biosciences, Inc. System for analyzing targets of a tissue section
US11519022B2 (en) 2010-04-05 2022-12-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11795498B2 (en) 2011-04-13 2023-10-24 10X Genomics Sweden Ab Methods of detecting analytes
US11788122B2 (en) 2011-04-13 2023-10-17 10X Genomics Sweden Ab Methods of detecting analytes
US11753674B2 (en) 2013-06-25 2023-09-12 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11821024B2 (en) 2013-06-25 2023-11-21 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11613773B2 (en) 2015-04-10 2023-03-28 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11933957B1 (en) 2018-12-10 2024-03-19 10X Genomics, Inc. Imaging system hardware
US11753675B2 (en) 2019-01-06 2023-09-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11808769B2 (en) 2019-11-08 2023-11-07 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11592447B2 (en) 2019-11-08 2023-02-28 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
US11560593B2 (en) * 2019-12-23 2023-01-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US20230160008A1 (en) * 2019-12-23 2023-05-25 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
US11795507B2 (en) 2019-12-23 2023-10-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11981965B2 (en) * 2019-12-23 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US20220282329A1 (en) * 2019-12-23 2022-09-08 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US11773433B2 (en) 2020-04-22 2023-10-03 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11959130B2 (en) * 2020-05-22 2024-04-16 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11866767B2 (en) 2020-05-22 2024-01-09 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US20230220455A1 (en) * 2020-05-22 2023-07-13 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US11845979B2 (en) 2020-06-02 2023-12-19 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US11512308B2 (en) 2020-06-02 2022-11-29 10X Genomics, Inc. Nucleic acid library methods
US11859178B2 (en) 2020-06-02 2024-01-02 10X Genomics, Inc. Nucleic acid library methods
US11692218B2 (en) 2020-06-02 2023-07-04 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US11840687B2 (en) 2020-06-02 2023-12-12 10X Genomics, Inc. Nucleic acid library methods
US11608498B2 (en) 2020-06-02 2023-03-21 10X Genomics, Inc. Nucleic acid library methods
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11624063B2 (en) 2020-06-08 2023-04-11 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11781130B2 (en) 2020-06-08 2023-10-10 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11492612B1 (en) 2020-06-08 2022-11-08 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11661626B2 (en) 2020-06-25 2023-05-30 10X Genomics, Inc. Spatial analysis of DNA methylation
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11952627B2 (en) 2020-07-06 2024-04-09 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11959076B2 (en) 2020-12-21 2024-04-16 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11680260B2 (en) 2020-12-21 2023-06-20 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11873482B2 (en) 2020-12-21 2024-01-16 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11739381B2 (en) 2021-03-18 2023-08-29 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
US11970739B2 (en) 2021-03-18 2024-04-30 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
US11840724B2 (en) 2021-09-01 2023-12-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023150163A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from lymphatic tissue
WO2023150171A1 (en) 2022-02-01 2023-08-10 10X Genomics, Inc. Methods, compositions, and systems for capturing analytes from glioblastoma samples
WO2023159028A1 (en) 2022-02-15 2023-08-24 10X Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
WO2023212532A1 (en) 2022-04-26 2023-11-02 10X Genomics, Inc. Systems and methods for evaluating biological samples
WO2023215552A1 (en) 2022-05-06 2023-11-09 10X Genomics, Inc. Molecular barcode readers for analyte detection
WO2023250077A1 (en) 2022-06-22 2023-12-28 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2024006814A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Method of generating arrays using microfluidics and photolithography
WO2024006816A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Compositions and methods for oligonucleotide inversion on arrays
WO2024006799A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Covalent attachment of splint oligonucleotides for molecular array generation using ligation
WO2024006832A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Click chemistry-based dna photo-ligation for manufacturing of high-resolution dna arrays
WO2024006826A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Compositions and methods for generating molecular arrays using oligonucleotide printing and photolithography
WO2024006830A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Methods and compositions for patterned molecular array generation by directed bead delivery
WO2024006798A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. High definition molecular array feature generation using photoresist
WO2024006797A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Methods and compositions for refining feature boundaries in molecular arrays
WO2024006827A1 (en) 2022-06-29 2024-01-04 10X Genomics, Inc. Methods and systems for light-controlled surface patterning using photomasks
WO2024015578A1 (en) 2022-07-15 2024-01-18 10X Genomics, Inc. Methods for determining a location of a target nucleic acid in a biological sample
WO2024035844A1 (en) 2022-08-12 2024-02-15 10X Genomics, Inc. Methods for reducing capture of analytes

Also Published As

Publication number Publication date
WO2021133849A1 (en) 2021-07-01
US20230392204A1 (en) 2023-12-07
CN114885610A (zh) 2022-08-09
US11560593B2 (en) 2023-01-24
US20230160008A1 (en) 2023-05-25
US20240124933A1 (en) 2024-04-18
US20220282329A1 (en) 2022-09-08
US11795507B2 (en) 2023-10-24
DK3891300T3 (da) 2023-05-22
AU2020412766A1 (en) 2022-06-09
EP4219754B1 (en) 2024-05-15
EP3891300B1 (en) 2023-03-29
US20230064372A1 (en) 2023-03-02
SG11202106899SA (en) 2021-09-29
US20210285046A1 (en) 2021-09-16
EP4219754A1 (en) 2023-08-02
US11981965B2 (en) 2024-05-14
EP3891300A1 (en) 2021-10-13
FI3891300T3 (fi) 2023-05-10
US20210348221A1 (en) 2021-11-11
ES2946357T3 (es) 2023-07-17
US11505828B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
US11332790B2 (en) Methods for spatial analysis using RNA-templated ligation
US11959130B2 (en) Spatial analysis to detect sequence variants
US11773433B2 (en) Methods for spatial analysis using targeted RNA depletion
US11732300B2 (en) Increasing efficiency of spatial analysis in a biological sample
US20230279477A1 (en) Methods for spatial analysis using targeted rna capture
US11898205B2 (en) Increasing capture efficiency of spatial assays
WO2022226057A1 (en) Methods for assessing sample quality prior to spatial analysis using templated ligation
WO2022236054A1 (en) Methods for increasing resolution of spatial analysis
EP4352252A1 (en) Methods for spatial analysis using targeted probe silencing
US20240182968A1 (en) Increasing capture efficiency of spatial assays

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: 10X GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SPATIAL TRANSCRIPTOMICS AB;REEL/FRAME:057105/0228

Effective date: 20210603

Owner name: SPATIAL TRANSCRIPTOMICS AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHELL, JAMES MICHAEL;STOECKIUS, MARLON;ALLES, JONATHAN;AND OTHERS;SIGNING DATES FROM 20210601 TO 20210602;REEL/FRAME:057105/0138

Owner name: 10X GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAVA, FELICE ALESSIO;KATIRAEE, LAYLA;REEL/FRAME:057105/0016

Effective date: 20210601

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE